0001213900-23-022296.txt : 20230323 0001213900-23-022296.hdr.sgml : 20230323 20230323110713 ACCESSION NUMBER: 0001213900-23-022296 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230323 DATE AS OF CHANGE: 20230323 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Heyu Biological Technology Corp CENTRAL INDEX KEY: 0001086303 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 870627910 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26731 FILM NUMBER: 23754930 BUSINESS ADDRESS: STREET 1: 4TH FLOOR, NO.10 BUILDING, XINGLIN BAY STREET 2: BUSINESS OPERATION CENTER JIMEI DISTRICT CITY: XIAMEN CITY, FUJIAN PROVINCE STATE: F4 ZIP: 361022 BUSINESS PHONE: 86 158 5924 0902 MAIL ADDRESS: STREET 1: 4TH FLOOR, NO.10 BUILDING, XINGLIN BAY STREET 2: BUSINESS OPERATION CENTER JIMEI DISTRICT CITY: XIAMEN CITY, FUJIAN PROVINCE STATE: F4 ZIP: 361022 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC WEBWORKS INC DATE OF NAME CHANGE: 19990715 10-K 1 f10k2022_heyubiological.htm ANNUAL REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-K

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM ______ TO ______

COMMISSION FILE NUMBER 000-26731

HEYU BIOLOGICAL TECHNOLOGY CORPORATION

(Exact name of Registrant as specified in its charter)

Nevada		87-0627910
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

Room 903&904, Huli Building,

619 Sishui Street,

Huli District, Xiamen City,

Fujian Province, China

361009

(Address of principal executive offices)

(Zip Code)

REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE: (86) 158 5924 0902

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None		None		None

SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:

Common Stock, $0.001 par value per share

(Title of Class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed be Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically, if any, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of June 30, 2022, the last business day of the registrant’s most recently completed secondfiscal quarter, the aggregate market value of the common stock outstanding held by non-affiliates of the registrant, computed by reference to the closing sales price for the common stock of $0.0013, as reported on the OTC Pink Market, was approximately $1,961,685.40.

As of March 23, 2023, there were 1,032,466,000 shares of the registrant’s Common Stock outstanding.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K (this “Report”) contains forward-looking statements. These forward-looking statements are not historical facts but rather are based on current expectations, estimates and projections. We may use words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “foresee,” “estimate” and variations of these words and similar expressions to identify forward-looking statements. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted. These risks and uncertainties include the following:

	●	The availability and adequacy of our cash flow to meet our requirements;

	●	Economic, competitive, demographic, business, and other conditions in our local and regional markets;

	●	Changes or developments in laws, regulations, or taxes in our industry;

	●	Actions taken or omitted to be taken by third parties including our suppliers and competitors, as well as legislative, regulatory, judicial, and other governmental authorities;

	●	Competition in our industry;

	●	The loss of or failure to obtain any license or permit necessary or desirable in the operation of our business;

	●	Changes in our business strategy, capital improvements, or development plans;

	●	The Company’s ability to devise and implement effective internal controls and procedures;

	●	The availability of additional capital to support capital improvements and development; and

	●	Other risks identified in this Report and in our other filings with the Securities and Exchange Commission or the SEC.

This Report should be read completely and with the understanding that actual future results may be materially different from what we expect. The forward-looking statements included in this Report are made as of the date of this Report and should be evaluated with consideration of any changes occurring after the date of this Report. We will not update forward-looking statements even though our situation may change in the future and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

TABLE OF CONTENTS

		Page
PART I

ITEM 1.	BUSINESS	1
ITEM 1A.	RISK FACTORS	5
ITEM 1B.	UNRESOLVED STAFF COMMENTS	5
ITEM 2.	PROPERTIES	5
ITEM 3.	LEGAL PROCEEDINGS	5
ITEM 4.	MINE SAFETY DISCLOSURES	5

PART II

ITEM 5.	MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES	6
ITEM 6.	[RESERVED]	7
ITEM 7.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	8
ITEM 7A.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	12
ITEM 8.	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA	12
ITEM 9.	CHANGES OF INDEPENDENT CERTIFYING ACCOUNTANT	12
ITEM 9A.	CONTROLS AND PROCEDURES	12
ITEM 9B.	OTHER INFORMATION	12
Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.	12

PART III

ITEM 10.	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE	13
ITEM 11.	EXECUTIVE COMPENSATION	16
ITEM 12.	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS	18
ITEM 13.	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE	19
ITEM 14.	PRINCIPAL ACCOUNTING FEES AND SERVICES	19

PART IV

ITEM 15.	EXHIBITS, FINANCIAL STATEMENT SCHEDULES	20
ITEM 16.	FORM 10-K SUMMARY	21
	SIGNATURES	22

PART I

Unless otherwise indicated, all share amounts and per share amounts in this Report have been presented giving effect to a 1-for-464 reverse split that became effective on April 11, 2018, and a 100-for-1 forward stock split that became effective on September 11, 2018.

ITEM 1. BUSINESS

Heyu Biological Technology Corporation (the “Company” or “we”) was incorporated in the state of Nevada on May 18, 1987, as Asphalt Associates, Inc. and changed its name to Pacific WebWorks in January 1999. From 1999 to 2016 the Company engaged in the development and distribution of web tools software, electronic business storefront hosting, and Internet payment systems for individuals and small to medium sized businesses. On February 23, 2016, the Company filed a voluntary petition for bankruptcy in the U.S. Bankruptcy Court for the District of Utah, and soon afterwards ceased its business activities. On August 19, 2016, the Company proposed a Plan of Liquidation and on November 28, 2016, the Court entered an order confirming the Plan of Liquidation and establishing a Liquidating Trust. On December 28, 2016, all assets and liabilities of the Company were transferred to the Liquidating Trust (the “Liquidation”).

On March 12, 2018, the Board of Directors of the Company (the “Board”), with the consent of the majority shareholder, approved a 1-for-464 reverse stock split. On April 11, 2018, the reverse split became effective.

On April 18, 2018, the Company entered into a Share Purchase Agreement (the “SPA”) with Mr. Ban Siong Ang (the “Purchaser”) and Mr. Dan Masters (the “Seller”), pursuant to which the Purchaser acquired 1,021,051,700 shares, representing 98.91% of the issued and outstanding shares of common stock of the Company (“Common Stock”) from Seller for an aggregate purchase price of $335,000 (“Share Purchase”). As a result of the SPA, the Company accepted the resignation of Dan Masters, as the Company’s President, Chief Executive Officer, Chief Financial Officer, Secretary and Chairman of the Board. This resignation was given in connection with the closing of the Share Purchase and was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. Additionally, all debt due to Mr. Masters from the Company was cancelled as of the closing of the Share Purchase and recognized as contributed capital.

On July 3, 2018, the Company changed its name to Heyu Biological Technology Corporation, with a new ticker symbol, HYBT. The Company currently has no business operations. On July 30, 2018, the Company amended its Articles of Incorporation with the State of Nevada in order to increase its authorized shares of Common Stock from 150,000,000 to 2,000,000,000.

On September 11, 2018, the Nevada Secretary of State approved the Company’s certificate of amendment to amend its Articles of Incorporation to effectuate a 100-for-1 forward stock split. The total issued and outstanding shares of Common Stock has been increased from 10,324,660 to 1,032,466,000 shares, with the par value unchanged at $0.001.

On September 25, 2018, the Financial Industry Regulatory Authority, Inc. (“FINRA”) approved the Forward Split with an Effective Date of September 25, 2018 and a Pay Date of September 24, 2018. In connection with the Forward Split, no fractional shares are necessary to be issued, and stockholders do not need to present certificates for exchange. The Forward Split will be payable directly to each stockholder by the issuance of shares representing the split differential.

On February 28, 2021, Ms. Wendy Wei Li resigned from her position with the Company as the Chief Financial Officer. To fill the vacancies created by Ms. Wendy Wei Li’s resignation, Mr. Ang was appointed as the Chief Financial Officer. On November 30, 2021, Mr. Bo Lyu has been appointed as the Chief Financial Officer.

On February 17, 2023, the board of directors of the Company appointed Mr. Zengqiang Lin as an independent director of the Company, effective February 17, 2023.

Non-Binding Letter of Intent with Fujian Shanzhiling Biological Technology Co., Ltd.

On October 8, 2018, the Company entered into a non-binding letter of intent with Fujian Shanzhiling Biological Technology Co., Ltd. (the “Acquirer”), a Chinese biotechnology product manufacturing corporation, whereby the Acquirer agreed to acquire 51% of the outstanding capital of the Company subject to certain adjustment provisions (the “Shanzhiling Acquisition”). The letter of intent has been terminated, and the Company is not pursuing this proposed acquisition any further.

Non-Binding Memorandum of Cooperation and Non-Binding Letter of Intent with Luoyang Ditiantai Agricultural Development Co., Ltd.

On October 18, 2018, the Company entered into a non-binding memorandum of cooperation with Luoyang Ditiantai Agricultural Development Co., Ltd. (“Ditiantai”), a Chinese industrial agricultural chain enterprise, and on October 19, 2018, the Company entered into a non-binding letter of intent with Ditiantai. Pursuant to the two documents, the Company agreed to acquire 51% of the outstanding capital of Ditiantai subject to certain adjustment provisions (the “Ditiantai Acquisition”). The letter of intent has been terminated, and the Company is not pursuing this proposed acquisition any further.

Share Transfer Agreement with Mr. Yu Xu

On January 17, 2019, Jiashierle (Xiamen) Healthcare Technology Co., Ltd. (“JSEL”), a limited liability company incorporated under the laws of the People’s Republic of China (the “PRC”), and an indirect wholly owned subsidiary of the Company, entered into a Share Transfer Agreement (the “Share Transfer Agreement”) with Mr. Yu Xu (“Mr. Xu”), an individual who owned 90% of the equity interests of Shanghai Kangzi Medical Technology Co., Ltd., a limited liability company organized under the laws of the PRC (“Kangzi”). Pursuant to the Share Transfer Agreement, Mr. Xu transferred 60% of the equity interests of Kangzi to JSEL on January 17, 2019 for the purpose of developing a joint venture in the business of selling medical equipment. In return, JSEL would fund the operations of Kangzi in proportion to its equity interest in Kangzi. Kangzi owned no assets and conducts no business operation of its own. As a result, as of January 17, 2019, Kangzi became an indirect subsidiary of the Company.

Share Cancellation Agreement with Mr. Ban Siong Ang

On March 15, 2019, the Company, with the approval of the Board, entered into a Share Cancellation Agreement (the “Share Cancellation Agreement”) with Mr. Ban Siong Ang, the President, Chief Executive Officer, and Chairman of the Board of the Company. Pursuant to the Share Cancellation Agreement, the Company and Mr. Ang agreed to cancel 109,006,861 shares of Common Stock previously issued to Mr. Ang.

Raspberry Purchase Agreement and Raspberry Juice Processing Agreement with Ditiantai

In March 2019, the Company entered into a Raspberry Purchase Agreement and a Raspberry Juice Processing Agreement with Ditiantai. Pursuant to these two agreements, the Company purchased six tons of raspberry from Ditiantai, which were processed by Ditiantai into raspberry juice and delivered to the Company. The Company then sold the raspberry juice to a corporate buyer and five individual buyers. The Company, however, does not plan to engage in the business of selling raspberry juice in the long term.

New Business Initiative – Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber Project

Since the beginning of 2019, Mr. Xu has led the core research and development team of Kangzi to develop and manufacture a new medical product, the Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber (the “Chamber”). Utilizing submillimeter waves, the Chamber is a medical equipment designed to treat cancer through cold nuclear fusion caused by cosmic ray muons in an enclosed chamber. Specifically, we believe that exposure to an appropriate amount of submillimeter waves could accelerate the generation of a large number of cosmic ray muons inside the human body and that such cosmic ray muons could further facilitate cold nuclear fusion, which could reverse the cancering process through which selenium is converted into nickel inside cells.

The team consists of researchers whom have extensive experience in medicine and physics. The lead scientist of the team, Mr. Xu, had served as the deputy chief engineer of the New Energy Base of the National Defense-Science and Technology Commission in 1995, as the chairman and chief scientist of Shanghai Guangcon New Energy Technology Co., Ltd. from 2011 to 2019, and the director of Shanghai Hengbian New Energy Research Institute from 2003 to 2008. In 2012, Mr. Xu was rewarded the “Harmony-Person of the Year in China” at the “2011 Harmony China Annual Summit” in Beijing and recognized as “Leaping China: One of the Most Influential People of the Year in 2011” by China International Economic and Technical Cooperation Promotion Association, China Elite Culture Promotion Association, and China Outstanding Chinese Merchants Association. In 2013, the Organizing Committee of Boau Forum on Asian SME Development awarded Mr. Xu “2013 China Economic Outstanding Contribution Award.”

Pursuant to the terms of the Share Transfer Agreement entered into by JSEL and Kangzi on January 17, 2019, JSEL has the right to monitor and manage all aspects of operation of Kangzi, including its research and development activities relating to the Chamber. As the development of the Chamber enters its final stage at Kangzi, JSEL started accepting pre-orders for the Chamber in September. Subsequently, on October 15 2019, JSEL entered into a clinical cooperation agreement (the “Clinical Cooperation Agreement”) with Shenzhen Saikun Biotechnology Co., Ltd. (“Saikun”). Pursuant to the Clinical Cooperation Agreement, Saikun agreed to pay JSEL 5.5 million RMB as the total preordering payment. 1.5 million RMB and 1.5 million RMB were delivered to JSEL respectively on September 7 and September 27, 2019. The parties are working on the timing for payment of the remaining 2.5 million RMB due under the Clinical Cooperation Agreement. In exchange, JSEL is obligated to purchase all the components of a Chamber from Kangzi, fully assemble it, and conduct a clinical trial with Saikun, third-party hospital partners, and patients using the Chamber. Specifically, after receiving the full amount of payment from Saikun, JSEL shall transport the Chamber to its preferred location, properly install it, and conduct a clinical trial that lasts at least one month. During the clinical trial, JSEL shall provide training sessions regarding the proper operation of the Chamber to Saikun’s employees. Both Saikun and JSEL are obligated to find third-party hospitals whom will agree to act as partners to co-host the clinical trial and patients whom will be voluntarily willing to undergo treatment provided by the Chamber. While Saikun is responsible for various expenses related to the clinical trial, JSEL is responsible for communicating with patients receiving treatment and other patient-related administrative matters. When JSEL determines that Saikun is capable of properly operating the Chamber and managing activities related to the Chamber, Saikun may request JSEL to move the Chamber to a location designated by Saikun and reinstall it. Furthermore, upon the successful completion of the clinical trial, JSEL shall provide Saikun governmental permits necessary for the operation of the Chamber, and Saikun shall operate the Chamber and provide related services to patients under the supervision of JSEL. In addition, JSEL shall transfer the right of using the Chamber and any beneficiary right affiliated to using the Chamber to Saikun upon receiving the full amount of payment from Saikun. JSEL, nevertheless, owns all the intellectual property rights affiliated with the Chamber. If the two parties decide to terminate the Clinical Cooperation Agreement prior to the expiration of the term, Saikun’s right of using the Chamber during the term is still effective as long as its use of the Chamber does not infringe any of JSEL’s intellectual property rights affiliated with the Chamber. The two parties agreed that the term of the Clinical Cooperation Agreement would not end until Kangzi successfully obtains permits issued by relevant government entities supervising development and sale of medical equipment.

To prepare for the mass production of Chambers, Kangzi is conducting clinical experiments to make further improvements on Chamber and adjusting features of the mass-production mold for Chamber. Kangzi is also in the process of obtaining official governmental permits from relevant government authorities to produce and sell Chambers on a national scale. As its long-term business strategy, Kangzi focuses on researching, developing, and manufacturing high-technology medical equipment while targeting both individual and institutional customers. It plans to massively manufacture Chambers in small and medium sizes, establish operation centers to sell Chambers in various cities across China, and initiate advertising and marketing campaigns on different media platforms. Kangzi will also monetize on services provided to customers who use Chambers and other medical products.

In addition to business activities related to Chamber, the Company will commit to the research, development, manufacturing, and sale of healthcare equipment and various health products containing natural plants, including cosmetics, nutritional supplements, and drugs. In the near future, the Company aims to standardize and internationalize the production and sale of healthcare equipment and health products, while increasing its brand awareness in the healthcare and consumer-product markets.

Corporate Structure

Currently, the Company owns 100% of HP TECHNOLOGY LIMITED, a British Virgin Islands business company incorporated on September 20, 2018. HP TECHNOLOGY LIMITED owns 100% of Heyu Healthcare Technology Limited, a Hong Kong company incorporated on March 29, 2018. Heyu Healthcare Technology Limited owns 100% of JSEL, which in turn holds 60% of Kangzi. The following diagram sets forth the structure of the Company as of the date of this Current Report:

Heyu Biological Technology Corp

↓ 100%

BVI offshore company
HP TECHNOLOGY LIMITED

↓ 100%

HK: Heyu Healthcare Technology Limited
和宇健康科技有限公司

↓ 100%

WOFE: Jasherle (Xiamen) Healthcare Technology Co., Ltd. 珈施尔乐（厦门）健康科技有限公司

↓ 60%

Shanghai Kangzi Medical Technology Co., Ltd.

Available Information

The Company expects to continue to file annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, proxy statements and other information with the SEC. Any materials filed by the Company with the SEC may be read and copied at the SEC’s Public Reference Room at 100 F Street, NE, Washington, D.C. 20549. Information on the operation of the SEC’s Public Reference Room is available by calling the SEC at 1-800-SEC-0330. The SEC maintains a website that contains annual, quarterly and current reports, proxy statements and other information that issuers (including the Company) file electronically with the SEC. The Internet address of the SEC’s website is http://www.sec.gov. The address of our principal executive offices and corporate offices is Room 903&904, Huli Building, 619 Sishui Street, Huli District, Xiamen City, Fujian Province, China, 361009. Our telephone number is (86) 158 5924 0902.

ITEM 1A. RISK FACTORS

Smaller reporting companies are not required to provide the information required by this item.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 2. PROPERTIES

We leased our principal executive offices and corporate offices which are located at Room 903&904, Huli Building, 619 Sishui Street, Huli District, Xiamen City, Fujian Province, China, 361009, the total gross floor area is approximately 755 square meters, or 8,126.75 square feet.

ITEM 3. LEGAL PROCEEDINGS

From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. There are currently no legal proceedings or claims that we believe will have a material adverse effect on our business, financial condition or operating results.

ITEM 4. MINE SAFETY DISCLOSURES

None.

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

There is limited public trading market for our Common Stock; our Common Stock is quoted on the OTC Pink Market under the symbol “HYBT.”

The market price of our Common Stock is subject to significant fluctuations in response to variations in our quarterly operating results, general trends in the market, and other factors, over many of which we have little or no control. In addition, broad market fluctuations, as well as general economic, business, and political conditions, may adversely affect the market for our Common Stock, regardless of our actual or projected performance. Trading in stocks quoted on the OTC Pink Market is often thin and is characterized by wide fluctuations in trading prices due to many factors that may have little to do with a company’s operations or business prospects. We cannot assure you that there will be a market for our Common Stock in the future.

The following table sets forth the quarterly high and low sales price per share of our Common Stock for the periods indicated. The prices represent inter-dealer quotations, which do not include retail mark-up, mark-down or commission and may not necessarily represent actual transactions.

FISCAL YEAR 2021	HIGH		LOW
First Quarter	$	0.0240	$	0.0057
Second Quarter		0.0200		0.0100
Third Quarter		0.0204		0.0030
Fourth Quarter		0.0030		0.0001

FISCAL YEAR 2022	HIGH		LOW
First Quarter	$	0.0003	$	0.0001
Second Quarter		0.0500		0.0003
Third Quarter		0.0098		0.0004
Fourth Quarter		0.0014		0.0004

As of March 22, 2023, the last sale price reported on the OTC Pink Market for our Common Stock was approximately $0.079 per share.

Dividend Policy

We have not paid any dividends on our Common Stock and do not intend to pay any dividends in the foreseeable future.

Stockholders of Record

As of March 23, 2023, we have 669 recorded holders of our Common Stock. This number excludes any estimate by us of the number of beneficial owners of shares held in street name, the accuracy of which cannot be guaranteed.

Effective August 11, 1993, the SEC adopted Rule 15g-9, which established the definition of a “penny stock,” for purposes relevant to the Company, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require: (i) that a broker or dealer approve a person’s account for transactions in penny stocks; and (ii) that the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased. In order to approve a person’s account for transactions in penny stocks, the broker or dealer must (i) obtain financial information and investment experience and objectives of the person; and (ii) make a reasonable determination that the transactions in penny stocks are suitable for that person and that person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks. The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prepared by the Commission relating to the penny stock market, which, in highlight form, (i) sets forth the basis on which the broker or dealer made the suitability determination; and (ii) states that the broker or dealer received a signed, written agreement from the investor prior to the transaction. Disclosure also has to be made about the risks of investing in penny stock in both public offerings and in secondary trading, and about commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.

Transfer Agent

The transfer agent for our capital stock is Standard Registrar and Transfer Company, Inc., located at 440 East 400 South, Suite 200, Salt Lake City, UT 84111. Their telephone number is (801) 571-8844.

Equity Compensation Plan Information

Currently, there is no equity compensation plan in place for the Company.

Recent Sales of Unregistered Securities

During the fiscal years ended December 31, 2022, 2021, and 2020, we did not have sales of unregistered securities other than those already disclosed in the quarterly reports on Form 10-Q in the fiscal years 2022, 2021, and 2020 and current affair reports on Form 8-K, and the following transaction.

ITEM 6. RESERVED

As a Smaller Reporting Company, as defined by Rule 12b-2 of the Exchange Act and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item.

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of financial condition and results of operations relates to the operations and financial condition reported in the consolidated financial statements of the Company thereto, which appear elsewhere in this Report, and should be read in conjunction with such financial statements and related notes included in this Report. Except for the historical information contained herein, the following discussion, as well as other information in this Report, contain “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the “safe harbor” created by those sections. Actual results and the timing of the events may differ materially from those contained in these forward-looking statements due to many factors, including those discussed in the “Forward-Looking Statements” set forth elsewhere in this Report.

Overview

Heyu Biological Technology Corporation (the “Company” or “we”) was incorporated in the state of Nevada on May 18, 1987, as Asphalt Associates, Inc. and changed its name to Pacific WebWorks in January 1999. From 1999 to 2016 the Company engaged in the development and distribution of web tools software, electronic business storefront hosting, and Internet payment systems for individuals and small to mid-sized businesses. On February 23, 2016, the Company filed a voluntary petition for bankruptcy in the U.S. Bankruptcy Court for the District of Utah, and soon afterwards ceased its business activities. On August 19, 2016 the Company proposed a Plan of Liquidation and on November 28, 2016, the Court entered an order confirming the Plan of Liquidation and establishing a Liquidating Trust. On December 28, 2016, all assets and liabilities of the Company were transferred to the Liquidating Trust.

On March 12, 2018, the Board, with the consent of the majority shareholder, approved a 1-for-464 reverse stock split. On April 11, 2018, the reverse split became effective.

On April 18, 2018, to fill the vacancies created by Mr. Masters’s resignations, Ban Siong Ang and Hung Seng Tan were elected as the directors of the Company. Mr. Ang was appointed as President, Chief Executive Officer, and Chairman of the Board of the Company. Mr. Tan was appointed as Executive Director of the Company. Ms. Wendy Wei Li was appointed as Chief Financial Officer. On February 28, 2021, Ms. Wendy Wei Li resigned from her position with the Company as the Chief Financial Officer. To fill the vacancies created by Ms. Wendy Wei Li’s resignation, Mr. Ang was appointed as the Chief Financial Officer. On November 30, 2021, Mr. Bo Lyu has been appointed as the Chief Financial Officer. On February 17, 2023, the board of directors of the Company appointed Mr. Zengqiang Lin as an independent director of the Company, effective 17, 2023

On September 25, 2018, the Financial Industry Regulatory Authority, Inc. (the “FINRA”) announced the Forward Split with an Effective Date of September 25, 2018 and a Pay Date of September 24, 2018. In connection with the Forward Split, no fractional shares are necessary to be issued, and stockholders do not need to present certificates for exchange. The Forward Split will be payable directly to each stockholder by the issuance of shares representing the split differential.

On October 8, 2018, the Company entered into a non-binding letter of intent with Fujian Shanzhiling Biological Technology Co., Ltd (the “Acquirer”), a Chinese biotechnology product manufacturing corporation, whereby the Acquirer agreed to acquire 51% of the outstanding capital of the Company subject to certain adjustment provisions (the “Shanzhiling Acquisition”). The closing of the Shanzhiling Acquisition is subject to customary terms and conditions, including, but not limited to, completion of due diligence, negotiation and execution of definitive transaction documents between the parties and the delivery of audited and unaudited financial statements of the Target as required under applicable rules of the Securities and Exchange Commission. In addition, completion of the transaction is subject to approval by our Board.

Liquidity and Capital Resources

The following chart provides a summary of our balance sheets on for the fiscal years ended December 31, 2022 and 2021, and should be read in conjunction with the financial statements, and notes thereto, included with this Report at Part II, Item 8, below.

Year ended December 31	2022			2021
Cash and cash equivalents	$	11,428		$	4,323
Other receivables, net	$	17,845		$	29,608
Advances to suppliers	$	3,131		$	3,446
Total current assets	$	32,404		$	37,377
Total assets	$	32,404		$	93,549
Accounts payable	$	16,150		$	17,356
Accrued expenses and other payable	$	285,081		$	283,874
Advances from customers	$	434,890		$	471,788
Related party payable	$	1,268,749		$	1,072,293
Total current liabilities	$	2,005,010		$	1,903,401
Total liabilities	$	2,005,010		$	1,903,401
Accumulated deficit	$	(19,886,700	)	$	(19,621,121	)
Total stockholders’ deficit	$	(1,972,606	)	$	(1,809,852	)

As of December 31, 2021, we had assets of $93,549, which mainly consisted of $29,608 in Other receivables, net and $56,172 in Operating lease right-of-use asset; we had liabilities of $1,903,401, which mainly consisted of $1,072,293 in Related party payables, $471,788 in Advances from customers, $283,874 in Accrued expenses and other payable and 58,073 in Operating lease liability - current portion; we had an accumulated deficit of $19,621,121.

As of December 31, 2022, we had assets of $32,404, which mainly consisted of $17,845 in Other receivables, net; we had liabilities of $2,005,010, which mainly consisted of $1,268,749 in Related party payables, $434,890 in Advances from customers, and $285,081 in Accrued expenses; we had an accumulated deficit of $19,886,700 .

Results of Operations

The following chart provides a summary of our results of operations for the fiscal years ended December 31, 2022 and 2021 and should be read in conjunction with the financial statements, and notes thereto, included with this Report at Part II, Item 8, below.

From the period of the Liquidation on December 28, 2016 to September 6, 2019, we had been a shell company without any significant assets or operations. Since September 7, 2019, we are no longer a shell company due to the business operation of Kangzi and the first amount of preordering payment received from Saikun. For a detailed description, please see “Overview” above.

	Fiscal Year ended December 31,
	2022			2021
Revenue – related parties, net	$	78,953		$	96,478
Total operating expenses		27,385			228,999
Loss from operations		(265,779	)		(162,836	)
Total other income (expense)		199			(184	)
Income tax		-			-
Net loss	$	(265,580	)	$	(163,020	)
Basic net loss per share	$	(0.00	)	$	(0.00	)

We had $78,953 in revenues in the fiscal year ended December 31, 2022 and $96,478 in revenues in the fiscal year ended December 31, 2021. Our expenses during the fiscal year ended December 31, 2022, were $317,347 , as compared to $228,999 for the fiscal year ended December 31, 2021. The increase in the expenses was mainly due to increase in agency expenses, consulting fees and other office expenditures. We will depend upon our shareholdersto make loans to the Company to meet any costs that may occur. All such advances will be interest-free loans or equity contributions. We have received customer prepayments for our new medical product and services pursuant to the Clinical Cooperation Agreement. When we start fulfilling our obligations under the Clinical Cooperation Agreement, we expect to see significant increase in revenue.

Going Concern

The accompanying financial statements are presented on a going concern basis. The Company’s financial condition raises substantial doubt about the Company’s ability to continue as a going concern. The Company had an accumulated deficit of $19,886,700 and a net loss of $265,580 for the fiscal year ended December 31, 2022.

Off-balance sheet arrangements

As of December 31, 2022 and 2021, we did not have any off-balance sheet arrangements.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Pursuant to Item 305(e) of Regulation S-K (§ 229.305(e)), the Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined by Rule 229.10(f)(1).

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The consolidated financial statements and supplementary data required with respect to this Item 8, and as identified in Item 15 of this Report, are included in this Report.

ITEM 9. CHANGES OF INDEPENDENT CERTIFYING ACCOUNTANT

None.

ITEM 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Management has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were not effective as a result of a material weakness primarily related to a lack of a sufficient number of personnel with appropriate training and experience in accounting principles generally accepted in the United States of America, or GAAP. To remediate the material weakness, our Chief Financial Officer, as a member of CPA Australia, hence a Certified Public Accountant in Australia, has attended professional trainings regarding applying GAAP on a regular basis. In the near future, we also intend to hire more personnel with sufficient training and experience in GAAP.

Management’s Annual Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such item is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, for the company. Internal control over financial reporting includes those policies and procedures that: (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of its management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.

Under the supervision and with the participation of our current chief executive officer we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2022, based on the framework set forth in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on our evaluation under this framework, current management concluded that our internal control over financial reporting was not effective as of the evaluation dates due to the same reasons illustrated in “Evaluation of Disclosure Controls and Procedures” above.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the fiscal year ended December 31, 2022, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within any company have been detected.

ITEM 9B. OTHER INFORMATION

None.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Not applicable.

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The following table sets forth information regarding each of our current directors and executive officers:

Name	Age	Position
Ban Siong Ang	49	Chairman of the Board, Chief Executive Officer, and President
Hung Seng Tan	62	Executive Director
Bo Lyu	44	Chief Financial Officer
Kwee Huwa Tan	59	Director
Stephan Truly Busch	70	Director
Senad Busatlic	44	Director
Zengqiang Lin	27	Director

Business Experience

The following is a brief account of the education and business experience of each director and executive officer of the Company: (1) such person’s name; (2) the year in which such person was first elected a director of the Company; (3) all positions and offices with the Company held by such person; (4) the business experience of such person during the past five years; (5) certain other directorships, if any, held by such person; and briefly discusses the specific experience, qualifications, attributes or skills that led to the conclusion that each such person should serve as a director for us.

Mr. Ban Siong Ang has been our Chairman of the Board, Chief Executive Officer, and President since April 18, 2018. Mr. Ang was appointed as the Group CEO and Managing Director of HEYU Leisure Holidays Corporation (“HEYU Leisure”) in 2014. He also served as interim CFO of HEYU Leisure prior to the joining of new CFO. He graduated from the University of Southern Queensland, Australia, in 1998 and completed his Doctor of Philosophy in International Finance (Honoris Causa) from Gideon Robert University in 2017. Upon his graduation from the University of Southern Queensland, he started his career and worked as Senior Officer in Bursa Malaysia Depository Sdn Bhd (formerly known as Kuala Lumpur Stock Exchange) between 1998 and 2004. From 2004 to 2009, he served as the Director and principal consultant for Golden Design Renovation and Construction Sdn Bhd. Between 2010 and 2011, he served as General Manager and Directors for E-World Films Production Limited, Big Mine (Hong Kong) Private Limited and Asia Morgan Foundation Financial Ltd. In 2012, he founded Heyu Group of Companies in China, Hong Kong, and Malaysia. Heyu Group of Companies are engaged in Leisure and Hotels management, club membership, Biotechnology, Finance and Investment, Food & Beverage, Brand Franchising, Advance Entertainment Technology, Event Management, Property Development and Management, land & real estate property development, etc. He is responsible for the formulation and implementation of the Heyu Group of Companies’ corporate strategies as well as in charge of the corporate finance and investment management aspects of the Group due to his acute knowledge with rich experience, strong commitment, innovative and dynamic personality. He obtained a few Professional Institution Fellowship recognitions from the United Kingdom and also as a member of “The Academic Council on the United Nations System (ACUNS)” in Canada. In view of Mr. Ang humanitarian contributions, he was certified as ASRIA CSR-CAP in recognizing his outstanding contributions to establish, promote and protect humanity, Peace, Culture Human resource development and Education for the well-being of human society through volunteerism. He was also bestowed the Royal Orders from the State of Pahang in Malaysia.

Mr. Hung Seng Tan has been our Executive Director since April 18, 2018. Mr. Tan was appointed as an Executive Director of HEYU Leisure from 2014 to March 2018. Between March 1980 and February 1984, he worked at Hotels and Restaurants in the United States of America. In June 1984, he started his own business venture in Malaysia and served as the Managing Director of Mesin Engineering Sdn Bhd in the field of quarry construction and trading business. Mr. Tan is a prominent hands-on specialist in town with 30 years’ experience in the quarry business (river and marine sand exploratory) and the earthworks construction business in Malaysia in which he has completed a few important infrastructure projects since 1984. He has been sitting on the Board of Directors of Mesin Engineering Sdn Bhd and Hang Seng Constructions in Malaysia since 1996. Mr. Tan’s individual qualifications and skills that led to the conclusion that he should serve as the Executive Director of our Company.

Mr. Bo Lyu has been our Chief Financial Officer since November 30, 2021. Prior to joining the Company, Mr. Bo Lyu served as financial controller of Building Dreamstar Technology Inc. from August 2020 to October 2021. From December 2017 to April 2019, Mr. Lyu served as the board secretary of Dragon Victory International Limited (Nasdaq: LYL). From 2014 to August 2017, Mr. Lyu served as the board secretary of Hailiang Education Group Inc. (Nasdaq: HLG). From 2009 to 2013, Mr. Lyu worked as an investment manager in Hailiang Group Co. Ltd., the then-parent company of Hailiang Education Group Inc., Zhejiang Hailiang Co. Ltd. (SSE Listed: 002203), and Hailiang International Holding Co. Ltd. (HKSE listed: 02336). Mr. Lyu received his bachelor’s degree in international investment from Wuhan University in 2001 and his master’s degree in Finance from the National Economics Department of Albert-Ludwigs-Universität Freiburg in 2008. He also holds the Certificate of Board Secretary from Shenzhen Stock Exchange and is a CFA II candidate. On February 28, 2021, Ms. Wendy Wei Li resigned from her position with the Company as the Chief Financial Officer.

Ms. Kwee Huwa Tan has been our director since October 12, 2018. She is a sales & marketing expert with a strong entrepreneurial spirit. She is the founder and Chief Executive Officer of Isbel Beauty Centre, a provider of primer skin care products, since its incorporation in 2012. Ms. Tan has also served as the Chief Advisor to Heyu Biological Technology Corporation (Xiamen) since 2013, where she was tasked with developing networking opportunities, analyzing profitability of products and market potentials, and cultivating prospective clients. Ms. Tan has also served as a director of Heyu Leisure and a member of its Nominating and Compensation Committee since 2017.

Mr. Stephan Truly Busch has been our director since July 1, 2019. He has served as a non-executive director of Heyu Leisure Holidays Corporation since March 2014, a Professor of Education and Linguistics of Manipur International University since May 2019, an accreditation officer of International Accreditation Organization since January 2014, an evaluation expert of California University Foreign Credentials Evaluation since 2010, a visiting professor of Universidad Empresarial de Costa Rica since December 2010, and an external professor at Ansted University since September 2011. Mr. Busch has been in the teaching profession for over 40 years at different schools in Germany, and is fluent in English, German, Bosnian, Croatian, and Serbian. From June 1973 to July 2014, Mr. Busch worked as a high school teacher at Lessing-Realschule, a school in Germany. Mr. Busch received his Ph.D. in Education in 2014 and his master’s degree in 2010 from Eastern Institute for Integrated Learning in Management University.

Dr. Senad Busatlic has been our director since July 1, 2019. Dr. Senad Busatlic is a sales and marketing expert with 10 years of experience in jump-starting sales, creating jobs, and capturing local, regional and international market trends. Dr, Busatlic has held leadership positions in the department of sales and marketing at several multinational companies, including being a Sales Manager at Orbico, an agent of Procter and Gamble, and Kraft Foods International from December 2001 to April 2003, a Sales Director at Megamix, an agent of Henkel, from April 2003 to April 2005, a Sales Director at Vispack from April 2005 to March 2007, a Marketing Manager at Coca Cola Hellenic Bottling Company from March till October 2007, and an Executive Director of Europapier-Hercegtisak from October 2007 to September 2009. Besides his professional experience, Dr. Busatlic has 10 years of academic research experience in B2B development. His master thesis and Ph.D. thesis were devoted to discussing strategic decision-making process in sales and marketing. Since 2008, he has published one book, three book chapters, 26 academic papers and 13 conference papers as author or co-author. In addition, since 2010, he has supervised 18 undergraduate thesis, 17 Master thesis, and three PhD dissertations. He is currently in the process of publishing a book with IGI Global, a leading international academic publisher headquartered in Pennsylvania, in the field of strategic management and another book in the field of operations management. Dr, Busatlic has had several positions at the International University of Sarajevo: from April 2012 to June 2017, Dr. Busatlic served as the head of Department of Economic and Management; from December 2014 to June 2016, Dr. Busatlic served as the coordinator of Leadership and Entrepreneurship Center; from January 2011 to April 2012, Dr. Busatlic served as the Vice Rector for Research and External Affairs; and from October 2010 to January 2011, Dr. Busatlic served as the Vice Dean for Faculty of Business Administration. Dr. Busatlic received his Ph.D. in Economics from Braca Karic University Belgrade in 2010.

Mr. Zengqiang Lin has been our independent director since February 17, 2023. Mr. Zengqiang Lin is the founder and has served as the chairman of the board of directors of Fuqing Hongchang Food Co., Ltd, a biotechnology-led food trading company since 2017. Prior to his current role, Mr. Lin served as the general manager of Fujian Yuweixiang Frozen Food Co., Ltd, a leading enterprise in the food operation and processing industry, from June 2016 to December 2017. He also held the position of manager at Xizang Changhui Construction Engineering Co., Ltd from July 2015 to May 2016. Mr. Lin has a wealth of experience in business operation, supply chain management, and market expansion. Mr. Lin graduated from Fuzhou Foreign Trade College.

Family Relationships

Our Executive Director, Mr. Tan, is the brother in law of our Chairman of the Board, Chief Executive Officer, and President, Mr. Ang. None of our other directors or executive officers has a family relationship as defined in Item 401 of Regulation S-K.

Involvement in Certain Legal Proceedings

To the best of our knowledge, none of our directors or executive officers has, during the past ten years:

●

been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);

●

had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time;

●

been subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or federal or state authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting, his involvement in any type of business, securities, futures, commodities, investment, banking, savings and loan, or insurance activities, or to be associated with persons engaged in any such activity;

●

been found by a court of competent jurisdiction in a civil action or by the SEC or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;

●

been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or

●

been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

Director Independence

After review of all relevant transactions or relationships between each director, or any of his or her family members, our Board has determined that Ms. Kwee Huwa Tan, Mr. Stephan Truly Busch, Mr. Senad Busatlic, and Mr. Zengqiang Lin are “independent directors” as defined under the NASDAQ listing standards. Pursuant to the applicable NASDAQ listing standards, an “independent director” refers to a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship which, in the opinion of the company’s board of directors, would interfere with the director’s exercise of independent judgment in carrying out the responsibilities of a director.

Board Meetings

The Board did not hold any meeting during the fiscal year ended December 31, 2022.

Committees of the Board of the Company

We do not have a standing nominating, compensation, or audit committee. Rather, our full Board performs the functions of these committees. We do not believe it is necessary for our Board to appoint such committees because the volume of matters that come before our Board for consideration permits the directors to give sufficient time and attention to such matters to be involved in all decision making. Additionally, because our Common Stock is not listed for trading or quotation on a national securities exchange, we are not required to have such committees.

Code of Ethics

We have not adopted a formal Code of Ethics. The Board evaluated the business of the Company and the number of employees and determined that since the business is operated by a small number of persons, general rules of fiduciary duty and federal and state criminal, business conduct, and securities laws are adequate ethical guidelines. In the event that our operations, employees, and directors expand in the future, we may take actions to adopt a formal Code of Ethics.

Compliance with Section 16(a) of the Securities Exchange Act

Section 16(a) of the Exchange Act requires our directors, executive officers, and greater than 10% beneficial owners of our Common Stock to file reports of ownership and changes in ownership with the SEC. Directors, executive officers, and greater than 10% stockholders are required by the rules and regulations of the SEC to furnish us with copies of all Section 16(a) reports they file. Based solely on the Company’s review of the copies of such forms it has received and written representations from certain reporting persons with respect to the period from January 1, 2021 through December 31, 2022, the Company believes that all of its officers, directors and greater than 10% beneficial owners, complied with all Section 16(a) filing requirements applicable to them during the Company’s most recently completed fiscal year.

ITEM 11. EXECUTIVE COMPENSATION

The following is a summary of the compensation we paid to our executive officers, for the fiscal years ended December 31, 2022 and 2021 for the Company.

Name and Principal Position	Year		Salary ($)		Bonus ($)		Stock Awards ($)		Option Awards ($)		Non-Equity Incentive Plan Compensation ($)		Nonqualified deferred compensation earnings ($)		All Other Compensation ($)		Total ($)
Ban Siong Ang,		2022	$	0		0		0		0		0		0		0		0
Chief Executive Officer and President⁽¹⁾		2021	$	0		0		0		0		0		0		0		0

Wendy Wei Li,		2022	$	0		0		0		0		0		0		0	$	0
Chief Financial Officer⁽²⁾		2021	$	0		0		0		0		0		0		0	$	0

Bo Lyu,		2022	$	0		0		0		0		0		0		0		0
Chief Financial Officer⁽³⁾		2021	$	NA		NA		NA		NA		NA		NA		NA		NA

(1)	Mr. Ang has served as the Chief Executive Officer and President of the Company since April 18, 2018.
(2)	Ms. Li served as the Chief Financial Officer of the Company from April 18, 2018 to February 28, 2021.
(3)	Mr. Lyu has served as the Chief Financial Officer of the Company since November 30, 2021

Aggregated Option Exercises and Fiscal Year-End Option Value Table

There were no stock options exercised since the date of our inception by the executive officers named in the Summary Compensation table above.

Long-Term Incentive Plan (“LTIP”) Awards Table

There were no awards made to any named executive officers in the last completed fiscal year under any LTIP.

Employment Agreements

The Company has entered into employment agreements with officers and other key employees.

Compensation of Directors

The following is a summary of the compensation we paid to our directors, for the fiscal years ended December 31, 2022 and 2021 for the Company.

Name	Year		Fees Earned or Paid in Cash ($)		Stock Awards ($)		Option Awards ($)		Non-Equity Incentive Plan Compensation ($)		Nonqualified deferred compensation earnings ($)		All Other Compensation ($)		Total ($)
Ban Siong Ang		2022	$	0		0		0		0		0		0		0
		2021	$	0		0		0		0		0		0		0

Kwee Huwa Tan		2022	$	0		0		0		0		0		0		0
		2021	$	0		0		0		0		0		0		0

Stephan Truly Busch		2022	$	0		0		0		0		0		0		0
		2021	$	0		0		0		0		0		0		0

Senad Busatlic		2022	$	0		0		0		0		0		0		0
		2021	$	0		0		0		0		0		0		0

We do not currently have an established policy to provide compensation to members of our Board for their services in that capacity.

Option Plan

We currently do not have a Stock Option Plan. However, we may to issue stock options pursuant to a Stock Option Plan in the future. Such stock options may be awarded to management, employees, and members of the Board and consultants of the Company.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

The following table provides the names and addresses of each person known to us to own more than 5% of our outstanding shares of common stock as of the date of this Report, and by the officers and directors, individually and as a group. Unless otherwise indicated herein, the address for the beneficial owners listed below is Room 903&904, Huli Building, 619 Sishui Street, Huli District, Xiamen City, Fujian Province, China, 361009.

Title of Class	Name and Address of Beneficial Owner⁽¹⁾	Amount⁽²⁾		Percent of Class⁽³⁾
	Directors and named Executive Officers
Common Stock	Ban Siong Ang		912,044,839		88.337	%

Common Stock	Hung Seng Tan		50,000,000		4.843	%

Common Stock	Bo Lyu		-		0	%

Common Stock	Kwee Huwa Tan EW15-5, Regency Condo, Jalan Pelangi, 41300 Klang, Selangor, Malaysia		8,000,000		0.775	%

Common Stock	All Directors and executive officers as a group (four persons)		970,044,839		93.955	%

	5% Security Holders
	N/A

(1)	Except as otherwise indicated, the persons named in this table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them, subject to community property laws where applicable and to the information contained in the footnotes to this table.
(2)	The number of shares of Common Stock reflect the 100-for-1 forward stock split effective on September 25, 2018.
(3)	Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment power with respect to securities. Pursuant to Rules 13d-3 and 13d-5 of the Exchange Act, beneficial ownership includes any shares as to which a stockholder has sole or shared voting power or investment power, and also any shares which the stockholder has the right to acquire within 60 days, including upon exercise of common shares purchase options or warrants.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

Related Person Transactions

Other than compensation agreements and other arrangements described herein and our transactions described below, since our inception there has not been, nor is there currently proposed, any transaction or series of similar transactions to which we were or will be a party:

●

in which the amount involved exceeded or will exceed $120,000; and

●

in which any current director, executive officer, holder of 5% or more of our shares of Common Stock on an as-converted basis or any member of their immediate family had or will have a direct or indirect material interest.

We had $96,478 revenues in the fiscal year ended December 31, 2021. A director of the Company extended a zero-interest loan for the Company to cover all the operation expenses totalling $162,410 for the year ended December 31, 2021. In the future, we might incur operating expenses without sufficient revenues, as we have just identified and determined to focus on the research, development, and manufacturing of healthcare equipment and health products. We will continue to depend upon our officers and directors to make loans to the Company to meet any costs that may occur. All such advances will be interest-free loans or equity contributions.

We had $78,953 revenues in the fiscal year ended December 31, 2022. Two shareholders of the Company extended a zero-interest loan for the Company to cover all the operation expenses totaling $196,457 for the year ended December 31, 2022. In the future, we might incur operating expenses without sufficient revenues, as we have just identified and determined to focus on the research, development, and manufacturing of healthcare equipment and health products. We will continue to depend upon our shareholders to make loans to the Company to meet any costs that may occur. All such advances will be interest-free loans or equity contributions.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

The following table provides information about the fees billed to us for professional services rendered by external accounting firms and auditing firms during fiscal years 2022 and 2021:

	2022		2021
Audit Fees	$	18,500	$	17,000
Audit-Related Fees		-		-
Tax Fees		-		-
All Other Fees		-
Total	$	18,500	$	17,000

Audit Fees. Audit fees consist of fees for the audit of our annual financial statements or services that are normally provided in connection with statutory and regulatory annual and quarterly filings or engagements.

Audit-Related Fees. Audit-related fees consist of fees for accounting, assurance and related services that are reasonably related to the performance of the audit or review of our financial statements and are not reported as Audit Fees.

Tax Fees. Tax fees consist of fees for tax compliance services, tax advice and tax planning. During the fiscal years of 2022 and 2021, the services provided in this category included assistance and advice in relation to the preparation of corporate income tax returns.

All Other Fees. Any other fees not included in Audit Fees, Audit-Related Fees, or Tax Fees.

Pre-Approval Policies and Procedures.

Our Board pre-approved all services to be provided by WWC, Professional Corporation.

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

(a) (1) Index to Financial Statements

Reports of Independent Registered Public Accounting Firms		F-1

Consolidated Balance Sheets		F-3

Consolidated Statements of Operations and Comprehensive Income		F-4

Consolidated Statements of Changes in Stockholders’ Equity (Deficit)		F-5

Consolidated Statements of Cash Flows		F-6

Notes to Consolidated Financial Statements		F-7

	(2)	ALL OTHER SCHEDULES HAVE BEEN OMITTED BECAUSE THEY ARE NOT APPLICABLE OR THE REQUIRED INFORMATION IS SHOWN IN THE FINANCIAL STATEMENTS OR NOTES THERETO.
	(3)	List of Exhibits

Exhibit		Exhibit Description
3.1⁽¹⁾		Articles of Incorporation.
3.2⁽²⁾		Certificate of Amendment.
3.3⁽³⁾		Certificate of Amendment.
3.4⁽⁴⁾		Certificate of Amendment.
3.5⁽⁵⁾		By-Laws.
3.6⁽⁶⁾		First Amendment to the By-Laws.
3.7⁽⁷⁾		Second Amendment to the By-Laws.
4.1*		Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.
10.1⁽⁸⁾		Share Cancellation Agreement by and between the Company and Ban Siong Ang dated March 15, 2019
10.2⁽⁹⁾		Director Offer Letter for a Director with Mr. Stephan Truly Busch dated April 16, 2019.
10.3⁽¹⁰⁾		Director Offer Letter for an Independent Director with Mr. Senad Busatlic dated April 16, 2019.
10.4⁽¹¹⁾		Clinical Cooperation Agreement entered into and by Jiashierle (Xiamen) Healthcare Technology Co., Ltd. And Shenzhen Saikun Biotechnology Co., Ltd., dated October 15, 2019.
16.1⁽¹²⁾		Letter from Haynie & Company dated October 29, 2018.
21.1⁽¹³⁾		Subsidiaries.

Exhibit		Exhibit Description
31.1*		Certification pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*		Certification pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101*		The following information from our 2022 Annual Report on Form 10-K, formatted in Inline XBRL: (i) Consolidated Statement of Income, (ii) Consolidated Statement of Comprehensive Income, (iii) Consolidated Balance Sheet, (iv) Consolidated Statement of Changes in Equity, (v) Consolidated Statement of Cash Flows, and (vi) the Notes to the Consolidated Financial Statements.
104*		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

(1)	Filed as an exhibit to the Company’s Registration Statement on Form 10-12G, as filed with the SEC on July 16, 1999, and incorporated herein by this reference.
(2)	Filed as an exhibit to the Company’s Form 8-K, as filed with the SEC on July 6, 2018, and incorporated herein by reference.
(3)	Filed as an exhibit to the Company’s Form 8-K, as filed with the SEC on August 3, 2018, and incorporated herein by reference.
(4)	Filed as an exhibit to the Company’s Form 8-K, as filed with the SEC on September 14, 2018, and incorporated herein by reference.
(5)	Filed as an exhibit to the Company’s Registration Statement on Form 10-12G, as filed with the SEC on July 16, 1999, and incorporated herein by this reference.
(6)	Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q, as filed with the SEC on November 13, 2018, and incorporated herein by this reference.
(7)	Filed as an exhibit to the Company’s Form 8-K, as filed with the SEC on July 1, 2019, and incorporated herein by reference.
(8)	Filed as an exhibit to the Company’s Form 8-K, as filed with the SEC on March 21, 2019, and incorporated herein by reference.
(9)	Filed as an exhibit to the Company’s Form 8-K, as filed with the SEC on July 1, 2019, and incorporated herein by reference.
(10)	Filed as an exhibit to the Company’s Form 8-K, as filed with the SEC on July 1, 2019, and incorporated herein by reference.
(11)	Filed as an exhibit to the Company’s Quarterly Report on Form 10-Q, as filed with the SEC on November 14, 2019, and incorporated herein by this reference.
(12)	Filed as an exhibit to the Company’s Form 8-K, as filed with the SEC on November 1, 2018, and incorporated herein by reference.
(13)	Filed as an exhibit to the Company’s Annual Report on Form 10-K, as filed with the SEC on March 28, 2019, and incorporated herein by this reference.

Filed herewith.

In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 34-47986, the certifications furnished in Exhibits 32.1 and 32.2 herewith are deemed to accompany this Form 10-K and will not be deemed filed for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act or the Exchange Act.

ITEM 16. FORM 10-K SUMMARY

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 23, 2023.

	HEYU BIOLOGICAL TECHNOLOGY CORPORATION

	By:	/s/ Ban Siong Ang
	Name:	Ban Siong Ang
	Title:	Chairman of the Board of Directors, Chief Executive Officer, and President (Principal Executive Officer and Director)

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the registrant and in the capacities, on March 23, 2023.

	/s/ Bo Lyu
	Name: Bo Lyu Chief Financial Officer
	(Principal Executive Officer)
	(Principal Financial Officer and Principal Accounting Officer)

	/s/ Kwee Huwa Tan
	Name: Kwee Huwa Tan Director

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To: The Board of Directors and Stockholders of

Heyu Biological Technology Corporation

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet of Heyu Biological Technology Corporation (the Company) as of December 31, 2022 and 2021, and the related consolidated statements of operations and comprehensive loss, statement of stockholders’ deficit, and cash flows for each of the two years in the period ended December 31, 2022, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

Explanatory Paragraph Regarding Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company had incurred substantial losses during the year, and has a working capital deficit, which raises substantial doubt about its ability to continue as a going concern. Management’s plan in regards to these matters are described in Note 2. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

F-1

Operating lease

As discussed in Note 6 to the financial statements, the Company recognized right-of-use assets and liabilities for certain operating lease. Determining the value of right-of-use assets and lease liabilities requires management to make judgements over key estimates and assumptions. Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. The audit engagement team performed procedures, which includes, among others, evaluating the accuracy of the calculation and assessing the inputs used in the calculation.

/s/ WWC, P.C.

WWC, P.C.

Certified Public Accountants

PCAOB ID: 1171

San Mateo, California

March 23, 2023

We have served as the Company’s auditor since 2018.

F-2

FINANCIAL STATEMENTS

Heyu Biological Technology Corporation

Consolidated Balance Sheets

	December 31,			December 31,
	2022			2021
ASSETS
Current Assets
Cash and cash equivalents	$	11,428		$	4,323
Other receivables, net		17,845			29,608
Advances to suppliers		3,131			3,446
Total current assets		32,404			37,377

Non-current Assets
Operating lease right-of-use asset		-			56,172
Total non-current assets		-			56,172

Total Assets	$	32,404		$	93,549

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Accounts payable	$	16,150		$	17,356
Accrued expenses and other payable		285,081			283,874
Advances from customers		434,890			471,788
Income tax and other taxes payable		140			17
Operating lease liability - current portion		-			58,073
Related party payables		1,268,749			1,072,293
Total current liabilities		2,005,010			1,903,401

Total Liabilities	$	2,005,010		$	1,903,401

Stockholders’ Deficit
Common stock ($0.001 par value, 2,000,000,000 shares authorized, 1,032,466,000 shares issued and outstanding as of December 31, 2022 and December 31, 2021)		1,032,466			1,032,466
Additional paid-in capital		17,149,050			17,149,050
Accumulated other comprehensive income		(52,298	)		(175,659	)
Accumulated deficit		(19,886,700	)		(19,621,121	)
Stockholders’ equity - HYBT and Subsidiaries		(1,757,482	)		(1,615,264	)
Noncontrolling interests in subsidiaries		(215,124	)		(194,588	)
Total stockholders’ deficit		(1,972,606	)		(1,809,852	)

Total Liabilities and Stockholders’ Deficit	$	32,404		$	93,549

F-3

Heyu Biological Technology Corporation

Consolidated Statements of Operations and Comprehensive Income

	For the year ended December 31,
	2022			2021
Revenue – related parties, net	$	78,953		$	96,478

Cost of Revenue		27,385			30,315

Gross Profit		51,568			66,163

Operating expenses
Selling expenses		404			1,284
Administrative expenses		316,943			227,715
Total operating expenses		317,347			228,999

Loss on operations		(265,779	)		(162,836	)

Other Income (Expenses)		200			(184	)

Loss on operations before income taxes		(265,579	)		(163,020	)

Income tax expense		-			-

Net Loss	$	(265,579	)	$	(163,020	)
Loss attributable to noncontrolling interests		-			-
Net loss attributable to HYBT shareholders		(265,579	)		(163,020	)

Other Comprehensive Income
Foreign currency translation adjustment		89,290			(90,821	)
Total Comprehensive Loss	$	(176,289	)	$	(253,841	)
Total comprehensive income attributable to noncontrolling interests		34,071			34,195
Total comprehensive loss attributable to HYBT shareholders		(142,218	)		(219,646	)

Net loss per share - basic and diluted	$	(0.00	)	$	(0.00	)

Weighted average shares - basic and diluted		1,032,466,000			1,032,466,000

F-4

Heyu Biological Technology Corporation

Consolidated Statements of Cash Flows

For the year Ended December 31,

	2022			2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(265,579	)		(163,020	)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in assets and liabilities
Accounts receivable		-			1,317
Other receivables, net		(5,115	)		20,205
Advance to suppliers		-			(101	)
Operating lease right-of-use asset		56,172			78,143
Accounts payable and accrued liabilities		15,986			(515	)
Accrued expenses and other payable		1,207			(10,359	)
Advances from customers		(36,898	)		12,205
Lease liability		(58,073	)		(79,019	)
Net cash used in operating activities		(292,300	)		(141,144	)

CASH FLOWS FROM INVESTING ACTIVITIES		-

CASH FLOWS FROM FINANCING ACTIVITIES					-
Proceeds from related party lending		330,598			162,410
Repayment to related party		(134,141	)
Net cash provided by financing activities		196,457			162,410

Effect of exchange rate changes on cash		102,948			(22,432	)

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		7,105			(1,166	)

CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD		4,323			5,489

CASH AND CASH EQUIVALENTS AT END OF PERIOD	$	11,428		$	4,323

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest	$	-		$	-
Cash paid for income tax	$	-		$	-

F-5

Heyu Biological Technology Corporation

Consolidated Statements of Stockholders’ Deficit

	Heyu Biological Shareholders’ Equity
	Common Stock				Additional		Accumulated Other						Non-
	Number of shares		Par value		Paid in Capital		Comprehensive Income			Accumulated Deficit			controlling Interest			Total
Balance at January 1, 2021		1,032,466,000		1,032,466		17,149,050		(119,033	)		(19,458,101	)		(228,783	)		(1,624,401	)
Foreign currency translation adjustment		-		-		-		(56,626	)		-			34,195			(22,431	)
Loss for the period		-		-		-		-			(163,020	)		-			(163,020	)
Balance at December 31, 2021		1,032,466,000	$	1,032,466	$	17,149,050	$	(175,659	)	$	(19,621,121	)	$	(194,588	)	$	(1,809,852	)

	Common Stock				Additional		Accumulated Other						Non-
	Number of shares		Par value		Paid in Capital		Comprehensive Income (Loss)			Accumulated Deficit			controlling Interest			Total
Balance at January 1, 2022		1,032,466,000		1,032,466		17,149,050		(175,659	)		(19,621,121	)		(194,588	)		(1,809,852	)
Foreign currency translation adjustment		-		-		-		123,361			-			(20,536	)		102,825
Loss for the period		-		-		-		-			(265,579	)		-			(265,579	)
Balance at December 31, 2022		1,032,466,000	$	1,032,466	$	17,149,050	$	(52,298	)	$	(19,886,700	)	$	(215,124	)	$	(1,972,606	)

The accompanying notes are an integral part of these consolidated financial statements.

F-6

Heyu Biological Technology Corporation

Notes to Consolidated Financial Statements

NOTE 1 – THE COMPANY AND SIGNIFICANT ACCOUNTING POLICIES

Heyu Biological Technology Corporation (the “Company”) was incorporated in the state of Nevada on May 18, 1987, as Asphalt Associates, Inc. and changed its name to Pacific WebWorks in January 1999. From 1999 to 2016 the Company engaged in the development and distribution of web tools software, electronic business storefront hosting, and Internet payment systems for individuals and small to mid-sized businesses. On February 23, 2016, the Company filed a voluntary petition for bankruptcy in the U.S. Bankruptcy Court for the District of Utah, and soon afterwards ceased its business activities. On August 19, 2016, the Company proposed a plan of liquidation and on November 28, 2016, the court entered an order confirming the plan of liquidation and establishing a liquidating trust. On December 28, 2016, all assets and liabilities of the Company were transferred to the liquidating trust.

On April 18, 2018, the Company entered into a share purchase agreement with Mr. Ban Siong Ang and Mr. Dan Masters (the “Share Purchase Agreement”), pursuant to which Mr. Ang acquired 1,021,051,700 shares, representing 98.91% of the issued and outstanding shares of common stock of the Company (“Common Stock”), from Mr. Masters for an aggregate purchase price of $335,000 (the “Share Purchase”). As a result of the Share Purchase, Dan Masters resigned from his positions as the President, Chief Executive Officer, Chief Financial Officer, Secretary and Chairman of the Board of the Company. Such resignations took place in connection with the closing of the Share Purchase and was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. Additionally, all debt due to Mr. Masters from the Company was cancelled as of the closing of the Share Purchase and recognized as contributed capital.

On April 18, 2018, to fill the vacancies created by Mr. Masters’ resignation, Ban Siong Ang and Hung Seng Tan were elected as the directors of the Company. Mr. Ang was appointed as President, Chief Executive Officer, and Chairman of the Board of the Company. Mr. Tan was appointed as the Executive Director of the Company. Ms. Wendy Li was appointed as the Chief Financial Officer of the Company. On February 28, 2021, Ms. Wendy Li resigned from her position with the Company as the Chief Financial Officer. To fill the vacancies created by Ms. Wendy Wei Li’s resignation, Mr. Ang was appointed as the Chief Financial Officer. On November 30, 2021, Mr. Bo Lyu has been appointed as the Chief Financial Officer.

On July 3, 2018, the Company changed its name to Heyu Biological Technology Corporation and applied for a new ticker symbol “HYBT”.

During 2018, the Company established the following subsidiaries: (1) HP Technology Limited, a British Virgin Islands business company incorporated on September 20, 2018, and (2) Heyu Healthcare Technology Limited, a Hong Kong company incorporated on March 29, 2018. On November 5, 2018, the Company acquired the following subsidiary: Jiashierle (Xiamen) Healthcare Technology Co., Ltd. (“JSEL”), a limited liability company incorporated under the laws of the People’s Republic of China (the “PRC”) on November 16, 2017.

On January 17, 2019, JSEL entered into a share transfer agreement (the “Share Transfer Agreement”) with Mr. Yu Xu (“Mr. Xu”), an individual with an address at No. 68 Chengde South Road, Qingpu District, Huaian City, Jiangsu Province, the PRC. Mr. Xu owned 90% of the equity interests of Shanghai Kangzi Medical Technology Co., Ltd., a limited liability company organized under the laws of the PRC (“Kangzi”). JSEL received 60% of the outstanding equity interest of Kangzi from Mr. Xu for the purpose of developing a joint venture in selling medical equipment. It was Mr. Xu and JSEL’s intention that JSEL would fund the operations of Kangzi in proportion to JSEL’s equity interest in Kangzi. At the time of the share transfer, Kangzi owned no assets and conducted no business operation.

Since the beginning of 2019, Mr. Xu has led the core research and development team of Kangzi to develop and manufacture a new medical product, the Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber (the “Chamber”). Utilizing submillimeter waves, the Chamber is a medical equipment designed to treat cancer through cold nuclear fusion caused by cosmic ray muons in an enclosed chamber. We believe that exposure to an appropriate amount of submillimeter waves would accelerate the generation of a large number of cosmic ray muons inside the human body and that such cosmic ray muons could further facilitate cold nuclear fusion, which could reverse the cancer by converting selenium into nickel inside cells.

F-7

Our team consists of researchers who have years of extensive experience in medicine and physics. The lead scientist of the team, Mr. Xu, had extensive professional experience in the aforementioned fields and has served as the deputy chief engineer of the New Energy Base of the National Defense-Science and Technology Commission in 1995, the chairman and chief scientist of Shanghai Guangzhui New Energy Technology Co., Ltd. from 2011 to 2019, and the director of Shanghai Hengbian New Energy Research Institute from 2003 to 2008. In 2012, Mr. Xu received the “Harmony-Person of the Year in China” award at the “2011 Harmony China Annual Summit” in Beijing. He was recognized as “Leaping China: One of the Most Influential People of the Year in 2011” by China International Economic and Technical Cooperation Promotion Association, China Elite Culture Promotion Association, and China Outstanding Chinese Merchants Association. Mr. Xu also received the “2013 China Economic Outstanding Contribution Award” from the Organizing Committee of Boau Forum on Asian SME Development.

Pursuant to the terms of the share transfer agreement entered into by JSEL and Kangzi on January 17, 2019, JSEL has the right to monitor and manage all aspects of operation of Kangzi, including its research and development activities relating to the Chamber. As the development of the Chamber enters its final stage, JSEL started accepting pre-orders for the Chamber in September 2019.

The outbreak of the novel coronavirus, commonly referred to as “COVID-19”, first found in mainland China, then in Asia and eventually throughout the world, has significantly affected business and manufacturing activities within China, including travel restrictions, widespread mandatory quarantines, and suspension of business activities within China. These measures have caused substantial disruptions to our business operations. We suspended our business operation in early February 2020 due to government mandates. We partially recovered our business operation on February 17, 2020, and on March 1, 2020, most of our staff members returned to the office and we fully resumed our business operations on the same day. Accordingly, our business, results of operations and financial condition were adversely affected. As of the date of this Report, Chinese industries have gradually resumed businesses as government officials started to ease the restrictive measures since April 2020. However, as most of our top management team is an overseas team, due to the international travel ban, we still operate under remote-working conditions, so the business of the Company is still recovering. Our management believes that our revenues will gradually improve as the epidemic and the travel ban are lifted.

On March 17, 2020, we entered into a business service cooperation agreement with Xiamen Qingda Intelligent Technology Co., Ltd., a wholly-owned subsidiary of Cross-strait Tsinghua Research Institute, pursuant to which we agreed to jointly improve the plant based disinfectant spray for treating skin infections and disinfecting wounds. The term of such agreement is three years, and can be renewed upon mutual agreement of both parties. The original plant based disinfectant spray was developed and owned by the Company, while the improved product shall be owned by both the Company and the Cross-strait Tsinghua Research Institute. The Cross-strait Tsinghua Research Institute will receive 2% of gross proceeds from the sales of such improved product.

Basis of Presentation

The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation.

F-8

As of December 31, 2022, the details of the consolidating subsidiaries are as follows:

Name of Company	Jurisdiction of Formation	Attributable equity interest %
HP Technology Limited	British Virgin Islands		100	%

Heyu Healthcare Technology Limited	Hong Kong		100	%

JSEL	PRC		100	%

Kangzi	PRC		60	%

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management believes that the estimates used in preparing the financial statements are reasonable and prudent; however, actual results could differ from these estimates. Significant estimates include the allowance for doubtful accounts, impairment assessments of goodwill, valuation of deferred tax assets, rebilling collections and certain accrued liabilities such as contingent liabilities. As of December 31, 2022, the Company considered the economic implications of the COVID-19 pandemic on its significant judgments and estimates. Given the impact and other unforeseen effects on the global economy from the COVID-19 pandemic, these estimates required increased judgment, and actual results could differ from these estimates.

Cash Equivalents

The Company considers all highly liquid debt instruments purchased with a maturity period of three months or less to be cash or cash equivalents. The carrying amounts reported in the accompanying consolidated balance sheets for cash and cash equivalents approximate their fair value. All of the Company’s cash that is held in bank accounts in the PRC and Hong Kong is not protected by Federal Deposit Insurance Corporation (“FDIC”) insurance or any other similar insurance in the PRC, or Hong Kong.

Accounts receivable and allowance for doubtful accounts

Accounts receivable are stated at the historical carrying amount net of allowance for doubtful accounts. The Company maintains an allowance for doubtful accounts which reflects its best estimate of amounts that potentially will not be collected. The Company determines the allowance for doubtful accounts taking into consideration various factors, including but not limited to historical collection experience and credit-worthiness of the debtors, as well as the age of the individual receivables balance. Additionally, the Company makes specific bad debt provisions based on any specific knowledge the Company has acquired that might indicate that an account is uncollectible. The facts and circumstances of each account may require the Company to use substantial judgment in assessing its collectability.

Inventories

Inventories consist of finished goods, work in process, and raw materials. Inventories are stated at the lower of cost or market value. The Company applies the weighted average cost method to its inventory.

F-9

Leases

The Company adopted Accounting Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02), as amended, which supersedes the lease accounting guidance under Topic 840, and generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use (ROU) assets on the balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements.

Operating leases are included in operating lease right-of-use (“ROU”) assets and short-term and long-term lease liabilities in our consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities in our consolidated balance sheets.

ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the leases do not provide an implicit rate, we use the industry incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

Adoption of the standard resulted in the initial recognition of $215,298 of ROU assets and $215,298 of lease liabilities on our consolidated balance sheet related to office space lease commitment on September 1, 2019.

Foreign Currency

For fiscal year 2021, the Company’s principal country of operations is the PRC. The accompanying consolidated financial statements are presented in US$. The functional currency of the Company is US$, and the functional currency of the Company’s subsidiaries is RMB. The consolidated financial statements are translated into US$ from RMB at year-end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Capital accounts are translated at their historical exchange rates when the capital transactions occurred. The resulting translation adjustments are recorded as a component of shareholders’ equity included in other comprehensive income. Gains and losses from foreign currency transactions are included in profit or loss.

	As of
	December 31, 2022		December 31, 2021
RMB: US$ exchange rate		6.8983		6.3588

	For the year ended December 31,
	2022		2021
RMB: US$ exchange rate		6.7279		6.4499

F-10

The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.

General and administrative costs

General and administrative expenses include personnel expenses for executive, finance, and internal support personnel. In addition, general and administrative expenses include fees for bad debt costs, professional legal and accounting services, insurance, office space, banking and merchant fees, and other overhead-related costs.

Income Taxes

The Company accounts for income taxes pursuant to ASC Topic 740, Income Taxes. Income taxes are provided on an asset and liability approach for financial accounting and reporting of income taxes. Any tax paid by subsidiaries during the year is recorded. Current tax is based on the profit or loss from ordinary activities adjusted for items that are non-assessable or disallowable for income tax purpose and is calculated using tax rates that have been enacted or substantively enacted at the balance sheet date. ASC Topic 740 also requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and the tax basis of assets and liabilities, and for the expected future tax benefit to be derived from tax losses and tax credit carry-forwards. ASC Topic 740 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Realization of deferred tax assets, including those related to the U.S. net operating loss carry-forwards, are dependent upon future earnings, if any, of which the timing and amount are uncertain.

The Company adopted ASC Topic 740-10-05, Income Tax, which provides guidance for recognizing and measuring uncertain tax positions. It prescribes a threshold condition that a tax position must meet for any of the benefits of the uncertain tax position to be recognized in the financial statements. It also provides accounting guidance on derecognizing, classification and disclosure of these uncertain tax positions.

The Company’s policy on classification of all interest and penalties related to unrecognized income tax positions, if any, is to present them as a component of income tax expense.

Capital Structure

The Company had 2,000,000,000 shares of common stock authorized, par value $0.001 per share, with 1,032,466,000 shares issued and outstanding as of December 31, 2022, and December 31, 2021.

Earnings (loss) per share

Basic net income (loss) per share of common stock attributable to common stockholders is calculated by dividing net income (loss) attributable to common stockholders by the weighted-average shares of common stock outstanding for the period. Potentially dilutive shares, which are based on the weighted-average shares of common stock underlying outstanding stock-based awards, warrants, options, or convertible debt using the treasury stock method or the if-converted method, as applicable, are included when calculating diluted net income (loss) per share of common stock attributable to common stockholders when their effect is dilutive.

F-11

Potential dilutive securities are excluded from the calculation of diluted EPS in loss periods as their effect would be antidilutive.

For the year ended December 31, 2022 and 2021, there were no potentially dilutive shares.

	For the year ended December 31,
	2022			2021
Statement of Operations Summary Information:
Net loss	$	(265,579	)	$	(163,020	)
Weighted-average common shares outstanding - basic and diluted		1,032,466,000			1,032,466,000
Net loss per share, basic and diluted	$	(0.00	)	$	(0.00	)

NOTE 2 – GOING CONCERN

During the year ended December 31, 2022, the Company was unable to generate cash flows sufficient to support its operations and was dependent on related party advances from the current controlling shareholder. In addition, the Company had experienced recurring net losses, and had an accumulated deficit of $19,886,700 and working capital deficit of $1,972,606 as of December 31, 2022. These factors raise doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.

There can be no assurance that sufficient funds required during the next year or thereafter will be generated from any future operations or that funds will be available from external sources such as debt or equity financings or other potential sources. If the Company is unable to raise capital from external sources when required, there will be a material adverse effect on its business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company’s existing stockholders. Management is now seeking an operating company with which to merge or acquire. In the foreseeable future, the Company will rely on related parties, such as its controlling shareholder, to provide advances to funds general corporate purposes and any potential acquisitions of profitable investments. There is no assurance, however, that the Company will achieve its objectives or goals.

NOTE 3 – CASH AND CASH EQUIVALENTS

Cash and cash equivalents consist of the following:

	As of December 31, 2022		As of December 31, 2021
Bank Deposits-China & HK		11,428		4,323
	$	11,428	$	4,323

F-12

NOTE 4 – OTHER RECEIVABLE

Other receivable consists of the following:

	As of December 31, 2022		As of December 31, 2021
Rental and POS machine deposits		13,954		15,603
Others		3,891		14,005
Less: Allowance for doubtful accounts		-		-
	$	17,845	$	29,608

Management periodically reviews account balance. If any indication occurs, the allowance for doubtful debts would be recognized. No such allowance has been recognized during the year ended December 31, 2022.

NOTE 5 – ADVANCES TO SUPPLIERS

Advances to suppliers consists of the following:

	As of December 31, 2022		As of December 31, 2021
Purchases of scientific research equipment		3,131		3,446
	$	3,131	$	3,446

NOTE 6 – OPERATING LEASE RIGHT-OF-USE ASSET AND LIABILITIES

On September 1, 2019, the Company entered in a lease agreement for office space, the right-of-use asset is recognized as following:

	As of December 31, 2022		As of December 31, 2021
Operating lease right-of-use asset		-		56,172
	$	-	$	56,172

F-13

Operating lease liability consist both current and noncurrent component as the following:

	As of December 31, 2022		As of December 31, 2021
Operating lease liability - current portion		-		58,073
Operating lease liability		-		-
	$	-	$	58,073

ASU 2016-02 requires that public companies use a secured incremental browning rate for the present value of lease payments when the rate implicit in the contract is not readily determinable. We determine a secured rate on a quarterly basis and update the weighted average discount rate accordingly. Lease terms and discount rate follow.

	December 31, 2022
Weighted Average Remaining Lease Term (Year)		-
Weighted Average Discount Rate		4.75	%

NOTE 7 – ADVANCES FROM CUSTOMERS

	As of December 31, 2022		As of December 31, 2021
Advances from customers⁽¹⁾		434,890		471,788
	$	434,890	$	471,788

⁽¹⁾

On October 15, 2019, JSEL entered into a clinical cooperation agreement (the “Clinical Cooperation Agreement”) with Shenzhen Saikun Biotechnology Co., Ltd. (“Saikun”). Pursuant to the Clinical Cooperation Agreement, Saikun agreed to pay JSEL 5.5 million RMB as the total preordering payment. 1.5 million RMB and 1.5 million RMB were delivered to JSEL respectively on September 7 and September 27, 2019. The parties are working on the timing for payment of the remaining 2.5 million RMB due under the Clinical Cooperation Agreement. In exchange, JSEL is obligated to purchase all the components of the Chamber from Kangzi, fully assemble it, and conduct a clinical trial with Saikun, third-party hospital partners, and patients using the Chamber. Specifically, after receiving the full amount of payment from Saikun, JSEL shall transport the Chamber to its preferred location, properly install it, and conduct a clinical trial that lasts at least one month.

F-14

NOTE 8 – ACCRUED EXPENSES AND OTHER PAYABLES

Accrued expenses and other payables consist of the following:

	As of December 31, 2022		As of December 31, 2021
Accrued payroll		155,078		166,337
Other Payables		130,003		117,537
	$	285,081	$	283,874

Accrued payroll includes all company employee payroll liabilities as of December 31, 2022, and other payables contains employee reimbursements.

NOTE 9 – RELATED PARTY TRANSACTIONS

As of December 31, 2022 and 2021, the Company owed related parties $ 1,268,749 and $1,072,293, respectively. As the Company has just started business activities in March 2019, all expenses incurred during this reporting period are paid by two of our shareholder, Mr. Hungseng Tan and Mr. Ban Siong Ang, who are also directors of the Company. Expenses mainly included auditing, consulting and legal advisory expenses, government registration expenses, and payrolls.

For the years ended December 31, 2022 and 2021, the Company earned revenues from related parties in the amount of $78,593 and $96,478, respectively.

NOTE 10 – EQUITY

The Company had not recorded any equity transactions during the year ended December 31, 2022.

The Company had not recorded any equity transactions during the year ended December 31, 2021.

NOTE 11 – INCOME TAXES

The Company is subject to U.S. Federal tax laws. The Company has not recognized an income tax benefit for its operating losses in the United States because the Company does not expect to commence active operations in the United States.

Heyu Healthcare Technology Limited was incorporated in Hong Kong and is subject to Hong Kong profits tax at a tax rate of 16.5%. Since Heyu Healthcare Technology Limited had no taxable income during the reporting period, it has not paid Hong Kong profits taxes. Heyu Healthcare Technology Limited has not recognized an income tax benefit for its operating losses in Hong Kong because the Company does not expect to commence active operations in Hong Kong.

The Company has been conducting and plans to continue to conduct its major operations in the PRC through JSEL in accordance with the relevant tax laws and regulations. The corporate income tax rate in China is 25%. The Company has not paid PRC profits taxes, since it had no taxable income during the reporting period.

F-15

EX-4.1 2 f10k2022ex4-1_heyubio.htm DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934.

Exhibit 4.1

DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO

SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

General

The following description summarizes the most important terms of our securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended. This summary does not purport to be complete and is qualified in its entirety by the provisions of our amended and restated Articles of Incorporation (“Articles of Incorporation”). For a complete description of our securities, you should refer to our Articles of Incorporation and the applicable provisions of Chapters 78 and 92A of the Nevada Revised Statutes (the “Nevada Statutes”).

We are incorporated as a Nevada company, and our affairs are governed by our Articles of Incorporation and the laws of the State of Nevada. As used in this section, “we,” “us,” “our,” and “the Company” mean Heyu Biological Technology Corporation and its successors, but not any of its subsidiaries.

Authorized Capital Stock

Under our Articles of Incorporation, our authorized capital stock consists of 2,000,000,000 shares of common stock, par value $0.001 per share. As of March 23, 2023, we had 1,032,466,000 shares of common stock outstanding, held of record by 669 stockholders. This number excludes any estimate by us of the number of beneficial owners of shares held in street name, the accuracy of which cannot be guaranteed.

Common Stock.

Our common stock is listed on The OTC Pink Market, under the symbol “HYBT.”

Voting. Holders of common stock are entitled to one vote per share. Holders of our common stock are not entitled to cumulative voting in the election of directors.

Dividends. Except as provided by law or in our articles of incorporation, the holders of common stock will be entitled to such cash dividends as may be declared from time to time by the board of directors of the Company (the “Board of Directors”) from funds available.

Liquidation. Upon liquidation, dissolution or winding up of the Company, the holders of common stock will be entitled to receive pro rata all assets available for distribution to such holders after payment of our liabilities.

Other Terms. Holders of common stock are not entitled to preemptive rights, nor is the common stock subject to redemption.

Provisions of our Articles of Incorporation and Bylaws with Anti-Takeover Implications

Certain provisions of our Articles of Incorporation and amended and restated bylaws (“Bylaws”) deal with matters of corporate governance and the rights of stockholders. Under our Articles of Incorporation, our Board of Directors may set the voting rights, preferences and other terms thereof. Our Bylaws provide that a special meeting of stockholders may be called only by the President, or by the President or Secretary at the request of a majority of the directors or stockholders owning not less than 25% of our issued and outstanding voting stock. Such provisions, together with certain provisions of the Nevada Statutes (see “Nevada Anti-Takeover Statutes”), could be deemed to have an anti-takeover effect and discourage takeover attempts not first approved by our Board of Directors. This may include takeovers that certain stockholders may deem to be in their best interest. Any such discouraging effect on takeover attempts could potentially depress the market price of our common stock or inhibit temporary fluctuations in the market price of our common stock that could result from actual or rumored takeover attempts.

Nevada Anti-Takeover Statutes

Business Combinations Act

We are subject to Nevada’s anti-takeover law because we have not opted out of the provisions of Sections 78.411-78.444 of the Nevada Statutes under the terms of our Articles of Incorporation. This law provides that specified persons who, together with affiliates and associates, own, or within two years did own, 10% or more of the outstanding voting stock of a corporation cannot engage in specified business combinations with the corporation for a period of two years after the date on which the person became an interested stockholder. The law defines the term “business combination” to encompass a wide variety of transactions with or caused by an interested stockholder, including mergers, asset sales and other transactions in which the interested stockholder receives or could receive a benefit on other than a pro rata basis with other stockholders. This provision may have an anti-takeover effect for transactions not approved in advance by our Board of Directors, including discouraging takeover attempts that might result in a premium over the market price for the shares of our common stock.

Control Share Statute

A corporation is subject to Nevada’s control share law if it has more than 200 stockholders, at least 100 of whom are stockholders of record and residents of Nevada, and if the corporation does business in Nevada, including through an affiliated corporation. This control share law may have the effect of discouraging corporate takeovers. We currently have less than 100 stockholders of record who are residents of Nevada.

The control share law focuses on the acquisition of a “controlling interest,” which means the ownership of outstanding voting shares that would be sufficient, but for the operation of the control share law, to enable the acquiring person to exercise the following proportions of the voting power of the corporation in the election of directors: (1) one-fifth or more but less than one-third; (2) one-third or more but less than a majority; or (3) a majority or more. The ability to exercise this voting power may be direct or indirect, as well as individual or in association with others.

The effect of the control share law is that an acquiring person, and those acting in association with that person, will obtain only such voting rights in the control shares as are conferred by a resolution of the stockholders of the corporation, approved at a special or annual meeting of stockholders. The control share law contemplates that voting rights will be considered only once by the other stockholders. Thus, there is no authority to take away voting rights from the control shares of an acquiring person once those rights have been approved. If the stockholders do not grant voting rights to the control shares acquired by an acquiring person, those shares do not become permanent non-voting shares. The acquiring person is free to sell the shares to others. If the buyer or buyers of those shares themselves do not acquire a controlling interest, the shares are not governed by the control share law.

If control shares are accorded full voting rights and the acquiring person has acquired control shares with a majority or more of the voting power, a stockholder of record, other than the acquiring person, who did not vote in favor of approval of voting rights, is entitled to demand fair value for such stockholder’s shares.

Transfer Agent

EX-31.1 3 f10k2022ex31-1_heyubio.htm CERTIFICATION

Exhibit 31.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Ban Siong Ang, certify that:

I have reviewed this report on Form 10-K of Heyu Biological Technology Corporation;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15I and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 23, 2023

/s/ Ban Siong Ang

Ban Siong Ang

Chairman of the Board of Directors,

Chief Executive Officer, and President
(Principal Executive Officer)

EX-31.2 4 f10k2022ex31-2_heyubio.htm CERTIFICATION

Exhibit 31.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Bo Lyu, certify that:

I have reviewed this report on Form 10-K of Heyu Biological Technology Corporation;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: March 23, 2023

	/s/ Bo Lyu
	Bo Lyu
	Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

EX-32.1 5 f10k2022ex32-1_heyubio.htm CERTIFICATION

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned hereby certifies, in the undersigned’s capacity as an officer of Heyu Biological Technology Corporation (the “Company”), for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1)	The Annual Report of the Company on Form 10-K for the year ended December 31, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 23, 2023

	/s/ Ban Siong Ang
	Ban Siong Ang
	Chairman of the Board of Directors, Chief Executive Officer, and President (Principal Executive Officer and Director)

The foregoing certification is being furnished solely pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) and is not being filed as part of a separate disclosure document.

EX-32.2 6 f10k2022ex32-2_heyubio.htm CERTIFICATION

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned hereby certifies, in his capacity as an officer of Heyu Biological Technology Corporation (the “Company”), for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1)	The Annual Report of the Company on Form 10-K for the year ended December 31, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 23, 2023

	/s/ Bo Lyu
	Bo Lyu
	Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)

GRAPHIC 7 image_001.jpg GRAPHIC begin 644 image_001.jpg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end GRAPHIC 8 image_002.jpg GRAPHIC begin 644 image_002.jpg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end EX-101.SCH 9 hybt-20221231.xsd XBRL SCHEMA FILE 001 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated Statements of Operations and Comprehensive Income link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Consolidated Statements of Stockholders’ Deficit link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - The Company and Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Cash and Cash Equivalents link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Other Receivable link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Advances to Suppliers link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Advances from Customers link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Accrued Expenses and Other Payables link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Equity link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - The Company and Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Cash and Cash Equivalents (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Other Receivable (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Advances to Suppliers (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Advances from Customers (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Accrued Expenses and Other Payables (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - The Company and Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - The Company and Significant Accounting Policies (Details) - Schedule of details of the consolidating subsidiaries link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - The Company and Significant Accounting Policies (Details) - Schedule of foreign currency transactions link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - The Company and Significant Accounting Policies (Details) - Schedule of potentially dilutive shares link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - The Company and Significant Accounting Policies (Details) - Schedule of potentially dilutive shares (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Going Concern (Details) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Other Receivable (Details) - Schedule of other receivable link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Advances to Suppliers (Details) - Schedule of advances to suppliers link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of right-of-use asset link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of operating lease liability link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of minimum lease payments link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Advances from Customers (Details) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Advances from Customers (Details) - Schedule of advances from Customers link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Accrued Expenses and Other Payables (Details) - Schedule of accrued expenses and other payables link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 10 hybt-20221231_cal.xml XBRL CALCULATION FILE EX-101.DEF 11 hybt-20221231_def.xml XBRL DEFINITION FILE EX-101.LAB 12 hybt-20221231_lab.xml XBRL LABEL FILE Total current assets Total non-current assets Total Assets Total current liabilities Total Liabilities Stockholders’ equity - HYBT and Subsidiaries Total stockholders’ deficit Balance Balance Total Liabilities and Stockholders’ Deficit Gross Profit Total operating expenses Loss on operations Loss on operations before income taxes Net Loss Net loss Loss for the period Net loss attributable to HYBT shareholders Total Comprehensive Loss Total comprehensive loss attributable to HYBT shareholders Net cash used in operating activities Net cash provided by financing activities NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS AT END OF PERIOD Balance (in Shares) Balance (in Shares) Equity Components [Axis] Ownership [Axis] Income Statement Location [Axis] Schedule of potentially dilutive shares [Abstract] Going Concern [Abstract] Geographical [Axis] Other Receivable [Abstract] Schedule of Other Receivable [Abstract] Advances to Suppliers [Abstract] Schedule of Advances to Suppliers [Abstract] Total Operating Lease Right-of-Use Asset and Liabilities [Abstract] Real Estate, Type of Property [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Schedule of Weighted Average Discount Rate [Abstract] Advances from Customers [Abstract] Schedule of Advances From Customers [Abstract] Schedule of Accrued Expenses and Other Payables [Abstract] Stockholders' Equity Note [Abstract] Document Type Document Annual Report Current Fiscal Year End Date Document Period End Date Document Fiscal Year Focus Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company ICFR Auditor Attestation Flag Entity Shell Company Entity Public Float Entity Common Stock, Shares Outstanding Auditor Name Auditor Firm ID Auditor Location Amendment Flag Document Fiscal Period Focus Entity Central Index Key ASSETS Current Assets Cash and cash equivalents Other receivables, net Advances to suppliers Non-current Assets Operating lease right-of-use asset Total LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities Accounts payable Accrued expenses and other payable Advances from customers Income tax and other taxes payable Operating lease liability - current portion Related party payables Stockholders’ Deficit Common stock ($0.001 par value, 2,000,000,000 shares authorized, 1,032,466,000 shares issued and outstanding as of December 31, 2022 and December 31, 2021) Common stock, par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Additional paid-in capital Accumulated other comprehensive income Accumulated deficit Noncontrolling interests in subsidiaries Revenue – related parties, net Cost of Revenue Operating expenses Selling expenses Administrative expenses Other Income (Expenses) Loss attributable to noncontrolling interests Other Comprehensive Income Net loss per share - basic and diluted (in Dollars per share) Net loss per share, basic and diluted Net loss per share - diluted Net loss per share diluted Weighted average shares - basic and diluted (in Shares) Weighted-average common shares outstanding - basic and diluted Weighted average shares - diluted Weighted-average common shares outstanding - diluted CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to reconcile net loss to net cash used in operating activities: Change in assets and liabilities Accounts payable and accrued liabilities Accrued expenses and other payable CASH FLOWS FROM INVESTING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from related party lending Effect of exchange rate changes on cash SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Cash paid for interest Cash paid for income tax Foreign currency translation adjustment Income tax expense Foreign currency translation adjustment Total comprehensive income attributable to noncontrolling interests Accounts receivable Other receivables, net Advance to suppliers Operating lease right-of-use asset Advances from customers Lease liability Repayment to related party Common Stock Additional Paid in Capital Accumulated Other Comprehensive Income Accumulated Deficit Non - controlling Interest THE COMPANY AND SIGNIFICANT ACCOUNTING POLICIES Schedule of details of the consolidating subsidiaries Name of Company Jurisdiction of Formation Attributable equity interest % Schedule of foreign currency transactions RMB: US$ exchange rate Schedule of potentially dilutive shares Statement of Operations Summary Information: Net loss GOING CONCERN CASH AND CASH EQUIVALENTS Schedule of cash and cash equivalents Cash and cash equivalents OTHER RECEIVABLE Schedule of other receivable Rental and POS machine deposits Others Other receivables, net EX-101.PRE 13 hybt-20221231_pre.xml XBRL PRESENTATION FILE XML 14 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2022	Mar. 23, 2023	Jun. 30, 2022
Document Information Line Items
Entity Registrant Name	HEYU BIOLOGICAL TECHNOLOGY CORPORATION
Trading Symbol	None
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		1,032,466,000
Entity Public Float			$ 1,961,685.4
Amendment Flag	false
Entity Central Index Key	0001086303
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
ICFR Auditor Attestation Flag	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	000-26731
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	87-0627910
Entity Address, Address Line One	Room 903&904
Entity Address, Address Line Two	Huli Building
Entity Address, Address Line Three	619 Sishui Street
Entity Address, City or Town	Xiamen City
Entity Address, Country	CN
Entity Address, Postal Zip Code	361009
City Area Code	(86)
Local Phone Number	158 5924 0902
Title of 12(b) Security	None
Security Exchange Name	NONE
Entity Interactive Data Current	Yes
Auditor Name	WWC, P.C.
Auditor Firm ID	1171
Auditor Location	San Mateo, California

XML 15 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current Assets
Cash and cash equivalents	$ 11,428	$ 4,323
Other receivables, net	17,845	29,608
Advances to suppliers	3,131	3,446
Total current assets	32,404	37,377
Non-current Assets
Operating lease right-of-use asset		56,172
Total non-current assets		56,172
Total Assets	32,404	93,549
Current Liabilities
Accounts payable	16,150	17,356
Accrued expenses and other payable	285,081	283,874
Advances from customers	434,890	471,788
Income tax and other taxes payable	140	17
Operating lease liability - current portion		58,073
Related party payables	1,268,749	1,072,293
Total current liabilities	2,005,010	1,903,401
Total Liabilities	2,005,010	1,903,401
Stockholders’ Deficit
Common stock ($0.001 par value, 2,000,000,000 shares authorized, 1,032,466,000 shares issued and outstanding as of December 31, 2022 and December 31, 2021)	1,032,466	1,032,466
Additional paid-in capital	17,149,050	17,149,050
Accumulated other comprehensive income	(52,298)	(175,659)
Accumulated deficit	(19,886,700)	(19,621,121)
Stockholders’ equity - HYBT and Subsidiaries	(1,757,482)	(1,615,264)
Noncontrolling interests in subsidiaries	(215,124)	(194,588)
Total stockholders’ deficit	(1,972,606)	(1,809,852)
Total Liabilities and Stockholders’ Deficit	$ 32,404	$ 93,549

XML 16 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	1,032,466,000	1,032,466,000
Common stock, shares outstanding	1,032,466,000	1,032,466,000

XML 17 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations and Comprehensive Income - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue – related parties, net	$ 78,953	$ 96,478
Cost of Revenue	27,385	30,315
Gross Profit	51,568	66,163
Operating expenses
Selling expenses	404	1,284
Administrative expenses	316,943	227,715
Total operating expenses	317,347	228,999
Loss on operations	(265,779)	(162,836)
Other Income (Expenses)	200	(184)
Loss on operations before income taxes	(265,579)	(163,020)
Income tax expense
Net Loss	(265,579)	(163,020)
Loss attributable to noncontrolling interests
Net loss attributable to HYBT shareholders	(265,579)	(163,020)
Other Comprehensive Income
Foreign currency translation adjustment	89,290	(90,821)
Total Comprehensive Loss	(176,289)	(253,841)
Total comprehensive income attributable to noncontrolling interests	34,071	34,195
Total comprehensive loss attributable to HYBT shareholders	$ (142,218)	$ (219,646)
Net loss per share - basic and diluted (in Dollars per share)	$ 0	$ 0
Weighted average shares - basic and diluted (in Shares)	1,032,466,000	1,032,466,000

XML 18 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations and Comprehensive Income (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net loss per share - diluted	$ 0.00	$ 0.00
Weighted average shares - diluted	1,032,466,000	1,032,466,000

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

XML 19 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (265,579)	$ (163,020)
Change in assets and liabilities
Accounts receivable		1,317
Other receivables, net	(5,115)	20,205
Advance to suppliers		(101)
Operating lease right-of-use asset	56,172	78,143
Accounts payable and accrued liabilities	15,986	(515)
Accrued expenses and other payable	1,207	(10,359)
Advances from customers	(36,898)	12,205
Lease liability	(58,073)	(79,019)
Net cash used in operating activities	(292,300)	(141,144)
Proceeds from related party lending	330,598	162,410
Repayment to related party	(134,141)
Net cash provided by financing activities	196,457	162,410
Effect of exchange rate changes on cash	102,948	(22,432)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	7,105	(1,166)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	4,323	5,489
CASH AND CASH EQUIVALENTS AT END OF PERIOD	11,428	4,323
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for interest
Cash paid for income tax

XML 20 R7.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Stockholders’ Deficit - USD ($)	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Income	Accumulated Deficit	Non - controlling Interest	Total
Balance at Dec. 31, 2020	$ 1,032,466	$ 17,149,050	$ (119,033)	$ (19,458,101)	$ (228,783)	$ (1,624,401)
Balance (in Shares) at Dec. 31, 2020	1,032,466,000
Foreign currency translation adjustment			(56,626)		34,195	(22,431)
Loss for the period				(163,020)		(163,020)
Balance at Dec. 31, 2021	$ 1,032,466	17,149,050	(175,659)	(19,621,121)	(194,588)	(1,809,852)
Balance (in Shares) at Dec. 31, 2021	1,032,466,000
Foreign currency translation adjustment			123,361		(20,536)	102,825
Loss for the period				(265,579)		(265,579)
Balance at Dec. 31, 2022	$ 1,032,466	$ 17,149,050	$ (52,298)	$ (19,886,700)	$ (215,124)	$ (1,972,606)
Balance (in Shares) at Dec. 31, 2022	1,032,466,000

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

+ Details

- Definition

Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(3)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 5
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(2)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 2
-Subparagraph (a)(3)(iii)(03)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(3)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333

Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333

+ Details

XML 21 R8.htm IDEA: XBRL DOCUMENT

The Company and Significant Accounting Policies

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

THE COMPANY AND SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 – THE COMPANY AND SIGNIFICANT ACCOUNTING POLICIES

On July 3, 2018, the Company changed its name to Heyu Biological Technology Corporation and applied for a new ticker symbol “HYBT”.

Since the beginning of 2019, Mr. Xu has led the core research and development team of Kangzi to develop and manufacture a new medical product, the Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber (the “Chamber”). Utilizing submillimeter waves, the Chamber is a medical equipment designed to treat cancer through cold nuclear fusion caused by cosmic ray muons in an enclosed chamber. We believe that exposure to an appropriate amount of submillimeter waves would accelerate the generation of a large number of cosmic ray muons inside the human body and that such cosmic ray muons could further facilitate cold nuclear fusion, which could reverse the cancer by converting selenium into nickel inside cells.

Basis of Presentation

As of December 31, 2022, the details of the consolidating subsidiaries are as follows:

Name of Company	Jurisdiction of Formation	Attributable equity interest %
HP Technology Limited	British Virgin Islands		100	%

Heyu Healthcare Technology Limited	Hong Kong		100	%

JSEL	PRC		100	%

Kangzi	PRC		60	%

Use of Estimates

Cash Equivalents

Accounts receivable and allowance for doubtful accounts

Inventories

Leases

Foreign Currency

	As of
	December 31, 2022		December 31, 2021
RMB: US$ exchange rate		6.8983		6.3588

	For the year ended December 31,
	2022		2021
RMB: US$ exchange rate		6.7279		6.4499

General and administrative costs

Income Taxes

The Company’s policy on classification of all interest and penalties related to unrecognized income tax positions, if any, is to present them as a component of income tax expense.

Capital Structure

The Company had 2,000,000,000 shares of common stock authorized, par value $0.001 per share, with 1,032,466,000 shares issued and outstanding as of December 31, 2022, and December 31, 2021.

Earnings (loss) per share

Potential dilutive securities are excluded from the calculation of diluted EPS in loss periods as their effect would be antidilutive.

For the year ended December 31, 2022 and 2021, there were no potentially dilutive shares.

	For the year ended December 31,
	2022			2021
Statement of Operations Summary Information:
Net loss	$	(265,579	)	$	(163,020	)
Weighted-average common shares outstanding - basic and diluted		1,032,466,000			1,032,466,000
Net loss per share, basic and diluted	$	(0.00	)	$	(0.00	)

XML 22 R9.htm IDEA: XBRL DOCUMENT

Going Concern

12 Months Ended

Dec. 31, 2022

Going Concern [Abstract]

GOING CONCERN

NOTE 2 – GOING CONCERN

XML 23 R10.htm IDEA: XBRL DOCUMENT

Cash and Cash Equivalents

12 Months Ended

Dec. 31, 2022

Cash and Cash Equivalents [Abstract]

CASH AND CASH EQUIVALENTS

NOTE 3 – CASH AND CASH EQUIVALENTS

Cash and cash equivalents consist of the following:

	As of December 31, 2022		As of December 31, 2021
Bank Deposits-China & HK		11,428		4,323
	$	11,428	$	4,323

XML 24 R11.htm IDEA: XBRL DOCUMENT

Other Receivable

12 Months Ended

Dec. 31, 2022

Other Receivable [Abstract]

OTHER RECEIVABLE

NOTE 4 – OTHER RECEIVABLE

Other receivable consists of the following:

	As of December 31, 2022		As of December 31, 2021
Rental and POS machine deposits		13,954		15,603
Others		3,891		14,005
Less: Allowance for doubtful accounts		-		-
	$	17,845	$	29,608

XML 25 R12.htm IDEA: XBRL DOCUMENT

Advances to Suppliers

12 Months Ended

Dec. 31, 2022

Advances to Suppliers [Abstract]

ADVANCES TO SUPPLIERS

NOTE 5 – ADVANCES TO SUPPLIERS

Advances to suppliers consists of the following:

	As of December 31, 2022		As of December 31, 2021
Purchases of scientific research equipment		3,131		3,446
	$	3,131	$	3,446

XML 26 R13.htm IDEA: XBRL DOCUMENT

Operating Lease Right-of-Use Asset and Liabilities

12 Months Ended

Dec. 31, 2022

Operating Lease Right-of-Use Asset and Liabilities [Abstract]

OPERATING LEASE RIGHT-OF-USE ASSET AND LIABILITIES

NOTE 6 – OPERATING LEASE RIGHT-OF-USE ASSET AND LIABILITIES

On September 1, 2019, the Company entered in a lease agreement for office space, the right-of-use asset is recognized as following:

	As of December 31, 2022		As of December 31, 2021
Operating lease right-of-use asset		-		56,172
	$	-	$	56,172

Operating lease liability consist both current and noncurrent component as the following:

	As of December 31, 2022		As of December 31, 2021
Operating lease liability - current portion		-		58,073
Operating lease liability		-		-
	$	-	$	58,073

	December 31, 2022
Weighted Average Remaining Lease Term (Year)		-
Weighted Average Discount Rate		4.75	%

XML 27 R14.htm IDEA: XBRL DOCUMENT

Advances from Customers

12 Months Ended

Dec. 31, 2022

Advances from Customers [Abstract]

ADVANCES FROM CUSTOMERS

NOTE 7 – ADVANCES FROM CUSTOMERS

	As of December 31, 2022		As of December 31, 2021
Advances from customers⁽¹⁾		434,890		471,788
	$	434,890	$	471,788

⁽¹⁾

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

+ Details

XML 28 R15.htm IDEA: XBRL DOCUMENT

Accrued Expenses and Other Payables

12 Months Ended

Dec. 31, 2022

Payables and Accruals [Abstract]

ACCRUED EXPENSES AND OTHER PAYABLES

NOTE 8 – ACCRUED EXPENSES AND OTHER PAYABLES

Accrued expenses and other payables consist of the following:

	As of December 31, 2022		As of December 31, 2021
Accrued payroll		155,078		166,337
Other Payables		130,003		117,537
	$	285,081	$	283,874

Accrued payroll includes all company employee payroll liabilities as of December 31, 2022, and other payables contains employee reimbursements.

XML 29 R16.htm IDEA: XBRL DOCUMENT

Related Party Transactions

12 Months Ended

Dec. 31, 2022

RELATED PARTY TRANSACTIONS

NOTE 9 – RELATED PARTY TRANSACTIONS

For the years ended December 31, 2022 and 2021, the Company earned revenues from related parties in the amount of $78,593 and $96,478, respectively.

XML 30 R17.htm IDEA: XBRL DOCUMENT

Equity

12 Months Ended

Dec. 31, 2022

Stockholders' Equity Note [Abstract]

EQUITY

NOTE 10 – EQUITY

The Company had not recorded any equity transactions during the year ended December 31, 2022.

The Company had not recorded any equity transactions during the year ended December 31, 2021.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

XML 31 R18.htm IDEA: XBRL DOCUMENT

Income Taxes

12 Months Ended

Dec. 31, 2022

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 11 – INCOME TAXES

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 32 R19.htm IDEA: XBRL DOCUMENT

Accounting Policies, by Policy (Policies)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

As of December 31, 2022, the details of the consolidating subsidiaries are as follows:

Name of Company	Jurisdiction of Formation	Attributable equity interest %
HP Technology Limited	British Virgin Islands		100	%

Heyu Healthcare Technology Limited	Hong Kong		100	%

JSEL	PRC		100	%

Kangzi	PRC		60	%

Use of Estimates

Use of Estimates

Cash Equivalents

Cash Equivalents

Accounts receivable and allowance for doubtful accounts

Accounts receivable and allowance for doubtful accounts

Inventories

Inventories

Leases

Leases

Foreign Currency

Foreign Currency

	As of
	December 31, 2022		December 31, 2021
RMB: US$ exchange rate		6.8983		6.3588

	For the year ended December 31,
	2022		2021
RMB: US$ exchange rate		6.7279		6.4499

General and administrative costs

General and administrative costs

Income Taxes

Income Taxes

The Company’s policy on classification of all interest and penalties related to unrecognized income tax positions, if any, is to present them as a component of income tax expense.

Capital Structure

Capital Structure

The Company had 2,000,000,000 shares of common stock authorized, par value $0.001 per share, with 1,032,466,000 shares issued and outstanding as of December 31, 2022, and December 31, 2021.

Earnings (loss) per share

Earnings (loss) per share

Potential dilutive securities are excluded from the calculation of diluted EPS in loss periods as their effect would be antidilutive.

For the year ended December 31, 2022 and 2021, there were no potentially dilutive shares.

	For the year ended December 31,
	2022			2021
Statement of Operations Summary Information:
Net loss	$	(265,579	)	$	(163,020	)
Weighted-average common shares outstanding - basic and diluted		1,032,466,000			1,032,466,000
Net loss per share, basic and diluted	$	(0.00	)	$	(0.00	)

XML 33 R20.htm IDEA: XBRL DOCUMENT

The Company and Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2022

Accounting Policies [Abstract]

Schedule of details of the consolidating subsidiaries

Name of Company	Jurisdiction of Formation	Attributable equity interest %
HP Technology Limited	British Virgin Islands		100	%

Heyu Healthcare Technology Limited	Hong Kong		100	%

JSEL	PRC		100	%

Kangzi	PRC		60	%

Schedule of foreign currency transactions

	As of
	December 31, 2022		December 31, 2021
RMB: US$ exchange rate		6.8983		6.3588

	For the year ended December 31,
	2022		2021
RMB: US$ exchange rate		6.7279		6.4499

Schedule of potentially dilutive shares

	For the year ended December 31,
	2022			2021
Statement of Operations Summary Information:
Net loss	$	(265,579	)	$	(163,020	)
Weighted-average common shares outstanding - basic and diluted		1,032,466,000			1,032,466,000
Net loss per share, basic and diluted	$	(0.00	)	$	(0.00	)

XML 34 R21.htm IDEA: XBRL DOCUMENT

Cash and Cash Equivalents (Tables)

12 Months Ended

Dec. 31, 2022

Cash and Cash Equivalents [Abstract]

Schedule of cash and cash equivalents

	As of December 31, 2022		As of December 31, 2021
Bank Deposits-China & HK		11,428		4,323
	$	11,428	$	4,323

XML 35 R22.htm IDEA: XBRL DOCUMENT

Other Receivable (Tables)

12 Months Ended

Dec. 31, 2022

Other Receivable [Abstract]

Schedule of other receivable

	As of December 31, 2022		As of December 31, 2021
Rental and POS machine deposits		13,954		15,603
Others		3,891		14,005
Less: Allowance for doubtful accounts		-		-
	$	17,845	$	29,608

XML 36 R23.htm IDEA: XBRL DOCUMENT

Advances to Suppliers (Tables)

12 Months Ended

Dec. 31, 2022

Advances to Suppliers [Abstract]

Schedule of advances to suppliers

	As of December 31, 2022		As of December 31, 2021
Purchases of scientific research equipment		3,131		3,446
	$	3,131	$	3,446

XML 37 R24.htm IDEA: XBRL DOCUMENT

Operating Lease Right-of-Use Asset and Liabilities (Tables)

12 Months Ended

Dec. 31, 2022

Operating Lease Right-of-Use Asset and Liabilities [Abstract]

Schedule of right-of-use asset

	As of December 31, 2022		As of December 31, 2021
Operating lease right-of-use asset		-		56,172
	$	-	$	56,172

Schedule of operating lease liability

	As of December 31, 2022		As of December 31, 2021
Operating lease liability - current portion		-		58,073
Operating lease liability		-		-
	$	-	$	58,073

Schedule of minimum lease payments

	December 31, 2022
Weighted Average Remaining Lease Term (Year)		-
Weighted Average Discount Rate		4.75	%

XML 38 R25.htm IDEA: XBRL DOCUMENT

Advances from Customers (Tables)

12 Months Ended

Dec. 31, 2022

Advances from Customers [Abstract]

Schedule of advances from customers

	As of December 31, 2022		As of December 31, 2021
Advances from customers⁽¹⁾		434,890		471,788
	$	434,890	$	471,788

⁽¹⁾

XML 39 R26.htm IDEA: XBRL DOCUMENT

Accrued Expenses and Other Payables (Tables)

12 Months Ended

Dec. 31, 2022

Payables and Accruals [Abstract]

Schedule of accrued expenses and other payables

	As of December 31, 2022		As of December 31, 2021
Accrued payroll		155,078		166,337
Other Payables		130,003		117,537
	$	285,081	$	283,874

XML 40 R27.htm IDEA: XBRL DOCUMENT

The Company and Significant Accounting Policies (Details) - USD ($)	1 Months Ended
	Mar. 17, 2020	Jan. 17, 2019	Apr. 18, 2018	Dec. 31, 2022	Dec. 31, 2021	Sep. 01, 2019
The Company and Significant Accounting Policies (Details) [Line Items]
Equity interests percentage		90.00%
Gross proceeds percentage	2.00%
ROU assets (in Dollars)						$ 215,298
Lease liabilities (in Dollars)						$ 215,298
Common stock shares authorized				2,000,000,000	2,000,000,000
Common stock, par value (in Dollars per share)				$ 0.001	$ 0.001
Number of shares issued and outstanding				1,032,466,000	1,032,466,000
Share Purchase Agreement [Member]
The Company and Significant Accounting Policies (Details) [Line Items]
Purchaser acquired shares			1,021,051,700
Percentage of issued and outstanding shares of common stock			98.91%
Aggregate purchase amount (in Dollars)			$ 335,000
JSEL [Member]
The Company and Significant Accounting Policies (Details) [Line Items]
Outstanding equity interest percentage		60.00%

XML 41 R28.htm IDEA: XBRL DOCUMENT

The Company and Significant Accounting Policies (Details) - Schedule of details of the consolidating subsidiaries	12 Months Ended
	Dec. 31, 2022
HP Technology Limited [Member]
The Company and Significant Accounting Policies (Details) - Schedule of details of the consolidating subsidiaries [Line Items]
Name of Company	HP Technology Limited
Jurisdiction of Formation	British Virgin Islands
Attributable equity interest %	100.00%
Heyu Healthcare Technology Limited [Member]
The Company and Significant Accounting Policies (Details) - Schedule of details of the consolidating subsidiaries [Line Items]
Name of Company	Heyu Healthcare Technology Limited
Jurisdiction of Formation	Hong Kong
Attributable equity interest %	100.00%
JSEL [Member]
The Company and Significant Accounting Policies (Details) - Schedule of details of the consolidating subsidiaries [Line Items]
Name of Company	JSEL
Jurisdiction of Formation	PRC
Attributable equity interest %	100.00%
Kangzi [Member]
The Company and Significant Accounting Policies (Details) - Schedule of details of the consolidating subsidiaries [Line Items]
Name of Company	Kangzi
Jurisdiction of Formation	PRC
Attributable equity interest %	60.00%

XML 42 R29.htm IDEA: XBRL DOCUMENT

The Company and Significant Accounting Policies (Details) - Schedule of foreign currency transactions	Dec. 31, 2022	Dec. 31, 2021
The Company and Significant Accounting Policies (Details) - Schedule of foreign currency transactions [Line Items]
RMB: US$ exchange rate	6.8983	6.3588
Foreign Currency [Member]
The Company and Significant Accounting Policies (Details) - Schedule of foreign currency transactions [Line Items]
RMB: US$ exchange rate	6.7279	6.4499

XML 43 R30.htm IDEA: XBRL DOCUMENT

The Company and Significant Accounting Policies (Details) - Schedule of potentially dilutive shares - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Statement of Operations Summary Information:
Net loss	$ (265,579)	$ (163,020)
Weighted-average common shares outstanding - basic and diluted	1,032,466,000	1,032,466,000
Net loss per share, basic and diluted	$ 0	$ 0

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

XML 44 R31.htm IDEA: XBRL DOCUMENT

The Company and Significant Accounting Policies (Details) - Schedule of potentially dilutive shares (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule of potentially dilutive shares [Abstract]
Weighted-average common shares outstanding - diluted	1,032,466,000	1,032,466,000
Net loss per share diluted	$ 0.00	$ 0.00

- Definition

+ References

+ Details

XML 45 R32.htm IDEA: XBRL DOCUMENT

Going Concern (Details)	Dec. 31, 2022 USD ($)
Going Concern [Abstract]
Accumulated deficit amount	$ 19,886,700
Working capital deficit	$ 1,972,606

XML 46 R33.htm IDEA: XBRL DOCUMENT

Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 11,428	$ 4,323
Bank Deposits-China & HK [Member]
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 11,428	$ 4,323

XML 47 R34.htm IDEA: XBRL DOCUMENT

Other Receivable (Details) - Schedule of other receivable - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Schedule of Other Receivable [Abstract]
Rental and POS machine deposits	$ 13,954	$ 15,603
Others	3,891	14,005
Less: Allowance for doubtful accounts
Other receivables, net	$ 17,845	$ 29,608

XML 48 R35.htm IDEA: XBRL DOCUMENT

Advances to Suppliers (Details) - Schedule of advances to suppliers - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Schedule of Advances to Suppliers [Abstract]
Purchases of scientific research equipment	$ 3,131	$ 3,446
Total	$ 3,131	$ 3,446

XML 49 R36.htm IDEA: XBRL DOCUMENT

Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of right-of-use asset - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of right-of-use asset [Line Items]
Total		$ 56,172
Office Space [Member]
Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of right-of-use asset [Line Items]
Total		$ 56,172

XML 50 R37.htm IDEA: XBRL DOCUMENT

Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of operating lease liability - Rights of use liability [Member] - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of operating lease liability [Line Items]
Operating lease liability - current portion		$ 58,073
Operating lease liability
Total		$ 58,073

XML 51 R38.htm IDEA: XBRL DOCUMENT

Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of minimum lease payments	Dec. 31, 2022
Schedule of Weighted Average Discount Rate [Abstract]
Weighted Average Remaining Lease Term(Year)
Weighted Average Discount Rate	4.75%

XML 52 R39.htm IDEA: XBRL DOCUMENT

Advances from Customers (Details)			1 Months Ended	12 Months Ended
Advances from Customers (Details)	Oct. 15, 2019 CNY (¥)	Sep. 07, 2019 USD ($)	Sep. 27, 2019 USD ($)	Dec. 31, 2022 USD ($)
Advances from Customers [Abstract]
Total preordering payment		$ 1.5	$ 1.5
Parties payment				$ 2.5
Agreed to pay amount (in Yuan Renminbi) \| ¥	¥ 5.5

XML 53 R40.htm IDEA: XBRL DOCUMENT

Advances from Customers (Details) - Schedule of advances from Customers - USD ($)

Dec. 31, 2022

Dec. 31, 2021

Schedule of Advances From Customers [Abstract]

Advances from customers

^[1]

$ 434,890

$ 471,788

Total

$ 434,890

$ 471,788

[1]

XML 54 R41.htm IDEA: XBRL DOCUMENT

Accrued Expenses and Other Payables (Details) - Schedule of accrued expenses and other payables - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Schedule of Accrued Expenses and Other Payables [Abstract]
Accrued payroll	$ 155,078	$ 166,337
Other Payables	130,003	117,537
Total accounts payable and accrued expenses	$ 285,081	$ 283,874

XML 55 R42.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details) - USD ($)	12 Months Ended
Related Party Transactions (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Related Party Transactions [Abstract]
Related party owed	$ 1,268,749	$ 1,072,293
Revenues from related parties	$ 78,593	$ 96,478

- Definition

Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

+ Details

- Definition

Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07.1(c))
-URI https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

XML 56 R43.htm IDEA: XBRL DOCUMENT

Income Taxes (Details)	12 Months Ended
Income Taxes (Details)	Dec. 31, 2022
Hong Kong [Member]
Income Taxes (Details) [Line Items]
Income tax rate	16.50%
China [Member]
Income Taxes (Details) [Line Items]
Income tax rate	25.00%

XML 57 f10k2022_heyubiological_htm.xml IDEA: XBRL DOCUMENT 0001086303 2022-01-01 2022-12-31 0001086303 2022-06-30 0001086303 2023-03-23 0001086303 2022-12-31 0001086303 2021-12-31 0001086303 2021-01-01 2021-12-31 0001086303 2020-12-31 0001086303 us-gaap:CommonStockMember 2020-12-31 0001086303 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001086303 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001086303 us-gaap:RetainedEarningsMember 2020-12-31 0001086303 us-gaap:NoncontrollingInterestMember 2020-12-31 0001086303 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001086303 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001086303 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001086303 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001086303 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0001086303 us-gaap:CommonStockMember 2021-12-31 0001086303 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001086303 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001086303 us-gaap:RetainedEarningsMember 2021-12-31 0001086303 us-gaap:NoncontrollingInterestMember 2021-12-31 0001086303 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001086303 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001086303 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001086303 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001086303 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0001086303 us-gaap:CommonStockMember 2022-12-31 0001086303 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001086303 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001086303 us-gaap:RetainedEarningsMember 2022-12-31 0001086303 us-gaap:NoncontrollingInterestMember 2022-12-31 0001086303 hybt:SharePurchaseAgreementMember 2018-04-02 2018-04-18 0001086303 hybt:SharePurchaseAgreementMember 2018-04-18 0001086303 2019-01-01 2019-01-17 0001086303 hybt:JSELMember 2019-01-01 2019-01-17 0001086303 2020-03-01 2020-03-17 0001086303 2019-09-01 0001086303 hybt:HPTechnologyLimitedMember 2022-01-01 2022-12-31 0001086303 hybt:HeyuHealthcareTechnologyLimitedMember 2022-01-01 2022-12-31 0001086303 hybt:JSELMember 2022-01-01 2022-12-31 0001086303 hybt:KangziMember 2022-01-01 2022-12-31 0001086303 us-gaap:ForeignCurrencyGainLossMember 2022-12-31 0001086303 us-gaap:ForeignCurrencyGainLossMember 2021-12-31 0001086303 hybt:BankDepositsChinaAndHKMember 2022-12-31 0001086303 hybt:BankDepositsChinaAndHKMember 2021-12-31 0001086303 srt:OtherPropertyMember 2022-12-31 0001086303 srt:OtherPropertyMember 2021-12-31 0001086303 hybt:RightsOfUseLiabilityMember 2022-12-31 0001086303 hybt:RightsOfUseLiabilityMember 2021-12-31 0001086303 2019-09-01 2019-09-07 0001086303 2019-09-01 2019-09-27 0001086303 2019-10-01 2019-10-15 0001086303 hybt:HKMember 2022-01-01 2022-12-31 0001086303 country:CN 2022-01-01 2022-12-31 iso4217:USD shares iso4217:USD shares pure iso4217:CNY 10-K true 2022-12-31 --12-31 2022 false 000-26731 HEYU BIOLOGICAL TECHNOLOGY CORPORATION NV 87-0627910 Room 903&904 Huli Building 619 Sishui Street Xiamen City CN 361009 (86) 158 5924 0902 None None No No Yes Yes Non-accelerated Filer true false false false 1961685.4 1032466000 WWC, P.C. 1171 San Mateo, California

11428

4323

17845 29608

3131

3446

32404

37377

56172

32404

93549

16150

17356

285081

283874

434890

471788

140

58073

1268749

1072293

2005010

1903401

2005010

1903401

0.001

2000000000

1032466000

1032466

17149050

-52298

-175659

-19886700

-19621121

-1757482

-1615264

-215124

-194588

-1972606

-1809852

32404

93549

78953

96478

27385

30315

51568

66163

404 1284

316943

227715

317347

228999

-265779

-162836

200

-184

-265579

-163020

-265579

-163020

-265579

-163020

-89290

90821

-176289

-253841

-34071

-34195

-142218

-219646

1032466000

-265579

-163020

-1317

5115

-20205

101

-56172 -78143

15986

-515

1207

-10359

36898 -12205 58073 79019

-292300

-141144

330598

162410

134141

196457

162410

102948

-22432

7105

-1166

4323

5489

11428

4323

1032466000

1032466

17149050

-119033

-19458101

-228783

-1624401

-56626

34195

-22431

-163020

1032466000

1032466

17149050

-175659

-19621121

-194588

-1809852

1032466000

1032466

17149050

-175659

-19621121

-194588

-1809852

123361

-20536

102825

-265579

1032466000

1032466

17149050

-52298

-19886700

-215124

-1972606

NOTE 1 – THE COMPANY AND SIGNIFICANT ACCOUNTING POLICIES Heyu Biological Technology Corporation (the “Company”) was incorporated in the state of Nevada on May 18, 1987, as Asphalt Associates, Inc. and changed its name to Pacific WebWorks in January 1999. From 1999 to 2016 the Company engaged in the development and distribution of web tools software, electronic business storefront hosting, and Internet payment systems for individuals and small to mid-sized businesses. On February 23, 2016, the Company filed a voluntary petition for bankruptcy in the U.S. Bankruptcy Court for the District of Utah, and soon afterwards ceased its business activities. On August 19, 2016, the Company proposed a plan of liquidation and on November 28, 2016, the court entered an order confirming the plan of liquidation and establishing a liquidating trust. On December 28, 2016, all assets and liabilities of the Company were transferred to the liquidating trust. On April 18, 2018, the Company entered into a share purchase agreement with Mr. Ban Siong Ang and Mr. Dan Masters (the “Share Purchase Agreement”), pursuant to which Mr. Ang acquired 1,021,051,700 shares, representing 98.91% of the issued and outstanding shares of common stock of the Company (“Common Stock”), from Mr. Masters for an aggregate purchase price of $335,000 (the “Share Purchase”). As a result of the Share Purchase, Dan Masters resigned from his positions as the President, Chief Executive Officer, Chief Financial Officer, Secretary and Chairman of the Board of the Company. Such resignations took place in connection with the closing of the Share Purchase and was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. Additionally, all debt due to Mr. Masters from the Company was cancelled as of the closing of the Share Purchase and recognized as contributed capital. On April 18, 2018, to fill the vacancies created by Mr. Masters’ resignation, Ban Siong Ang and Hung Seng Tan were elected as the directors of the Company. Mr. Ang was appointed as President, Chief Executive Officer, and Chairman of the Board of the Company. Mr. Tan was appointed as the Executive Director of the Company. Ms. Wendy Li was appointed as the Chief Financial Officer of the Company. On February 28, 2021, Ms. Wendy Li resigned from her position with the Company as the Chief Financial Officer. To fill the vacancies created by Ms. Wendy Wei Li’s resignation, Mr. Ang was appointed as the Chief Financial Officer. On November 30, 2021, Mr. Bo Lyu has been appointed as the Chief Financial Officer. On July 3, 2018, the Company changed its name to Heyu Biological Technology Corporation and applied for a new ticker symbol “HYBT”. During 2018, the Company established the following subsidiaries: (1) HP Technology Limited, a British Virgin Islands business company incorporated on September 20, 2018, and (2) Heyu Healthcare Technology Limited, a Hong Kong company incorporated on March 29, 2018. On November 5, 2018, the Company acquired the following subsidiary: Jiashierle (Xiamen) Healthcare Technology Co., Ltd. (“JSEL”), a limited liability company incorporated under the laws of the People’s Republic of China (the “PRC”) on November 16, 2017. On January 17, 2019, JSEL entered into a share transfer agreement (the “Share Transfer Agreement”) with Mr. Yu Xu (“Mr. Xu”), an individual with an address at No. 68 Chengde South Road, Qingpu District, Huaian City, Jiangsu Province, the PRC. Mr. Xu owned 90% of the equity interests of Shanghai Kangzi Medical Technology Co., Ltd., a limited liability company organized under the laws of the PRC (“Kangzi”). JSEL received 60% of the outstanding equity interest of Kangzi from Mr. Xu for the purpose of developing a joint venture in selling medical equipment. It was Mr. Xu and JSEL’s intention that JSEL would fund the operations of Kangzi in proportion to JSEL’s equity interest in Kangzi. At the time of the share transfer, Kangzi owned no assets and conducted no business operation. Since the beginning of 2019, Mr. Xu has led the core research and development team of Kangzi to develop and manufacture a new medical product, the Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber (the “Chamber”). Utilizing submillimeter waves, the Chamber is a medical equipment designed to treat cancer through cold nuclear fusion caused by cosmic ray muons in an enclosed chamber. We believe that exposure to an appropriate amount of submillimeter waves would accelerate the generation of a large number of cosmic ray muons inside the human body and that such cosmic ray muons could further facilitate cold nuclear fusion, which could reverse the cancer by converting selenium into nickel inside cells. Our team consists of researchers who have years of extensive experience in medicine and physics. The lead scientist of the team, Mr. Xu, had extensive professional experience in the aforementioned fields and has served as the deputy chief engineer of the New Energy Base of the National Defense-Science and Technology Commission in 1995, the chairman and chief scientist of Shanghai Guangzhui New Energy Technology Co., Ltd. from 2011 to 2019, and the director of Shanghai Hengbian New Energy Research Institute from 2003 to 2008. In 2012, Mr. Xu received the “Harmony-Person of the Year in China” award at the “2011 Harmony China Annual Summit” in Beijing. He was recognized as “Leaping China: One of the Most Influential People of the Year in 2011” by China International Economic and Technical Cooperation Promotion Association, China Elite Culture Promotion Association, and China Outstanding Chinese Merchants Association. Mr. Xu also received the “2013 China Economic Outstanding Contribution Award” from the Organizing Committee of Boau Forum on Asian SME Development. Pursuant to the terms of the share transfer agreement entered into by JSEL and Kangzi on January 17, 2019, JSEL has the right to monitor and manage all aspects of operation of Kangzi, including its research and development activities relating to the Chamber. As the development of the Chamber enters its final stage, JSEL started accepting pre-orders for the Chamber in September 2019. The outbreak of the novel coronavirus, commonly referred to as “COVID-19”, first found in mainland China, then in Asia and eventually throughout the world, has significantly affected business and manufacturing activities within China, including travel restrictions, widespread mandatory quarantines, and suspension of business activities within China. These measures have caused substantial disruptions to our business operations. We suspended our business operation in early February 2020 due to government mandates. We partially recovered our business operation on February 17, 2020, and on March 1, 2020, most of our staff members returned to the office and we fully resumed our business operations on the same day. Accordingly, our business, results of operations and financial condition were adversely affected. As of the date of this Report, Chinese industries have gradually resumed businesses as government officials started to ease the restrictive measures since April 2020. However, as most of our top management team is an overseas team, due to the international travel ban, we still operate under remote-working conditions, so the business of the Company is still recovering. Our management believes that our revenues will gradually improve as the epidemic and the travel ban are lifted. On March 17, 2020, we entered into a business service cooperation agreement with Xiamen Qingda Intelligent Technology Co., Ltd., a wholly-owned subsidiary of Cross-strait Tsinghua Research Institute, pursuant to which we agreed to jointly improve the plant based disinfectant spray for treating skin infections and disinfecting wounds. The term of such agreement is three years, and can be renewed upon mutual agreement of both parties. The original plant based disinfectant spray was developed and owned by the Company, while the improved product shall be owned by both the Company and the Cross-strait Tsinghua Research Institute. The Cross-strait Tsinghua Research Institute will receive 2% of gross proceeds from the sales of such improved product. Basis of Presentation The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. As of December 31, 2022, the details of the consolidating subsidiaries are as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name of Company</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Jurisdiction of Formation</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Attributable equity interest %</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">HP Technology Limited</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center; padding-left: 5.4pt">British Virgin Islands</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Heyu Healthcare Technology Limited</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">Hong Kong</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>JSEL</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Kangzi</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left">%</td></tr> </table> Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management believes that the estimates used in preparing the financial statements are reasonable and prudent; however, actual results could differ from these estimates. Significant estimates include the allowance for doubtful accounts, impairment assessments of goodwill, valuation of deferred tax assets, rebilling collections and certain accrued liabilities such as contingent liabilities. As of December 31, 2022, the Company considered the economic implications of the COVID-19 pandemic on its significant judgments and estimates. Given the impact and other unforeseen effects on the global economy from the COVID-19 pandemic, these estimates required increased judgment, and actual results could differ from these estimates. Cash Equivalents The Company considers all highly liquid debt instruments purchased with a maturity period of three months or less to be cash or cash equivalents. The carrying amounts reported in the accompanying consolidated balance sheets for cash and cash equivalents approximate their fair value. All of the Company’s cash that is held in bank accounts in the PRC and Hong Kong is not protected by Federal Deposit Insurance Corporation (“FDIC”) insurance or any other similar insurance in the PRC, or Hong Kong. Accounts receivable and allowance for doubtful accounts Accounts receivable are stated at the historical carrying amount net of allowance for doubtful accounts. The Company maintains an allowance for doubtful accounts which reflects its best estimate of amounts that potentially will not be collected. The Company determines the allowance for doubtful accounts taking into consideration various factors, including but not limited to historical collection experience and credit-worthiness of the debtors, as well as the age of the individual receivables balance. Additionally, the Company makes specific bad debt provisions based on any specific knowledge the Company has acquired that might indicate that an account is uncollectible. The facts and circumstances of each account may require the Company to use substantial judgment in assessing its collectability. Inventories Inventories consist of finished goods, work in process, and raw materials. Inventories are stated at the lower of cost or market value. The Company applies the weighted average cost method to its inventory. Leases The Company adopted Accounting Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02), as amended, which supersedes the lease accounting guidance under Topic 840, and generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use (ROU) assets on the balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. Operating leases are included in operating lease right-of-use (“ROU”) assets and short-term and long-term lease liabilities in our consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities in our consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the leases do not provide an implicit rate, we use the industry incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Adoption of the standard resulted in the initial recognition of $215,298 of ROU assets and $215,298 of lease liabilities on our consolidated balance sheet related to office space lease commitment on September 1, 2019. Foreign Currency For fiscal year 2021, the Company’s principal country of operations is the PRC. The accompanying consolidated financial statements are presented in US$. The functional currency of the Company is US$, and the functional currency of the Company’s subsidiaries is RMB. The consolidated financial statements are translated into US$ from RMB at year-end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Capital accounts are translated at their historical exchange rates when the capital transactions occurred. The resulting translation adjustments are recorded as a component of shareholders’ equity included in other comprehensive income. Gains and losses from foreign currency transactions are included in profit or loss. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">RMB: US$ exchange rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.8983</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.3588</td><td style="width: 1%; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">RMB: US$ exchange rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.7279</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.4499</td><td style="width: 1%; text-align: left"> </td></tr> </table> The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation. General and administrative costs General and administrative expenses include personnel expenses for executive, finance, and internal support personnel. In addition, general and administrative expenses include fees for bad debt costs, professional legal and accounting services, insurance, office space, banking and merchant fees, and other overhead-related costs. Income Taxes The Company accounts for income taxes pursuant to ASC Topic 740, Income Taxes. Income taxes are provided on an asset and liability approach for financial accounting and reporting of income taxes. Any tax paid by subsidiaries during the year is recorded. Current tax is based on the profit or loss from ordinary activities adjusted for items that are non-assessable or disallowable for income tax purpose and is calculated using tax rates that have been enacted or substantively enacted at the balance sheet date. ASC Topic 740 also requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and the tax basis of assets and liabilities, and for the expected future tax benefit to be derived from tax losses and tax credit carry-forwards. ASC Topic 740 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Realization of deferred tax assets, including those related to the U.S. net operating loss carry-forwards, are dependent upon future earnings, if any, of which the timing and amount are uncertain. The Company adopted ASC Topic 740-10-05, Income Tax, which provides guidance for recognizing and measuring uncertain tax positions. It prescribes a threshold condition that a tax position must meet for any of the benefits of the uncertain tax position to be recognized in the financial statements. It also provides accounting guidance on derecognizing, classification and disclosure of these uncertain tax positions. The Company’s policy on classification of all interest and penalties related to unrecognized income tax positions, if any, is to present them as a component of income tax expense. Capital Structure The Company had 2,000,000,000 shares of common stock authorized, par value $0.001 per share, with 1,032,466,000 shares issued and outstanding as of December 31, 2022, and December 31, 2021. Earnings (loss) per share Basic net income (loss) per share of common stock attributable to common stockholders is calculated by dividing net income (loss) attributable to common stockholders by the weighted-average shares of common stock outstanding for the period. Potentially dilutive shares, which are based on the weighted-average shares of common stock underlying outstanding stock-based awards, warrants, options, or convertible debt using the treasury stock method or the if-converted method, as applicable, are included when calculating diluted net income (loss) per share of common stock attributable to common stockholders when their effect is dilutive. Potential dilutive securities are excluded from the calculation of diluted EPS in loss periods as their effect would be antidilutive. For the year ended December 31, 2022 and 2021, there were no potentially dilutive shares. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Statement of Operations Summary Information:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(265,579</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(163,020</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"><div style="-sec-ix-hidden: hidden-fact-33; -sec-ix-hidden: hidden-fact-32">Weighted-average common shares outstanding - basic and diluted</div></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,032,466,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,032,466,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><div style="-sec-ix-hidden: hidden-fact-35; -sec-ix-hidden: hidden-fact-34">Net loss per share, basic and diluted</div></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> </table>

1021051700

0.9891

335000

0.90 0.60 0.02

Basis of Presentation The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. As of December 31, 2022, the details of the consolidating subsidiaries are as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name of Company</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Jurisdiction of Formation</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Attributable equity interest %</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">HP Technology Limited</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center; padding-left: 5.4pt">British Virgin Islands</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Heyu Healthcare Technology Limited</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">Hong Kong</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>JSEL</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Kangzi</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left">%</td></tr> </table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name of Company</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Jurisdiction of Formation</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Attributable equity interest %</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">HP Technology Limited</td><td style="width: 1%"> </td> <td style="width: 11%; text-align: center; padding-left: 5.4pt">British Virgin Islands</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Heyu Healthcare Technology Limited</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">Hong Kong</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>JSEL</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td> </td><td> </td> <td style="text-align: center; padding-left: 5.4pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Kangzi</td><td> </td> <td style="text-align: center; padding-left: 5.4pt">PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">60</td><td style="text-align: left">%</td></tr> </table> HP Technology Limited

British Virgin Islands

Heyu Healthcare Technology Limited

Hong Kong

JSEL

PRC

Kangzi

PRC

0.60

Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management believes that the estimates used in preparing the financial statements are reasonable and prudent; however, actual results could differ from these estimates. Significant estimates include the allowance for doubtful accounts, impairment assessments of goodwill, valuation of deferred tax assets, rebilling collections and certain accrued liabilities such as contingent liabilities. As of December 31, 2022, the Company considered the economic implications of the COVID-19 pandemic on its significant judgments and estimates. Given the impact and other unforeseen effects on the global economy from the COVID-19 pandemic, these estimates required increased judgment, and actual results could differ from these estimates.

Cash Equivalents The Company considers all highly liquid debt instruments purchased with a maturity period of three months or less to be cash or cash equivalents. The carrying amounts reported in the accompanying consolidated balance sheets for cash and cash equivalents approximate their fair value. All of the Company’s cash that is held in bank accounts in the PRC and Hong Kong is not protected by Federal Deposit Insurance Corporation (“FDIC”) insurance or any other similar insurance in the PRC, or Hong Kong.

Accounts receivable and allowance for doubtful accounts Accounts receivable are stated at the historical carrying amount net of allowance for doubtful accounts. The Company maintains an allowance for doubtful accounts which reflects its best estimate of amounts that potentially will not be collected. The Company determines the allowance for doubtful accounts taking into consideration various factors, including but not limited to historical collection experience and credit-worthiness of the debtors, as well as the age of the individual receivables balance. Additionally, the Company makes specific bad debt provisions based on any specific knowledge the Company has acquired that might indicate that an account is uncollectible. The facts and circumstances of each account may require the Company to use substantial judgment in assessing its collectability.

Inventories Inventories consist of finished goods, work in process, and raw materials. Inventories are stated at the lower of cost or market value. The Company applies the weighted average cost method to its inventory.

Leases The Company adopted Accounting Standards Update No. 2016-02, Leases (Topic 842) (ASU 2016-02), as amended, which supersedes the lease accounting guidance under Topic 840, and generally requires lessees to recognize operating and financing lease liabilities and corresponding right-of-use (ROU) assets on the balance sheet and to provide enhanced disclosures surrounding the amount, timing and uncertainty of cash flows arising from leasing arrangements. Operating leases are included in operating lease right-of-use (“ROU”) assets and short-term and long-term lease liabilities in our consolidated balance sheets. Finance leases are included in property and equipment, other current liabilities, and other long-term liabilities in our consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of the leases do not provide an implicit rate, we use the industry incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Adoption of the standard resulted in the initial recognition of $215,298 of ROU assets and $215,298 of lease liabilities on our consolidated balance sheet related to office space lease commitment on September 1, 2019.

215298 215298

Foreign Currency For fiscal year 2021, the Company’s principal country of operations is the PRC. The accompanying consolidated financial statements are presented in US$. The functional currency of the Company is US$, and the functional currency of the Company’s subsidiaries is RMB. The consolidated financial statements are translated into US$ from RMB at year-end exchange rates as to assets and liabilities and average exchange rates as to revenues and expenses. Capital accounts are translated at their historical exchange rates when the capital transactions occurred. The resulting translation adjustments are recorded as a component of shareholders’ equity included in other comprehensive income. Gains and losses from foreign currency transactions are included in profit or loss. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">RMB: US$ exchange rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.8983</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.3588</td><td style="width: 1%; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">RMB: US$ exchange rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.7279</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.4499</td><td style="width: 1%; text-align: left"> </td></tr> </table> The RMB is not freely convertible into foreign currency and all foreign exchange transactions must take place through authorized institutions. No representation is made that the RMB amounts could have been, or could be, converted into US$ at the rates used in translation.

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">RMB: US$ exchange rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.8983</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.3588</td><td style="width: 1%; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify">RMB: US$ exchange rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.7279</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">6.4499</td><td style="width: 1%; text-align: left"> </td></tr> </table>

6.8983

6.3588

6.7279

6.4499

General and administrative costs General and administrative expenses include personnel expenses for executive, finance, and internal support personnel. In addition, general and administrative expenses include fees for bad debt costs, professional legal and accounting services, insurance, office space, banking and merchant fees, and other overhead-related costs.

Income Taxes The Company accounts for income taxes pursuant to ASC Topic 740, Income Taxes. Income taxes are provided on an asset and liability approach for financial accounting and reporting of income taxes. Any tax paid by subsidiaries during the year is recorded. Current tax is based on the profit or loss from ordinary activities adjusted for items that are non-assessable or disallowable for income tax purpose and is calculated using tax rates that have been enacted or substantively enacted at the balance sheet date. ASC Topic 740 also requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statements and the tax basis of assets and liabilities, and for the expected future tax benefit to be derived from tax losses and tax credit carry-forwards. ASC Topic 740 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Realization of deferred tax assets, including those related to the U.S. net operating loss carry-forwards, are dependent upon future earnings, if any, of which the timing and amount are uncertain. The Company adopted ASC Topic 740-10-05, Income Tax, which provides guidance for recognizing and measuring uncertain tax positions. It prescribes a threshold condition that a tax position must meet for any of the benefits of the uncertain tax position to be recognized in the financial statements. It also provides accounting guidance on derecognizing, classification and disclosure of these uncertain tax positions. The Company’s policy on classification of all interest and penalties related to unrecognized income tax positions, if any, is to present them as a component of income tax expense.

Capital Structure The Company had 2,000,000,000 shares of common stock authorized, par value $0.001 per share, with 1,032,466,000 shares issued and outstanding as of December 31, 2022, and December 31, 2021.

2000000000

0.001

1032466000 1032466000

Earnings (loss) per share Basic net income (loss) per share of common stock attributable to common stockholders is calculated by dividing net income (loss) attributable to common stockholders by the weighted-average shares of common stock outstanding for the period. Potentially dilutive shares, which are based on the weighted-average shares of common stock underlying outstanding stock-based awards, warrants, options, or convertible debt using the treasury stock method or the if-converted method, as applicable, are included when calculating diluted net income (loss) per share of common stock attributable to common stockholders when their effect is dilutive. Potential dilutive securities are excluded from the calculation of diluted EPS in loss periods as their effect would be antidilutive. For the year ended December 31, 2022 and 2021, there were no potentially dilutive shares. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Statement of Operations Summary Information:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(265,579</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(163,020</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"><div style="-sec-ix-hidden: hidden-fact-33; -sec-ix-hidden: hidden-fact-32">Weighted-average common shares outstanding - basic and diluted</div></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,032,466,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,032,466,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><div style="-sec-ix-hidden: hidden-fact-35; -sec-ix-hidden: hidden-fact-34">Net loss per share, basic and diluted</div></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td>Statement of Operations Summary Information:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(265,579</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(163,020</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt"><div style="-sec-ix-hidden: hidden-fact-33; -sec-ix-hidden: hidden-fact-32">Weighted-average common shares outstanding - basic and diluted</div></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,032,466,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,032,466,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><div style="-sec-ix-hidden: hidden-fact-35; -sec-ix-hidden: hidden-fact-34">Net loss per share, basic and diluted</div></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(0.00</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> </table>

-265579

-163020

1032466000

NOTE 2 – GOING CONCERN During the year ended December 31, 2022, the Company was unable to generate cash flows sufficient to support its operations and was dependent on related party advances from the current controlling shareholder. In addition, the Company had experienced recurring net losses, and had an accumulated deficit of $19,886,700 and working capital deficit of $1,972,606 as of December 31, 2022. These factors raise doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. There can be no assurance that sufficient funds required during the next year or thereafter will be generated from any future operations or that funds will be available from external sources such as debt or equity financings or other potential sources. If the Company is unable to raise capital from external sources when required, there will be a material adverse effect on its business. Furthermore, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significant dilutive effect on the Company’s existing stockholders. Management is now seeking an operating company with which to merge or acquire. In the foreseeable future, the Company will rely on related parties, such as its controlling shareholder, to provide advances to funds general corporate purposes and any potential acquisitions of profitable investments. There is no assurance, however, that the Company will achieve its objectives or goals. 19886700 1972606

NOTE 3 – CASH AND CASH EQUIVALENTS Cash and cash equivalents consist of the following: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Bank Deposits-China & HK</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">11,428</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">4,323</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt; padding-left: 5.4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">11,428</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,323</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table>

11428

4323

11428

4323

NOTE 4 – OTHER RECEIVABLE Other receivable consists of the following: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Rental and POS machine deposits</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">13,954</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">15,603</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Others</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,891</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,005</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">17,845</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">29,608</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> Management periodically reviews account balance. If any indication occurs, the allowance for doubtful debts would be recognized. No such allowance has been recognized during the year ended December 31, 2022. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Rental and POS machine deposits</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">13,954</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">15,603</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td>Others</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,891</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,005</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: Allowance for doubtful accounts</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">17,845</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">29,608</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table>

13954

15603

3891

14005

17845

29608

NOTE 5 – ADVANCES TO SUPPLIERS Advances to suppliers consists of the following: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Purchases of scientific research equipment</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">3,131</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">3,446</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,131</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,446</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Purchases of scientific research equipment</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">3,131</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">3,446</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,131</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,446</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table>

3131

3446

3131

3446

NOTE 6 – OPERATING LEASE RIGHT-OF-USE ASSET AND LIABILITIES On September 1, 2019, the Company entered in a lease agreement for office space, the right-of-use asset is recognized as following: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Operating lease right-of-use asset</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-38"> -</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">56,172</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 5.4pt">　</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">56,172</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> Operating lease liability consist both current and noncurrent component as the following: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease liability - current portion</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-40"> -</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">58,073</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 5.4pt">　</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">58,073</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> ASU 2016-02 requires that public companies use a secured incremental browning rate for the present value of lease payments when the rate implicit in the contract is not readily determinable. We determine a secured rate on a quarterly basis and update the weighted average discount rate accordingly. Lease terms and discount rate follow. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Weighted Average Remaining Lease Term (Year)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="width: 88%">Weighted Average Discount Rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4.75</td><td style="width: 1%; text-align: left">%</td></tr> </table>

56172

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Operating lease liability - current portion</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-40"> -</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">58,073</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 5.4pt">　</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">58,073</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> 58073

58073

0.0475

NOTE 7 – ADVANCES FROM CUSTOMERS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Advances from customers(1)</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">434,890</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">471,788</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 5.4pt">　</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">434,890</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">471,788</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">On October 15, 2019, JSEL entered into a clinical cooperation agreement (the “Clinical Cooperation Agreement”) with Shenzhen Saikun Biotechnology Co., Ltd. (“Saikun”). Pursuant to the Clinical Cooperation Agreement, Saikun agreed to pay JSEL 5.5 million RMB as the total preordering payment. 1.5 million RMB and 1.5 million RMB were delivered to JSEL respectively on September 7 and September 27, 2019. The parties are working on the timing for payment of the remaining 2.5 million RMB due under the Clinical Cooperation Agreement. In exchange, JSEL is obligated to purchase all the components of the Chamber from Kangzi, fully assemble it, and conduct a clinical trial with Saikun, third-party hospital partners, and patients using the Chamber. Specifically, after receiving the full amount of payment from Saikun, JSEL shall transport the Chamber to its preferred location, properly install it, and conduct a clinical trial that lasts at least one month.</td> </tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-bottom: 1.5pt">Advances from customers(1)</td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">434,890</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td><td style="width: 1%; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">471,788</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="font-weight: bold; padding-bottom: 4pt; padding-left: 5.4pt">　</td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">434,890</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">471,788</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">On October 15, 2019, JSEL entered into a clinical cooperation agreement (the “Clinical Cooperation Agreement”) with Shenzhen Saikun Biotechnology Co., Ltd. (“Saikun”). Pursuant to the Clinical Cooperation Agreement, Saikun agreed to pay JSEL 5.5 million RMB as the total preordering payment. 1.5 million RMB and 1.5 million RMB were delivered to JSEL respectively on September 7 and September 27, 2019. The parties are working on the timing for payment of the remaining 2.5 million RMB due under the Clinical Cooperation Agreement. In exchange, JSEL is obligated to purchase all the components of the Chamber from Kangzi, fully assemble it, and conduct a clinical trial with Saikun, third-party hospital partners, and patients using the Chamber. Specifically, after receiving the full amount of payment from Saikun, JSEL shall transport the Chamber to its preferred location, properly install it, and conduct a clinical trial that lasts at least one month.</td> </tr></table> 434890 471788

434890

471788

5.5

1.5 1.5

2.5

NOTE 8 – ACCRUED EXPENSES AND OTHER PAYABLES Accrued expenses and other payables consist of the following: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As of December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Accrued payroll</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">155,078</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">166,337</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt">Other Payables</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">130,003</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">117,537</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">285,081</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">283,874</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left"> </td></tr> </table> Accrued payroll includes all company employee payroll liabilities as of December 31, 2022, and other payables contains employee reimbursements.

155078

166337

130003

117537

285081

283874

NOTE 9 – RELATED PARTY TRANSACTIONS As of December 31, 2022 and 2021, the Company owed related parties $ 1,268,749 and $1,072,293, respectively. As the Company has just started business activities in March 2019, all expenses incurred during this reporting period are paid by two of our shareholder, Mr. Hungseng Tan and Mr. Ban Siong Ang, who are also directors of the Company. Expenses mainly included auditing, consulting and legal advisory expenses, government registration expenses, and payrolls. For the years ended December 31, 2022 and 2021, the Company earned revenues from related parties in the amount of $78,593 and $96,478, respectively.

1268749

1072293

78593

96478

NOTE 10 – EQUITY The Company had not recorded any equity transactions during the year ended December 31, 2022. The Company had not recorded any equity transactions during the year ended December 31, 2021.

NOTE 11 – INCOME TAXES The Company is subject to U.S. Federal tax laws. The Company has not recognized an income tax benefit for its operating losses in the United States because the Company does not expect to commence active operations in the United States. Heyu Healthcare Technology Limited was incorporated in Hong Kong and is subject to Hong Kong profits tax at a tax rate of 16.5%. Since Heyu Healthcare Technology Limited had no taxable income during the reporting period, it has not paid Hong Kong profits taxes. Heyu Healthcare Technology Limited has not recognized an income tax benefit for its operating losses in Hong Kong because the Company does not expect to commence active operations in Hong Kong. The Company has been conducting and plans to continue to conduct its major operations in the PRC through JSEL in accordance with the relevant tax laws and regulations. The corporate income tax rate in China is 25%. The Company has not paid PRC profits taxes, since it had no taxable income during the reporting period.

0.165

0.25

NONE

0.00

1032466000

0.00

false FY 0001086303 On October 15, 2019, JSEL entered into a clinical cooperation agreement (the “Clinical Cooperation Agreement”) with Shenzhen Saikun Biotechnology Co., Ltd. (“Saikun”). Pursuant to the Clinical Cooperation Agreement, Saikun agreed to pay JSEL 5.5 million RMB as the total preordering payment. 1.5 million RMB and 1.5 million RMB were delivered to JSEL respectively on September 7 and September 27, 2019. The parties are working on the timing for payment of the remaining 2.5 million RMB due under the Clinical Cooperation Agreement. In exchange, JSEL is obligated to purchase all the components of the Chamber from Kangzi, fully assemble it, and conduct a clinical trial with Saikun, third-party hospital partners, and patients using the Chamber. Specifically, after receiving the full amount of payment from Saikun, JSEL shall transport the Chamber to its preferred location, properly install it, and conduct a clinical trial that lasts at least one month.

EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 55 177 1 true 16 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://heyu.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://heyu.com/role/ConsolidatedBalanceSheet Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://heyu.com/role/ConsolidatedBalanceSheet_Parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations and Comprehensive Income Sheet http://heyu.com/role/ConsolidatedIncomeStatement Consolidated Statements of Operations and Comprehensive Income Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Parentheticals) Sheet http://heyu.com/role/ConsolidatedIncomeStatement_Parentheticals Consolidated Statements of Operations and Comprehensive Income (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Cash Flows Sheet http://heyu.com/role/ConsolidatedCashFlow Consolidated Statements of Cash Flows Statements 6 false false R7.htm 006 - Statement - Consolidated Statements of Stockholders??? Deficit Sheet http://heyu.com/role/ShareholdersEquityType2or3 Consolidated Statements of Stockholders??? Deficit Statements 7 false false R8.htm 007 - Disclosure - The Company and Significant Accounting Policies Sheet http://heyu.com/role/TheCompanyandSignificantAccountingPolicies The Company and Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Going Concern Sheet http://heyu.com/role/GoingConcern Going Concern Notes 9 false false R10.htm 009 - Disclosure - Cash and Cash Equivalents Sheet http://heyu.com/role/CashandCashEquivalents Cash and Cash Equivalents Notes 10 false false R11.htm 010 - Disclosure - Other Receivable Sheet http://heyu.com/role/OtherReceivable Other Receivable Notes 11 false false R12.htm 011 - Disclosure - Advances to Suppliers Sheet http://heyu.com/role/AdvancestoSuppliers Advances to Suppliers Notes 12 false false R13.htm 012 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities Sheet http://heyu.com/role/OperatingLeaseRightofUseAssetandLiabilities Operating Lease Right-of-Use Asset and Liabilities Notes 13 false false R14.htm 013 - Disclosure - Advances from Customers Sheet http://heyu.com/role/AdvancesfromCustomers Advances from Customers Notes 14 false false R15.htm 014 - Disclosure - Accrued Expenses and Other Payables Sheet http://heyu.com/role/AccruedExpensesandOtherPayables Accrued Expenses and Other Payables Notes 15 false false R16.htm 015 - Disclosure - Related Party Transactions Sheet http://heyu.com/role/RelatedPartyTransactions Related Party Transactions Notes 16 false false R17.htm 016 - Disclosure - Equity Sheet http://heyu.com/role/Equity Equity Notes 17 false false R18.htm 017 - Disclosure - Income Taxes Sheet http://heyu.com/role/IncomeTaxes Income Taxes Notes 18 false false R19.htm 018 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://heyu.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://heyu.com/role/TheCompanyandSignificantAccountingPolicies 19 false false R20.htm 019 - Disclosure - The Company and Significant Accounting Policies (Tables) Sheet http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesTables The Company and Significant Accounting Policies (Tables) Tables http://heyu.com/role/TheCompanyandSignificantAccountingPolicies 20 false false R21.htm 020 - Disclosure - Cash and Cash Equivalents (Tables) Sheet http://heyu.com/role/CashandCashEquivalentsTables Cash and Cash Equivalents (Tables) Tables http://heyu.com/role/CashandCashEquivalents 21 false false R22.htm 021 - Disclosure - Other Receivable (Tables) Sheet http://heyu.com/role/OtherReceivableTables Other Receivable (Tables) Tables http://heyu.com/role/OtherReceivable 22 false false R23.htm 022 - Disclosure - Advances to Suppliers (Tables) Sheet http://heyu.com/role/AdvancestoSuppliersTables Advances to Suppliers (Tables) Tables http://heyu.com/role/AdvancestoSuppliers 23 false false R24.htm 023 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Tables) Sheet http://heyu.com/role/OperatingLeaseRightofUseAssetandLiabilitiesTables Operating Lease Right-of-Use Asset and Liabilities (Tables) Tables http://heyu.com/role/OperatingLeaseRightofUseAssetandLiabilities 24 false false R25.htm 024 - Disclosure - Advances from Customers (Tables) Sheet http://heyu.com/role/AdvancesfromCustomersTables Advances from Customers (Tables) Tables http://heyu.com/role/AdvancesfromCustomers 25 false false R26.htm 025 - Disclosure - Accrued Expenses and Other Payables (Tables) Sheet http://heyu.com/role/AccruedExpensesandOtherPayablesTables Accrued Expenses and Other Payables (Tables) Tables http://heyu.com/role/AccruedExpensesandOtherPayables 26 false false R27.htm 026 - Disclosure - The Company and Significant Accounting Policies (Details) Sheet http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesDetails The Company and Significant Accounting Policies (Details) Details http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesTables 27 false false R28.htm 027 - Disclosure - The Company and Significant Accounting Policies (Details) - Schedule of details of the consolidating subsidiaries Sheet http://heyu.com/role/ScheduleofdetailsoftheconsolidatingsubsidiariesTable The Company and Significant Accounting Policies (Details) - Schedule of details of the consolidating subsidiaries Details http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesTables 28 false false R29.htm 028 - Disclosure - The Company and Significant Accounting Policies (Details) - Schedule of foreign currency transactions Sheet http://heyu.com/role/ScheduleofforeigncurrencytransactionsTable The Company and Significant Accounting Policies (Details) - Schedule of foreign currency transactions Details http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesTables 29 false false R30.htm 029 - Disclosure - The Company and Significant Accounting Policies (Details) - Schedule of potentially dilutive shares Sheet http://heyu.com/role/ScheduleofpotentiallydilutivesharesTable The Company and Significant Accounting Policies (Details) - Schedule of potentially dilutive shares Details http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesTables 30 false false R31.htm 030 - Disclosure - The Company and Significant Accounting Policies (Details) - Schedule of potentially dilutive shares (Parentheticals) Sheet http://heyu.com/role/ScheduleofpotentiallydilutivesharesTable_Parentheticals The Company and Significant Accounting Policies (Details) - Schedule of potentially dilutive shares (Parentheticals) Details http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesTables 31 false false R32.htm 031 - Disclosure - Going Concern (Details) Sheet http://heyu.com/role/GoingConcernDetails Going Concern (Details) Details http://heyu.com/role/GoingConcern 32 false false R33.htm 032 - Disclosure - Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents Sheet http://heyu.com/role/ScheduleofcashandcashequivalentsTable Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents Details http://heyu.com/role/CashandCashEquivalentsTables 33 false false R34.htm 033 - Disclosure - Other Receivable (Details) - Schedule of other receivable Sheet http://heyu.com/role/ScheduleofotherreceivableTable Other Receivable (Details) - Schedule of other receivable Details http://heyu.com/role/OtherReceivableTables 34 false false R35.htm 034 - Disclosure - Advances to Suppliers (Details) - Schedule of advances to suppliers Sheet http://heyu.com/role/ScheduleofadvancestosuppliersTable Advances to Suppliers (Details) - Schedule of advances to suppliers Details http://heyu.com/role/AdvancestoSuppliersTables 35 false false R36.htm 035 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of right-of-use asset Sheet http://heyu.com/role/ScheduleofrightofuseassetTable Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of right-of-use asset Details http://heyu.com/role/OperatingLeaseRightofUseAssetandLiabilitiesTables 36 false false R37.htm 036 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of operating lease liability Sheet http://heyu.com/role/ScheduleofoperatingleaseliabilityTable Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of operating lease liability Details http://heyu.com/role/OperatingLeaseRightofUseAssetandLiabilitiesTables 37 false false R38.htm 037 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of minimum lease payments Sheet http://heyu.com/role/ScheduleofminimumleasepaymentsTable Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of minimum lease payments Details http://heyu.com/role/OperatingLeaseRightofUseAssetandLiabilitiesTables 38 false false R39.htm 038 - Disclosure - Advances from Customers (Details) Sheet http://heyu.com/role/AdvancesfromCustomersDetails Advances from Customers (Details) Details http://heyu.com/role/AdvancesfromCustomersTables 39 false false R40.htm 039 - Disclosure - Advances from Customers (Details) - Schedule of advances from Customers Sheet http://heyu.com/role/ScheduleofadvancesfromCustomersTable Advances from Customers (Details) - Schedule of advances from Customers Details http://heyu.com/role/AdvancesfromCustomersTables 40 false false R41.htm 040 - Disclosure - Accrued Expenses and Other Payables (Details) - Schedule of accrued expenses and other payables Sheet http://heyu.com/role/ScheduleofaccruedexpensesandotherpayablesTable Accrued Expenses and Other Payables (Details) - Schedule of accrued expenses and other payables Details http://heyu.com/role/AccruedExpensesandOtherPayablesTables 41 false false R42.htm 041 - Disclosure - Related Party Transactions (Details) Sheet http://heyu.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://heyu.com/role/RelatedPartyTransactions 42 false false R43.htm 042 - Disclosure - Income Taxes (Details) Sheet http://heyu.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://heyu.com/role/IncomeTaxes 43 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022_heyubiological.htm 3347, 3348 [dq-0542-Deprecated-Concept] Concept AccountsPayableRelatedPartiesCurrentAndNoncurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022_heyubiological.htm 3359, 3360 [dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionDueFromToRelatedParty in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022_heyubiological.htm 4618 [dq-0542-Deprecated-Concept] Concept RevenueFromRelatedParties in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. f10k2022_heyubiological.htm 4626 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 9 fact(s) appearing in ix:hidden were eligible for transformation: dei:SecurityExchangeName, us-gaap:EarningsPerShareDiluted, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding - f10k2022_heyubiological.htm 4685, 4693, 4694, 4695, 4696, 4717, 4718, 4719, 4720 f10k2022_heyubiological.htm f10k2022ex31-1_heyubio.htm f10k2022ex31-2_heyubio.htm f10k2022ex32-1_heyubio.htm f10k2022ex32-2_heyubio.htm f10k2022ex4-1_heyubio.htm hybt-20221231.xsd hybt-20221231_cal.xml hybt-20221231_def.xml hybt-20221231_lab.xml hybt-20221231_pre.xml image_001.jpg image_002.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 64 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10k2022_heyubiological.htm": { "axisCustom": 0, "axisStandard": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 267, "http://xbrl.sec.gov/dei/2022": 38 }, "contextCount": 55, "dts": { "calculationLink": { "local": [ "hybt-20221231_cal.xml" ] }, "definitionLink": { "local": [ "hybt-20221231_def.xml" ] }, "inline": { "local": [ "f10k2022_heyubiological.htm" ] }, "labelLink": { "local": [ "hybt-20221231_lab.xml" ] }, "presentationLink": { "local": [ "hybt-20221231_pre.xml" ] }, "schema": { "local": [ "hybt-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd" ] } }, "elementCount": 263, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 42, "http://heyu.com/20221231": 2, "http://xbrl.sec.gov/dei/2022": 4, "total": 48 }, "keyCustom": 27, "keyStandard": 150, "memberCustom": 8, "memberStandard": 8, "nsprefix": "hybt", "nsuri": "http://heyu.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://heyu.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Cash and Cash Equivalents", "menuCat": "Notes", "order": "10", "role": "http://heyu.com/role/CashandCashEquivalents", "shortName": "Cash and Cash Equivalents", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hybt:OtherReceivableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Other Receivable", "menuCat": "Notes", "order": "11", "role": "http://heyu.com/role/OtherReceivable", "shortName": "Other Receivable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hybt:OtherReceivableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hybt:AdvancesToSuppliersTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Advances to Suppliers", "menuCat": "Notes", "order": "12", "role": "http://heyu.com/role/AdvancestoSuppliers", "shortName": "Advances to Suppliers", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hybt:AdvancesToSuppliersTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities", "menuCat": "Notes", "order": "13", "role": "http://heyu.com/role/OperatingLeaseRightofUseAssetandLiabilities", "shortName": "Operating Lease Right-of-Use Asset and Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Advances from Customers", "menuCat": "Notes", "order": "14", "role": "http://heyu.com/role/AdvancesfromCustomers", "shortName": "Advances from Customers", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Accrued Expenses and Other Payables", "menuCat": "Notes", "order": "15", "role": "http://heyu.com/role/AccruedExpensesandOtherPayables", "shortName": "Accrued Expenses and Other Payables", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "16", "role": "http://heyu.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Equity", "menuCat": "Notes", "order": "17", "role": "http://heyu.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "18", "role": "http://heyu.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Accounting Policies, by Policy (Policies)", "menuCat": "Policies", "order": "19", "role": "http://heyu.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://heyu.com/role/ConsolidatedBalanceSheet", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hybt:ScheduleOfDetailsOfConsolidatingSubsidiariesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - The Company and Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "20", "role": "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesTables", "shortName": "The Company and Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hybt:ScheduleOfDetailsOfConsolidatingSubsidiariesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Cash and Cash Equivalents (Tables)", "menuCat": "Tables", "order": "21", "role": "http://heyu.com/role/CashandCashEquivalentsTables", "shortName": "Cash and Cash Equivalents (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hybt:ScheduleOfOtherReceivableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Other Receivable (Tables)", "menuCat": "Tables", "order": "22", "role": "http://heyu.com/role/OtherReceivableTables", "shortName": "Other Receivable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hybt:ScheduleOfOtherReceivableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hybt:ScheduleOfAdvancesToSuppliersTableTextBlack", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Advances to Suppliers (Tables)", "menuCat": "Tables", "order": "23", "role": "http://heyu.com/role/AdvancestoSuppliersTables", "shortName": "Advances to Suppliers (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hybt:ScheduleOfAdvancesToSuppliersTableTextBlack", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hybt:OperatingLeaseRightOfUseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Tables)", "menuCat": "Tables", "order": "24", "role": "http://heyu.com/role/OperatingLeaseRightofUseAssetandLiabilitiesTables", "shortName": "Operating Lease Right-of-Use Asset and Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hybt:OperatingLeaseRightOfUseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hybt:ScheduleOfAdvancesFromCustomersTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Advances from Customers (Tables)", "menuCat": "Tables", "order": "25", "role": "http://heyu.com/role/AdvancesfromCustomersTables", "shortName": "Advances from Customers (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hybt:ScheduleOfAdvancesFromCustomersTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Accrued Expenses and Other Payables (Tables)", "menuCat": "Tables", "order": "26", "role": "http://heyu.com/role/AccruedExpensesandOtherPayablesTables", "shortName": "Accrued Expenses and Other Payables (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c34", "decimals": "2", "first": true, "lang": null, "name": "hybt:EquityInterests", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - The Company and Significant Accounting Policies (Details)", "menuCat": "Details", "order": "27", "role": "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesDetails", "shortName": "The Company and Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c34", "decimals": "2", "first": true, "lang": null, "name": "hybt:EquityInterests", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "hybt:ScheduleOfDetailsOfConsolidatingSubsidiariesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c38", "decimals": null, "first": true, "lang": "en-US", "name": "hybt:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - The Company and Significant Accounting Policies (Details) - Schedule of details of the consolidating subsidiaries", "menuCat": "Details", "order": "28", "role": "http://heyu.com/role/ScheduleofdetailsoftheconsolidatingsubsidiariesTable", "shortName": "The Company and Significant Accounting Policies (Details) - Schedule of details of the consolidating subsidiaries", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "hybt:ScheduleOfDetailsOfConsolidatingSubsidiariesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c38", "decimals": null, "first": true, "lang": "en-US", "name": "hybt:SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "hybt:ScheduleOfForeignCurrencyTransactionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c3", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - The Company and Significant Accounting Policies (Details) - Schedule of foreign currency transactions", "menuCat": "Details", "order": "29", "role": "http://heyu.com/role/ScheduleofforeigncurrencytransactionsTable", "shortName": "The Company and Significant Accounting Policies (Details) - Schedule of foreign currency transactions", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "hybt:ScheduleOfForeignCurrencyTransactionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c3", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c3", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://heyu.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c3", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - The Company and Significant Accounting Policies (Details) - Schedule of potentially dilutive shares", "menuCat": "Details", "order": "30", "role": "http://heyu.com/role/ScheduleofpotentiallydilutivesharesTable", "shortName": "The Company and Significant Accounting Policies (Details) - Schedule of potentially dilutive shares", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - The Company and Significant Accounting Policies (Details) - Schedule of potentially dilutive shares (Parentheticals)", "menuCat": "Details", "order": "31", "role": "http://heyu.com/role/ScheduleofpotentiallydilutivesharesTable_Parentheticals", "shortName": "The Company and Significant Accounting Policies (Details) - Schedule of potentially dilutive shares (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R32": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "hybt:RetainedEarningAccumulatedDeficit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Going Concern (Details)", "menuCat": "Details", "order": "32", "role": "http://heyu.com/role/GoingConcernDetails", "shortName": "Going Concern (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "hybt:RetainedEarningAccumulatedDeficit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents", "menuCat": "Details", "order": "33", "role": "http://heyu.com/role/ScheduleofcashandcashequivalentsTable", "shortName": "Cash and Cash Equivalents (Details) - Schedule of cash and cash equivalents", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "hybt:ScheduleOfOtherReceivableTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Deposits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Other Receivable (Details) - Schedule of other receivable", "menuCat": "Details", "order": "34", "role": "http://heyu.com/role/ScheduleofotherreceivableTable", "shortName": "Other Receivable (Details) - Schedule of other receivable", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "hybt:ScheduleOfOtherReceivableTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Deposits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "hybt:ScheduleOfAdvancesToSuppliersTableTextBlack", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherPrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Advances to Suppliers (Details) - Schedule of advances to suppliers", "menuCat": "Details", "order": "35", "role": "http://heyu.com/role/ScheduleofadvancestosuppliersTable", "shortName": "Advances to Suppliers (Details) - Schedule of advances to suppliers", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "hybt:ScheduleOfAdvancesToSuppliersTableTextBlack", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherPrepaidExpenseCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of right-of-use asset", "menuCat": "Details", "order": "36", "role": "http://heyu.com/role/ScheduleofrightofuseassetTable", "shortName": "Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of right-of-use asset", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "hybt:OperatingLeaseRightOfUseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c47", "decimals": "0", "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "hybt:ScheduleOfOperatingLeaseLiabilityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c49", "decimals": "0", "first": true, "lang": null, "name": "hybt:OperatingLeaseLiabilityCurrentPortion", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of operating lease liability", "menuCat": "Details", "order": "37", "role": "http://heyu.com/role/ScheduleofoperatingleaseliabilityTable", "shortName": "Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of operating lease liability", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "hybt:ScheduleOfOperatingLeaseLiabilityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c49", "decimals": "0", "first": true, "lang": null, "name": "hybt:OperatingLeaseLiabilityCurrentPortion", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c3", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of minimum lease payments", "menuCat": "Details", "order": "38", "role": "http://heyu.com/role/ScheduleofminimumleasepaymentsTable", "shortName": "Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of minimum lease payments", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c3", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "link:footnote", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c50", "decimals": "1", "first": true, "lang": null, "name": "hybt:TotalPreorderingPaymentAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Advances from Customers (Details)", "menuCat": "Details", "order": "39", "role": "http://heyu.com/role/AdvancesfromCustomersDetails", "shortName": "Advances from Customers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "link:footnote", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c50", "decimals": "1", "first": true, "lang": null, "name": "hybt:TotalPreorderingPaymentAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Income", "menuCat": "Statements", "order": "4", "role": "http://heyu.com/role/ConsolidatedIncomeStatement", "shortName": "Consolidated Statements of Operations and Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "hybt:ScheduleOfAdvancesFromCustomersTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "hybt:AdvancesFromCustomers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Advances from Customers (Details) - Schedule of advances from Customers", "menuCat": "Details", "order": "40", "role": "http://heyu.com/role/ScheduleofadvancesfromCustomersTable", "shortName": "Advances from Customers (Details) - Schedule of advances from Customers", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "hybt:ScheduleOfAdvancesFromCustomersTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "hybt:AdvancesFromCustomers", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Accrued Expenses and Other Payables (Details) - Schedule of accrued expenses and other payables", "menuCat": "Details", "order": "41", "role": "http://heyu.com/role/ScheduleofaccruedexpensesandotherpayablesTable", "shortName": "Accrued Expenses and Other Payables (Details) - Schedule of accrued expenses and other payables", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionDueFromToRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Related Party Transactions (Details)", "menuCat": "Details", "order": "42", "role": "http://heyu.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RelatedPartyTransactionDueFromToRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c53", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Income Taxes (Details)", "menuCat": "Details", "order": "43", "role": "http://heyu.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c53", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Operations and Comprehensive Income (Parentheticals)", "menuCat": "Statements", "order": "5", "role": "http://heyu.com/role/ConsolidatedIncomeStatement_Parentheticals", "shortName": "Consolidated Statements of Operations and Comprehensive Income (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://heyu.com/role/ConsolidatedCashFlow", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c5", "decimals": "0", "lang": null, "name": "us-gaap:IncreaseDecreaseInAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c7", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "006 - Statement - Consolidated Statements of Stockholders\u2019 Deficit", "menuCat": "Statements", "order": "7", "role": "http://heyu.com/role/ShareholdersEquityType2or3", "shortName": "Consolidated Statements of Stockholders\u2019 Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c7", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - The Company and Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://heyu.com/role/TheCompanyandSignificantAccountingPolicies", "shortName": "The Company and Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hybt:GoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Going Concern", "menuCat": "Notes", "order": "9", "role": "http://heyu.com/role/GoingConcern", "shortName": "Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10k2022_heyubiological.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "hybt:GoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 16, "tag": { "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA", "terseLabel": "China [Member]" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://heyu.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r331", "r332", "r333" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r331", "r332", "r333" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r331", "r332", "r333" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r331", "r332", "r333" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r329" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r331", "r332", "r333" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://heyu.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "hybt_AdvancesFromCustomer": { "auth_ref": [], "calculation": { "http://heyu.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Advances From Customer", "negatedLabel": "Advances from customers" } } }, "localname": "AdvancesFromCustomer", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "hybt_AdvancesFromCustomers": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Advances From Customers", "terseLabel": "Advances from customers" } } }, "localname": "AdvancesFromCustomers", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/ScheduleofadvancesfromCustomersTable" ], "xbrltype": "monetaryItemType" }, "hybt_AdvancesToSuppliersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Advances to Suppliers [Abstract]" } } }, "localname": "AdvancesToSuppliersAbstract", "nsuri": "http://heyu.com/20221231", "xbrltype": "stringItemType" }, "hybt_AdvancesToSuppliersTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Advances To Suppliers Text Block", "terseLabel": "ADVANCES TO SUPPLIERS" } } }, "localname": "AdvancesToSuppliersTextBlock", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/AdvancestoSuppliers" ], "xbrltype": "textBlockItemType" }, "hybt_BankDepositsChinaAndHKMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Bank Deposits China And HKMember", "terseLabel": "Bank Deposits-China & HK [Member]" } } }, "localname": "BankDepositsChinaAndHKMember", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/ScheduleofcashandcashequivalentsTable" ], "xbrltype": "domainItemType" }, "hybt_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://heyu.com/20221231", "xbrltype": "stringItemType" }, "hybt_EquityInterests": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity interest percentage.", "label": "Equity Interests", "terseLabel": "Equity interests percentage" } } }, "localname": "EquityInterests", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "hybt_GoingConcernAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern [Abstract]" } } }, "localname": "GoingConcernAbstract", "nsuri": "http://heyu.com/20221231", "xbrltype": "stringItemType" }, "hybt_GoingConcernLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern Line Items", "terseLabel": "Going Concern [Abstract]" } } }, "localname": "GoingConcernLineItems", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/GoingConcern" ], "xbrltype": "stringItemType" }, "hybt_GoingConcernTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern [Table]" } } }, "localname": "GoingConcernTable", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/GoingConcern" ], "xbrltype": "stringItemType" }, "hybt_GoingConcernTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for going concern.", "label": "Going Concern Text Block", "terseLabel": "GOING CONCERN" } } }, "localname": "GoingConcernTextBlock", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "hybt_GrossProceedsPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross proceeds percentage.", "label": "Gross Proceeds Percentage", "terseLabel": "Gross proceeds percentage" } } }, "localname": "GrossProceedsPercentage", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "hybt_HKMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "HKMember", "terseLabel": "Hong Kong [Member]" } } }, "localname": "HKMember", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "hybt_HPTechnologyLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "HPTechnology Limited Member", "terseLabel": "HP Technology Limited [Member]" } } }, "localname": "HPTechnologyLimitedMember", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/ScheduleofdetailsoftheconsolidatingsubsidiariesTable" ], "xbrltype": "domainItemType" }, "hybt_HeyuHealthcareTechnologyLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Heyu Healthcare Technology Limited Member", "terseLabel": "Heyu Healthcare Technology Limited [Member]" } } }, "localname": "HeyuHealthcareTechnologyLimitedMember", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/ScheduleofdetailsoftheconsolidatingsubsidiariesTable" ], "xbrltype": "domainItemType" }, "hybt_IncomeTaxesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) [Line Items]" } } }, "localname": "IncomeTaxesDetailsLineItems", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "hybt_IncomeTaxesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) [Table]" } } }, "localname": "IncomeTaxesDetailsTable", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "hybt_IncreaseDecreaseLeaseLiability": { "auth_ref": [], "calculation": { "http://heyu.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value represents lease liability.", "label": "Increase Decrease Lease Liability", "negatedLabel": "Lease liability" } } }, "localname": "IncreaseDecreaseLeaseLiability", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "hybt_IncreaseDecreaseOperatingLeaseRightofuseAsset": { "auth_ref": [], "calculation": { "http://heyu.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value represents operating lease right-of-use asset.", "label": "Increase Decrease Operating Lease Rightofuse Asset", "negatedLabel": "Operating lease right-of-use asset" } } }, "localname": "IncreaseDecreaseOperatingLeaseRightofuseAsset", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "hybt_JSELMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JSELMember", "terseLabel": "JSEL [Member]" } } }, "localname": "JSELMember", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/ScheduleofdetailsoftheconsolidatingsubsidiariesTable", "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "hybt_KangziMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Kangzi Member", "terseLabel": "Kangzi [Member]" } } }, "localname": "KangziMember", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/ScheduleofdetailsoftheconsolidatingsubsidiariesTable" ], "xbrltype": "domainItemType" }, "hybt_NumberOfSharesIssuedAndOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number Of Shares Issued And Outstanding", "terseLabel": "Number of shares issued and outstanding" } } }, "localname": "NumberOfSharesIssuedAndOutstanding", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "hybt_OfficeSpaceLease": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Office space lease.", "label": "Office Space Lease", "terseLabel": "Lease liabilities (in Dollars)" } } }, "localname": "OfficeSpaceLease", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "hybt_OperatingLeaseLiabilityCurrentPortion": { "auth_ref": [], "calculation": { "http://heyu.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://heyu.com/role/ScheduleofoperatingleaseliabilityTable": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating lease liability - current portion.", "label": "Operating Lease Liability Current Portion", "terseLabel": "Operating lease liability - current portion" } } }, "localname": "OperatingLeaseLiabilityCurrentPortion", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet", "http://heyu.com/role/ScheduleofoperatingleaseliabilityTable" ], "xbrltype": "monetaryItemType" }, "hybt_OperatingLeaseRightOfUseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease Right Of Use Table Text Block", "terseLabel": "Schedule of right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseTableTextBlock", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/OperatingLeaseRightofUseAssetandLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "hybt_OperatingLeaseRightOfUsesAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Uses Asset", "terseLabel": "ROU assets (in Dollars)" } } }, "localname": "OperatingLeaseRightOfUsesAsset", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "hybt_OperatingLeaseRightofUseAssetandLiabilitiesDetailsScheduleofoperatingleaseliabilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of operating lease liability [Line Items]" } } }, "localname": "OperatingLeaseRightofUseAssetandLiabilitiesDetailsScheduleofoperatingleaseliabilityLineItems", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/ScheduleofoperatingleaseliabilityTable" ], "xbrltype": "stringItemType" }, "hybt_OperatingLeaseRightofUseAssetandLiabilitiesDetailsScheduleofoperatingleaseliabilityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of operating lease liability [Table]" } } }, "localname": "OperatingLeaseRightofUseAssetandLiabilitiesDetailsScheduleofoperatingleaseliabilityTable", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/ScheduleofoperatingleaseliabilityTable" ], "xbrltype": "stringItemType" }, "hybt_OperatingLeaseRightofUseAssetandLiabilitiesDetailsScheduleofrightofuseassetLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of right-of-use asset [Line Items]" } } }, "localname": "OperatingLeaseRightofUseAssetandLiabilitiesDetailsScheduleofrightofuseassetLineItems", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/ScheduleofrightofuseassetTable" ], "xbrltype": "stringItemType" }, "hybt_OperatingLeaseRightofUseAssetandLiabilitiesDetailsScheduleofrightofuseassetTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease Right-of-Use Asset and Liabilities (Details) - Schedule of right-of-use asset [Table]" } } }, "localname": "OperatingLeaseRightofUseAssetandLiabilitiesDetailsScheduleofrightofuseassetTable", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/ScheduleofrightofuseassetTable" ], "xbrltype": "stringItemType" }, "hybt_OtherReceivableDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Receivable [Abstract]" } } }, "localname": "OtherReceivableDisclosureAbstract", "nsuri": "http://heyu.com/20221231", "xbrltype": "stringItemType" }, "hybt_OtherReceivableDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Receivable Disclosure Text Block", "terseLabel": "OTHER RECEIVABLE" } } }, "localname": "OtherReceivableDisclosureTextBlock", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/OtherReceivable" ], "xbrltype": "textBlockItemType" }, "hybt_OtherReceivablesNet": { "auth_ref": [], "calculation": { "http://heyu.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Other Receivables Net", "terseLabel": "Other receivables, net" } } }, "localname": "OtherReceivablesNet", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "hybt_OutstandingEquityInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding equity interest.", "label": "Outstanding Equity Interest", "terseLabel": "Outstanding equity interest percentage" } } }, "localname": "OutstandingEquityInterest", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "hybt_RetainedEarningAccumulatedDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earning Accumulated Deficit", "terseLabel": "Accumulated deficit amount" } } }, "localname": "RetainedEarningAccumulatedDeficit", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/GoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "hybt_RightsOfUseLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rights Of Use Liability Member", "terseLabel": "Rights of use liability [Member]" } } }, "localname": "RightsOfUseLiabilityMember", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/ScheduleofoperatingleaseliabilityTable" ], "xbrltype": "domainItemType" }, "hybt_ScheduleOfAccruedExpensesAndOtherPayablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Expenses and Other Payables [Abstract]" } } }, "localname": "ScheduleOfAccruedExpensesAndOtherPayablesAbstract", "nsuri": "http://heyu.com/20221231", "xbrltype": "stringItemType" }, "hybt_ScheduleOfAdvancesFromCustomersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Advances From Customers [Abstract]" } } }, "localname": "ScheduleOfAdvancesFromCustomersAbstract", "nsuri": "http://heyu.com/20221231", "xbrltype": "stringItemType" }, "hybt_ScheduleOfAdvancesFromCustomersTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Advances From Customers Table Text Block", "terseLabel": "Schedule of advances from customers" } } }, "localname": "ScheduleOfAdvancesFromCustomersTableTextBlock", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/AdvancesfromCustomersTables" ], "xbrltype": "textBlockItemType" }, "hybt_ScheduleOfAdvancesToSuppliersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Advances to Suppliers [Abstract]" } } }, "localname": "ScheduleOfAdvancesToSuppliersAbstract", "nsuri": "http://heyu.com/20221231", "xbrltype": "stringItemType" }, "hybt_ScheduleOfAdvancesToSuppliersTableTextBlack": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Advances To Suppliers Table Text Black", "terseLabel": "Schedule of advances to suppliers" } } }, "localname": "ScheduleOfAdvancesToSuppliersTableTextBlack", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/AdvancestoSuppliersTables" ], "xbrltype": "textBlockItemType" }, "hybt_ScheduleOfCashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Cash And Cash Equivalents Abstract" } } }, "localname": "ScheduleOfCashAndCashEquivalentsAbstract", "nsuri": "http://heyu.com/20221231", "xbrltype": "stringItemType" }, "hybt_ScheduleOfDetailsOfConsolidatingSubsidiariesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Details Of Consolidating Subsidiaries Table Text Block", "terseLabel": "Schedule of details of the consolidating subsidiaries" } } }, "localname": "ScheduleOfDetailsOfConsolidatingSubsidiariesTableTextBlock", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "hybt_ScheduleOfDetailsOfTheConsolidatingSubsidiariesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Details Of The Consolidating Subsidiaries Abstract" } } }, "localname": "ScheduleOfDetailsOfTheConsolidatingSubsidiariesAbstract", "nsuri": "http://heyu.com/20221231", "xbrltype": "stringItemType" }, "hybt_ScheduleOfForeignCurrencyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Foreign Currency Transactions Abstract" } } }, "localname": "ScheduleOfForeignCurrencyTransactionsAbstract", "nsuri": "http://heyu.com/20221231", "xbrltype": "stringItemType" }, "hybt_ScheduleOfForeignCurrencyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Foreign Currency Transactions Table Text Block", "terseLabel": "Schedule of foreign currency transactions" } } }, "localname": "ScheduleOfForeignCurrencyTransactionsTableTextBlock", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "hybt_ScheduleOfMinimumLeasePaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Weighted Average Discount Rate [Abstract]" } } }, "localname": "ScheduleOfMinimumLeasePaymentsAbstract", "nsuri": "http://heyu.com/20221231", "xbrltype": "stringItemType" }, "hybt_ScheduleOfOperatingLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Operating Lease Liability Abstract" } } }, "localname": "ScheduleOfOperatingLeaseLiabilityAbstract", "nsuri": "http://heyu.com/20221231", "xbrltype": "stringItemType" }, "hybt_ScheduleOfOperatingLeaseLiabilityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Operating Lease Liability Table Text Block", "terseLabel": "Schedule of operating lease liability" } } }, "localname": "ScheduleOfOperatingLeaseLiabilityTableTextBlock", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/OperatingLeaseRightofUseAssetandLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "hybt_ScheduleOfOtherReceivableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Other Receivable [Abstract]" } } }, "localname": "ScheduleOfOtherReceivableAbstract", "nsuri": "http://heyu.com/20221231", "xbrltype": "stringItemType" }, "hybt_ScheduleOfOtherReceivableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Other Receivable Table Text Block", "terseLabel": "Schedule of other receivable" } } }, "localname": "ScheduleOfOtherReceivableTableTextBlock", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/OtherReceivableTables" ], "xbrltype": "textBlockItemType" }, "hybt_ScheduleOfPotentiallyDilutiveSharesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of potentially dilutive shares [Abstract]" } } }, "localname": "ScheduleOfPotentiallyDilutiveSharesAbstract", "nsuri": "http://heyu.com/20221231", "xbrltype": "stringItemType" }, "hybt_ScheduleOfRightOfUseAssetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule Of Right Of Use Asset Abstract" } } }, "localname": "ScheduleOfRightOfUseAssetAbstract", "nsuri": "http://heyu.com/20221231", "xbrltype": "stringItemType" }, "hybt_SellingExpenses": { "auth_ref": [], "calculation": { "http://heyu.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Selling Expenses", "terseLabel": "Selling expenses" } } }, "localname": "SellingExpenses", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "hybt_SharePurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Purchase Agreement Member", "terseLabel": "Share Purchase Agreement [Member]" } } }, "localname": "SharePurchaseAgreementMember", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "hybt_StatementOfOperationsSummaryInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Operations Summary Information Abstract", "terseLabel": "Statement of Operations Summary Information:" } } }, "localname": "StatementOfOperationsSummaryInformationAbstract", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/ScheduleofpotentiallydilutivesharesTable" ], "xbrltype": "stringItemType" }, "hybt_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the company.", "label": "Subsidiary Of Limited Liability Company Or Limited Partnership Name", "terseLabel": "Name of Company" } } }, "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipName", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/ScheduleofdetailsoftheconsolidatingsubsidiariesTable" ], "xbrltype": "stringItemType" }, "hybt_TheCompanyandSignificantAccountingPoliciesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "The Company and Significant Accounting Policies (Details) [Line Items]" } } }, "localname": "TheCompanyandSignificantAccountingPoliciesDetailsLineItems", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "hybt_TheCompanyandSignificantAccountingPoliciesDetailsScheduleofdetailsoftheconsolidatingsubsidiariesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "The Company and Significant Accounting Policies (Details) - Schedule of details of the consolidating subsidiaries [Line Items]" } } }, "localname": "TheCompanyandSignificantAccountingPoliciesDetailsScheduleofdetailsoftheconsolidatingsubsidiariesLineItems", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/ScheduleofdetailsoftheconsolidatingsubsidiariesTable" ], "xbrltype": "stringItemType" }, "hybt_TheCompanyandSignificantAccountingPoliciesDetailsScheduleofdetailsoftheconsolidatingsubsidiariesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "The Company and Significant Accounting Policies (Details) - Schedule of details of the consolidating subsidiaries [Table]" } } }, "localname": "TheCompanyandSignificantAccountingPoliciesDetailsScheduleofdetailsoftheconsolidatingsubsidiariesTable", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/ScheduleofdetailsoftheconsolidatingsubsidiariesTable" ], "xbrltype": "stringItemType" }, "hybt_TheCompanyandSignificantAccountingPoliciesDetailsScheduleofforeigncurrencytransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "The Company and Significant Accounting Policies (Details) - Schedule of foreign currency transactions [Line Items]" } } }, "localname": "TheCompanyandSignificantAccountingPoliciesDetailsScheduleofforeigncurrencytransactionsLineItems", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/ScheduleofforeigncurrencytransactionsTable" ], "xbrltype": "stringItemType" }, "hybt_TheCompanyandSignificantAccountingPoliciesDetailsScheduleofforeigncurrencytransactionsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "The Company and Significant Accounting Policies (Details) - Schedule of foreign currency transactions [Table]" } } }, "localname": "TheCompanyandSignificantAccountingPoliciesDetailsScheduleofforeigncurrencytransactionsTable", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/ScheduleofforeigncurrencytransactionsTable" ], "xbrltype": "stringItemType" }, "hybt_TheCompanyandSignificantAccountingPoliciesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "The Company and Significant Accounting Policies (Details) [Table]" } } }, "localname": "TheCompanyandSignificantAccountingPoliciesDetailsTable", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "hybt_TotalPreorderingPaymentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of total preordering payment.", "label": "Total Preordering Payment Amount", "terseLabel": "Total preordering payment" } } }, "localname": "TotalPreorderingPaymentAmount", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/AdvancesfromCustomersDetails" ], "xbrltype": "monetaryItemType" }, "hybt_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Working Capital Deficit", "terseLabel": "Working capital deficit" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://heyu.com/20221231", "presentation": [ "http://heyu.com/role/GoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "auth_ref": [ "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314" ], "lang": { "en-us": { "role": { "label": "Real Estate, Type of Property [Axis]" } } }, "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://heyu.com/role/ScheduleofrightofuseassetTable" ], "xbrltype": "stringItemType" }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "auth_ref": [ "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314" ], "lang": { "en-us": { "role": { "label": "Real Estate [Domain]" } } }, "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://heyu.com/role/ScheduleofrightofuseassetTable" ], "xbrltype": "domainItemType" }, "srt_OtherPropertyMember": { "auth_ref": [ "r362", "r363" ], "lang": { "en-us": { "role": { "label": "Other Property [Member]", "terseLabel": "Office Space [Member]" } } }, "localname": "OtherPropertyMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://heyu.com/role/ScheduleofrightofuseassetTable" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://heyu.com/role/ScheduleofdetailsoftheconsolidatingsubsidiariesTable", "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r172", "r173", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r320", "r327", "r353" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://heyu.com/role/ScheduleofcashandcashequivalentsTable" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r172", "r173", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r320", "r327", "r353" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://heyu.com/role/IncomeTaxesDetails", "http://heyu.com/role/ScheduleofcashandcashequivalentsTable" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r80", "r91" ], "calculation": { "http://heyu.com/role/ScheduleofaccruedexpensesandotherpayablesTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.", "label": "Accounts Payable and Accrued Liabilities", "totalLabel": "Total accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofaccruedexpensesandotherpayablesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "ACCRUED EXPENSES AND OTHER PAYABLES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/AccruedExpensesandOtherPayables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilities": { "auth_ref": [], "calculation": { "http://heyu.com/role/ScheduleofaccruedexpensesandotherpayablesTable": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.", "label": "Accounts Payable and Other Accrued Liabilities", "terseLabel": "Other Payables" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofaccruedexpensesandotherpayablesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r6", "r326" ], "calculation": { "http://heyu.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r73", "r81", "r92", "r344" ], "calculation": { "http://heyu.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties.", "label": "Accounts Payable, Related Parties", "terseLabel": "Related party payables" } } }, "localname": "AccountsPayableRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r11" ], "calculation": { "http://heyu.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other payable" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r19", "r21", "r22", "r105", "r292", "r301", "r302" ], "calculation": { "http://heyu.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r18", "r22", "r68", "r277", "r298", "r299", "r340", "r341", "r342", "r345", "r346", "r347" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r2", "r326" ], "calculation": { "http://heyu.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r223", "r224", "r225", "r345", "r346", "r347", "r356" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdvancesOnInventoryPurchases": { "auth_ref": [ "r339" ], "calculation": { "http://heyu.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.", "label": "Advances on Inventory Purchases", "terseLabel": "Advances to suppliers" } } }, "localname": "AdvancesOnInventoryPurchases", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent": { "auth_ref": [ "r104" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on receivable, classified as other and current.", "label": "Allowance for Credit Loss, Receivable, Other, Current", "negatedLabel": "Less: Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulOtherReceivablesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofotherreceivableTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r75", "r86", "r103", "r129", "r162", "r165", "r169", "r175", "r186", "r187", "r189", "r190", "r191", "r192", "r193", "r195", "r196", "r249", "r253", "r259", "r326", "r351", "r352", "r360" ], "calculation": { "http://heyu.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r99", "r108", "r129", "r175", "r186", "r187", "r189", "r190", "r191", "r192", "r193", "r195", "r196", "r249", "r253", "r259", "r326", "r351", "r352", "r360" ], "calculation": { "http://heyu.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r129", "r175", "r186", "r187", "r189", "r190", "r191", "r192", "r193", "r195", "r196", "r249", "r253", "r259", "r351", "r352", "r360" ], "calculation": { "http://heyu.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total non-current assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Non-current Assets" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r247", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r59", "r60", "r247", "r321", "r322" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": { "auth_ref": [ "r61" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned", "terseLabel": "Aggregate purchase amount (in Dollars)" } } }, "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of equity interests issued or issuable to acquire entity.", "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares", "terseLabel": "Purchaser acquired shares" } } }, "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r58" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Percentage of issued and outstanding shares of common stock" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r245", "r246" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Net loss" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofpotentiallydilutivesharesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r303", "r304", "r326", "r337" ], "calculation": { "http://heyu.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash and cash equivalents" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r37", "r102", "r315" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofcashandcashequivalentsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": { "auth_ref": [ "r102" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.", "label": "Cash and Cash Equivalents Disclosure [Text Block]", "terseLabel": "CASH AND CASH EQUIVALENTS" } } }, "localname": "CashAndCashEquivalentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/CashandCashEquivalents" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Cash and Cash Equivalents [Line Items]" } } }, "localname": "CashAndCashEquivalentsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofcashandcashequivalentsTable" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r32", "r37", "r40" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "CASH AND CASH EQUIVALENTS AT END OF PERIOD", "periodStartLabel": "CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r32", "r72" ], "calculation": { "http://heyu.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r345", "r346", "r356" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r1", "r55" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r1", "r326" ], "calculation": { "http://heyu.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock ($0.001 par value, 2,000,000,000 shares authorized, 1,032,466,000 shares issued and outstanding as of December 31, 2022 and December 31, 2021)" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r23", "r110", "r112", "r120", "r289", "r295" ], "calculation": { "http://heyu.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss attributable to HYBT shareholders" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r65", "r66", "r71", "r110", "r112", "r119", "r288", "r294" ], "calculation": { "http://heyu.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "negatedLabel": "Total comprehensive income attributable to noncontrolling interests" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r64", "r71", "r110", "r112", "r118", "r287", "r293" ], "calculation": { "http://heyu.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total Comprehensive Loss" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r210", "r211", "r220" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Total" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofadvancesfromCustomersTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r28", "r129", "r175", "r186", "r187", "r189", "r190", "r191", "r192", "r193", "r195", "r196", "r259", "r351" ], "calculation": { "http://heyu.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of Revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r13", "r84" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument, Periodic Payment", "terseLabel": "Agreed to pay amount (in Yuan Renminbi)" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/AdvancesfromCustomersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Deposits": { "auth_ref": [ "r79" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.", "label": "Deposits", "terseLabel": "Rental and POS machine deposits" } } }, "localname": "Deposits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofotherreceivableTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease Right-of-Use Asset and Liabilities [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r0", "r51" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "OPERATING LEASE RIGHT-OF-USE ASSET AND LIABILITIES" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/OperatingLeaseRightofUseAssetandLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r6", "r188", "r189", "r190", "r194", "r195", "r196", "r280", "r344" ], "calculation": { "http://heyu.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Advances from customers" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r121", "r137", "r138", "r139", "r140", "r141", "r145", "r147", "r149", "r150", "r151", "r152", "r257", "r258", "r290", "r296", "r317" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share - basic and diluted (in Dollars per share)", "verboseLabel": "Net loss per share, basic and diluted" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedIncomeStatement", "http://heyu.com/role/ScheduleofpotentiallydilutivesharesTable" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r121", "r137", "r138", "r139", "r140", "r141", "r147", "r149", "r150", "r151", "r152", "r257", "r258", "r290", "r296", "r317" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share - diluted", "verboseLabel": "Net loss per share diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedIncomeStatement_Parentheticals", "http://heyu.com/role/ScheduleofpotentiallydilutivesharesTable_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r43", "r44" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Earnings (loss) per share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r261" ], "calculation": { "http://heyu.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r239", "r354" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "terseLabel": "Income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r81", "r90" ], "calculation": { "http://heyu.com/role/ScheduleofaccruedexpensesandotherpayablesTable": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Employee-related Liabilities", "terseLabel": "Accrued payroll" } } }, "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofaccruedexpensesandotherpayablesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r55", "r96", "r114", "r115", "r116", "r132", "r133", "r134", "r136", "r142", "r144", "r154", "r176", "r209", "r223", "r224", "r225", "r235", "r236", "r256", "r262", "r263", "r264", "r265", "r266", "r268", "r277", "r298", "r299", "r300" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_ExcessStockSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of excess stock shares permitted to be issued.", "label": "Excess Stock, Shares Authorized", "terseLabel": "Common stock shares authorized" } } }, "localname": "ExcessStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r180", "r181", "r182", "r183", "r285", "r286" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofoperatingleaseliabilityTable" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyExchangeRateTranslation1": { "auth_ref": [ "r269", "r270" ], "lang": { "en-us": { "role": { "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.", "label": "Foreign Currency Exchange Rate, Translation", "terseLabel": "RMB: US$ exchange rate" } } }, "localname": "ForeignCurrencyExchangeRateTranslation1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofforeigncurrencytransactionsTable" ], "xbrltype": "pureItemType" }, "us-gaap_ForeignCurrencyGainLossMember": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing foreign currency gain (loss).", "label": "Foreign Currency Gain (Loss) [Member]", "terseLabel": "Foreign Currency [Member]" } } }, "localname": "ForeignCurrencyGainLossMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofforeigncurrencytransactionsTable" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r27", "r129", "r162", "r164", "r168", "r170", "r175", "r186", "r187", "r189", "r190", "r191", "r192", "r193", "r195", "r196", "r259", "r319", "r351" ], "calculation": { "http://heyu.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r24", "r74", "r82", "r94", "r162", "r164", "r168", "r170", "r291", "r319" ], "calculation": { "http://heyu.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss on operations before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r184", "r185" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofforeigncurrencytransactionsTable" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofforeigncurrencytransactionsTable" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r130", "r229", "r230", "r233", "r237", "r240", "r242", "r243", "r244" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r131", "r143", "r144", "r161", "r228", "r238", "r241", "r297" ], "calculation": { "http://heyu.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r113", "r226", "r227", "r230", "r231", "r232", "r234" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r33", "r39" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Cash paid for income tax" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "auth_ref": [ "r35" ], "calculation": { "http://heyu.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.", "label": "Increase (Decrease) in Accounts and Other Receivables", "negatedLabel": "Other receivables, net" } } }, "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r35" ], "calculation": { "http://heyu.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r35" ], "calculation": { "http://heyu.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r35" ], "calculation": { "http://heyu.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Accrued expenses and other payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Change in assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidSupplies": { "auth_ref": [ "r35" ], "calculation": { "http://heyu.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for supplies that provide economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Supplies", "negatedLabel": "Advance to suppliers" } } }, "localname": "IncreaseDecreaseInPrepaidSupplies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r122", "r125", "r126" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r101", "r106", "r153", "r177", "r178", "r179", "r283", "r316" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/OperatingLeaseRightofUseAssetandLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r10", "r129", "r175", "r186", "r187", "r189", "r190", "r191", "r192", "r193", "r195", "r196", "r250", "r253", "r254", "r259", "r318", "r351", "r360", "r361" ], "calculation": { "http://heyu.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r5", "r77", "r88", "r326", "r343", "r349", "r357" ], "calculation": { "http://heyu.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders\u2019 Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r12", "r100", "r129", "r175", "r186", "r187", "r189", "r190", "r191", "r192", "r193", "r195", "r196", "r250", "r253", "r254", "r259", "r326", "r351", "r360", "r361" ], "calculation": { "http://heyu.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityPeriodicPayment": { "auth_ref": [ "r8" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments of both interest and principal.", "label": "Line of Credit Facility, Periodic Payment", "terseLabel": "Parties payment" } } }, "localname": "LineOfCreditFacilityPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/AdvancesfromCustomersDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r15", "r76", "r87", "r129", "r175", "r186", "r189", "r190", "r191", "r195", "r196", "r259" ], "calculation": { "http://heyu.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests in subsidiaries" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r124" ], "calculation": { "http://heyu.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r32", "r34", "r36" ], "calculation": { "http://heyu.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r25", "r36", "r83", "r93", "r98", "r109", "r111", "r116", "r129", "r135", "r137", "r138", "r139", "r140", "r143", "r144", "r148", "r162", "r164", "r168", "r170", "r175", "r186", "r187", "r189", "r190", "r191", "r192", "r193", "r195", "r196", "r258", "r259", "r319", "r351" ], "calculation": { "http://heyu.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss attributable to HYBT shareholders" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r67", "r70", "r109", "r111", "r143", "r144", "r342" ], "calculation": { "http://heyu.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Loss attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r62", "r209", "r345", "r346", "r347" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non - controlling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r30" ], "calculation": { "http://heyu.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Other Income (Expenses)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://heyu.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r162", "r164", "r168", "r170", "r319" ], "calculation": { "http://heyu.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss on operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r273" ], "calculation": { "http://heyu.com/role/ScheduleofoperatingleaseliabilityTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Total" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofoperatingleaseliabilityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r273" ], "calculation": { "http://heyu.com/role/ScheduleofoperatingleaseliabilityTable": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofoperatingleaseliabilityTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r272" ], "calculation": { "http://heyu.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset", "verboseLabel": "Total" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet", "http://heyu.com/role/ScheduleofrightofuseassetTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r276", "r325" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted Average Discount Rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofminimumleasepaymentsTable" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r275", "r325" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted Average Remaining Lease Term(Year)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofminimumleasepaymentsTable" ], "xbrltype": "durationItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "auth_ref": [ "r17", "r20", "r260", "r267" ], "calculation": { "http://heyu.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax", "negatedLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other Comprehensive Income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_OtherGeneralAndAdministrativeExpense": { "auth_ref": [ "r29" ], "calculation": { "http://heyu.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense classified as other.", "label": "Other General and Administrative Expense", "terseLabel": "Administrative expenses" } } }, "localname": "OtherGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r338", "r350" ], "calculation": { "http://heyu.com/role/ScheduleofadvancestosuppliersTable": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseCurrentAndNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other Prepaid Expense, Current", "terseLabel": "Purchases of scientific research equipment" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofadvancestosuppliersTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivablesGrossCurrent": { "auth_ref": [ "r104" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Receivables, Gross, Current", "terseLabel": "Others" } } }, "localname": "OtherReceivablesGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofotherreceivableTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivablesNetCurrent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Receivables, Net, Current", "terseLabel": "Other receivables, net" } } }, "localname": "OtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofotherreceivableTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseCurrentAndNoncurrent": { "auth_ref": [ "r78", "r89", "r107" ], "calculation": { "http://heyu.com/role/ScheduleofadvancestosuppliersTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.", "label": "Prepaid Expense", "totalLabel": "Total" } } }, "localname": "PrepaidExpenseCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofadvancestosuppliersTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "auth_ref": [], "calculation": { "http://heyu.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.", "label": "Proceeds from (Repayments of) Related Party Debt", "terseLabel": "Proceeds from related party lending" } } }, "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r98", "r109", "r111", "r123", "r129", "r135", "r143", "r144", "r162", "r164", "r168", "r170", "r175", "r186", "r187", "r189", "r190", "r191", "r192", "r193", "r195", "r196", "r248", "r251", "r252", "r258", "r259", "r291", "r319", "r323", "r324", "r342", "r351" ], "calculation": { "http://heyu.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://heyu.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net Loss", "verboseLabel": "Loss for the period" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedCashFlow", "http://heyu.com/role/ConsolidatedIncomeStatement", "http://heyu.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.", "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]", "terseLabel": "Accounts receivable and allowance for doubtful accounts" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyTransactionDueFromToRelatedParty": { "auth_ref": [ "r188", "r189", "r190", "r194", "r195", "r196", "r344", "r359" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.", "label": "Related Party Transaction, Due from (to) Related Party", "terseLabel": "Related party owed" } } }, "localname": "RelatedPartyTransactionDueFromToRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r278", "r279", "r280", "r281", "r282" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfOtherDebt": { "auth_ref": [ "r31" ], "calculation": { "http://heyu.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the payment of debt classified as other.", "label": "Repayments of Other Debt", "negatedLabel": "Repayment to related party" } } }, "localname": "RepaymentsOfOtherDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAppropriated": { "auth_ref": [ "r16", "r52", "r53", "r85", "r128" ], "calculation": { "http://heyu.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "A segregation of retained earnings which is unavailable for dividend distribution. Includes also retained earnings appropriated for loss contingencies.", "label": "Retained Earnings, Appropriated", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAppropriated", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r96", "r132", "r133", "r134", "r136", "r142", "r144", "r176", "r223", "r224", "r225", "r235", "r236", "r256", "r298", "r300" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Advances from Customers [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r221", "r222" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "ADVANCES FROM CUSTOMERS" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/AdvancesfromCustomers" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r26", "r95", "r188", "r189", "r190", "r194", "r195", "r196" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Revenues from related parties" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r117", "r129", "r159", "r160", "r163", "r166", "r167", "r171", "r172", "r174", "r175", "r186", "r187", "r189", "r190", "r191", "r192", "r193", "r195", "r196", "r259", "r291", "r351" ], "calculation": { "http://heyu.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenue \u2013 related parties, net" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses and other payables" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/AccruedExpensesandOtherPayablesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.", "label": "Schedule of Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofcashandcashequivalentsTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of cash and cash equivalents" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/CashandCashEquivalentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": { "auth_ref": [ "r42", "r45", "r348" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.", "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]", "terseLabel": "Schedule of potentially dilutive shares" } } }, "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/TheCompanyandSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.", "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "terseLabel": "General and administrative costs" } } }, "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r41", "r127" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "THE COMPANY AND SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/TheCompanyandSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r14", "r55", "r96", "r114", "r115", "r116", "r132", "r133", "r134", "r136", "r142", "r144", "r154", "r176", "r209", "r223", "r224", "r225", "r235", "r236", "r256", "r262", "r263", "r264", "r265", "r266", "r268", "r277", "r298", "r299", "r300" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r132", "r133", "r134", "r154", "r284" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r1", "r3", "r4", "r50", "r326", "r343", "r349", "r357" ], "calculation": { "http://heyu.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Stockholders\u2019 equity - HYBT and Subsidiaries" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 Deficit" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r62", "r63", "r69", "r96", "r97", "r115", "r132", "r133", "r134", "r136", "r142", "r176", "r209", "r223", "r224", "r225", "r235", "r236", "r256", "r262", "r263", "r268", "r277", "r299", "r300", "r343", "r349", "r357" ], "calculation": { "http://heyu.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 deficit" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet", "http://heyu.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r56", "r128", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r255" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityPolicyTextBlock": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.", "label": "Stockholders' Equity, Policy [Policy Text Block]", "terseLabel": "Capital Structure" } } }, "localname": "StockholdersEquityPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of units or percentage investment held in the subsidiary by the limited liability company or limited partnership.", "label": "Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest", "terseLabel": "Attributable equity interest %" } } }, "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipOwnershipInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofdetailsoftheconsolidatingsubsidiariesTable" ], "xbrltype": "percentItemType" }, "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "State in which the subsidiary of the limited liability company or limited partnership was organized.", "label": "Subsidiary of Limited Liability Company or Limited Partnership, State", "terseLabel": "Jurisdiction of Formation" } } }, "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipState", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ScheduleofdetailsoftheconsolidatingsubsidiariesTable" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r9" ], "calculation": { "http://heyu.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Taxes Payable, Current", "terseLabel": "Income tax and other taxes payable" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r46", "r47", "r48", "r155", "r156", "r157", "r158" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r146", "r151" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares - diluted", "verboseLabel": "Weighted-average common shares outstanding - diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedIncomeStatement_Parentheticals", "http://heyu.com/role/ScheduleofpotentiallydilutivesharesTable_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r145", "r151" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares - basic and diluted (in Shares)", "verboseLabel": "Weighted-average common shares outstanding - basic and diluted" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://heyu.com/role/ConsolidatedIncomeStatement", "http://heyu.com/role/ScheduleofpotentiallydilutivesharesTable" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=2122178", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(30)(a)(3)(ii))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r328": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r329": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r331": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r332": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r333": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r334": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r335": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r336": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r41": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21332-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21346-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21459-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(4)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.12)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(1),(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(23)(a)(4)(i))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.10)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 65 0001213900-23-022296-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-022296-xbrl.zip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end